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ABSTRACT  
Background 
A high rate of sleep disturbances have been reported in individuals with Williams 
syndrome (WS), but the underlying aetiology has yet to be identified. Melatonin and 
cortisol levels are known to affect and regulate sleep/wake patterns. We investigated 
the changing levels of these hormones in order to explore any relationship with sleep 
disturbances in children with WS. 
Methods 
Twenty seven children with WS and 27 typically developing (TD) children were 
recruited. Sleep was monitored using actigraphy and pulse oximetry. Parents 
completed Children’s Sleep Habit Questionnaire (CSHQ). Saliva and first void 
morning urine samples were collected from the children. Saliva was collected at 
three time points: 4-6pm, before bedtime and first thing after awakening. Levels of 
salivary melatonin and cortisol were analysed by enzyme linked immunoassays. For 
determination of melatonin, cortisol and their metabolites in urine samples, specific 
Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry 
(UHPLC-MS/MS) method was developed.  
Results 
CSHQ and actigraphy indicated that children with WS were significantly affected by 
several types of sleep disturbances, including: abnormally high sleep latency and 
excessive night waking. Children in WS group had shallower falls in salivary 
cortisol levels and less pronounced rises in salivary melatonin at bedtime compared 
to TD controls (p < 0.01 and p = 0.04 respectively). Furthermore, it was found that 
children with WS also had significantly higher levels of bedtime cortisol compared 
to TD controls (p = 0.03). Using UHPLC-MS/MS analysis it was shown that 
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children with WS secrete less melatonin during the night compared to healthy 
controls (p < 0.01). Also, levels of cortisone, a metabolite of cortisol were 
significantly higher in the WS group (p = 0.05).  
Conclusions 
We found that children with WS had significant sleep disturbances which may be 
associated with their increased bedtime cortisol and lower evening melatonin. Both 
hormones play a significant role in the circadian rhythm and sleep/wake cycle, 
therefore it was necessary to look closely at these endocrine markers in individuals 
suffering from sleep disorders. Sleep problems in children with WS may adversely 
affect daytime activity and the quality of life, as well as social, emotional, health and 
economic functioning of the entire family. Hence, finding their cause is of great 
importance for affected children and their families. 
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STATEMENT OF ORIGINALITY 
My contribution to knowledge is the identification of the biomedical markers of 
sleep disturbances in Williams syndrome (WS) using saliva and urine samples; 
examination of associations between these markers and sleep parameters; as well as 
the development of a novel, fast ultra-high performance liquid chromatography-  
tandem mass spectrometry (UHPLC-MS/MS) method for simultaneous analysis of 
endocrine markers of sleep, namely 6-sulfatoxymelatonin, cortisol and cortisone in 
urine. Studies were approved by Middlesex Natural Sciences Ethics sub-Committee 
(Approval Letter 524) and the Williams Syndrome Foundation, UK. All work was 
carried out independently. 
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THESIS OVERVIEW 
The main aim of this work was to examine sleep problems observed in children with 
Williams syndrome (WS) in relation to secretion of the endocrine markers-  
melatonin and cortisol. The first chapter of the thesis focuses on sleep and circadian 
rhythm and includes an overview of WS as well as techniques used for studying 
sleep. The second part (Chapter 2) describes the methods used to study sleep 
behaviour at participants’ homes, namely actigraphy and questionnaires. The results 
of this investigation are also presented (Chapter 3). The next part consists of 
description of laboratory methods used for analysis of biochemical markers of sleep, 
namely melatonin and cortisol (Chapter 4). This part is followed by the results 
section (Chapter 5). The final chapter of the thesis focuses on discussion, 
conclusions and possible future work (Chapter 6).   
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1. INTRODUCTION 
 
This chapter provides an introduction of sleep and its functions in adults and 
typically developing children. Endocrine markers of sleep, in particular melatonin 
and cortisol are also outlined. Due to the fact that sleep research on children is still in 
its infancy, in particular in developmental disorders, it is then necessary to focus on 
adult studies rather than children. The second part of this chapter addresses studies 
on WS. The final part includes techniques used for the measurement of sleep as well 
as its endocrine markers.  
 
1.1. Sleep physiology and circadian rhythm 
 
The accepted view of sleep is generally defined as: “Sleep has survived ubiquitously 
throughout all of mammalian evolution; some experiments have shown that animals 
cannot survive without sleep; and animals have made numerous behavioural and 
physiological accommodations to permit the survival of sleep in dif ferent habitats 
and life styles. Sleep persists in predators and prey; in carnivores and vegetarians; 
on the land and in the water (marine mammals); in most mammals as they lie down 
relaxed, in ruminants while they stand, in birds while they perch, and in dolphins 
which constantly swim; in hot and cold climates; in elephants and shrews; in sloths 
that hardly move and mice that hardly sit still; in the smartest and the dumbest of all 
mammalian species. These facts suggest a primary, essential, functional core to 
sleep…” (Rechtschaffen, 1998) 
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1.1.1.   Sleep  
 
Sleep involves specific activity of the brain, controlled by elaborate and precise 
mechanisms (Hobson, 1995). Sleep is a physiological process controlled by two 
different biological clocks: the circadian rhythm – daily sleep- wake cycle, and the 
ultradian rhythm, which refer to processes with a period shorter than a 24h cycle 
(e.g. sleep stages) (Steriade & McCarley, 2005; Goldson & Reynolds, 2006). The 
circadian clock is a self- sustaining oscillator controlling many physiological and 
behavioral systems. The period of this oscillator lasts approximately 24 h (Albrecht, 
2002).  
 
1.1.1.1. Sleep stages 
 
In adults as well as children, sleep can be divided into a sequence of five recurring 
stages of sleep (Loomis et al., 1937) - four non-rapid eye movement stages (NREM) 
and a rapid eye movement stage (REM) (Hobson, 1995). After sleep onset, 
electroencephalography (EEG) recording changes progressively from a pattern of 
low voltage and high frequency to one of high voltage and low frequency. Thus, 
initially while falling asleep, the frequency spectrum of the EEG is shifted toward 
lower values and the amplitude of the cortical waves increases slightly. This period 
is called stage I sleep. In stage II, the frequency of EEG waves decreases and their 
amplitude increases (Loomis et al., 1938; Purves et al., 2008). In this stage, the first 
definitive EEG sign of sleep can be observed, and a complex wave sequences called 
sleep spindles are seen in the EEG recording (Hobson, 1995). Stage II is also 
characterised by reduced eye movements, respirations and heart rate. Stages III and 
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IV are the deepest non-REM stages (Goldson & Reynolds, 2006). In stage III sleep, 
the number of high- frequency spike clusters decreases, while the amplitude of low-  
frequency waves increases. The EEG activity of the stage IV sleep (slow- wave 
sleep, SWS) consists of low frequency (1–4 Hz), high-amplitude fluctuations 
called delta waves (Purves et al., 2008). In the deepest stages of sleep the body is 
relaxed, breathing is slow and shallow, and the heart rate is low (Goldson & 
Reynolds, 2006).  
In REM sleep, muscle tone is relaxed and the eyes move rapidly beneath the lids and 
the EEG recordings are highly similar to that of the awake state as the brain cycles 
back to the non-REM sleep stages (Purves et al., 2008). It is this phase of sleep when 
dreams occur (Hobson, 1995) (Figure.1.1).  
 
Thus, the full adult sleep cycle includes four NREM sleep stages and REM sleep and 
lasts approximately 90 to 100 min (Hobson, 1995). The time of one sleep cycle is 
relatively constant for the same person and for individuals of the same age. 
However, the proportion of REM sleep in each cycle is variable. This proportion is 
usually quite small in the first cycle, but increases through the night. Thus, half of 
the total REM sleep occurs in the last third of the night. The NREM sleep has an 
opposite distribution, occurring more in the first and second cycles than later during  
the sleeping period (Hobson, 1995). 
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Figure 1.1. Adult sleep stage changes through the night (adapted from Walker & 
Stickgold, 2004). Figure demonstrate distribution of particular sleep stages during the night 
time sleep. It can be seen that the slow wave sleep (SWS) occurs during the first half of 
sleep time, while the proportion of REM sleep increases with the sleep time. NREM-1 to 
NREM-4 indicates four stages of non-rapid eye movement sleep. 
 
During sleep cycles aminergic and cholinergic neurons secreting specific 
neurotransmitters play an important role. The aminergic neurons secrete serotonin 
and noradrenaline, while acetylocholine is secreted by cholinergic neurons. In 
contrast to action of serotonin or noradrenaline which is often inhibitory, 
acetylocholine is excitatory. In 1966, Jouvet proposed that the brainstem exerted its 
control of NREM sleep via serotonin and of REM sleep via noradrenaline (Jouvet, 
1966). Taking into account this finding, Hobson and colleagues (1975), using the 
microelectrode technique, found that group of cells (cholinergic) were turned on and 
others (noradrenergic and serotonergic) turned off during REM sleep. The REM-on 
cells did not release serotonin or noradrenaline but possibly released acetylocholine. 
This hypothesis was called the reciprocal interaction model: when the aminergic 
(REM-off) cells were on (in waking), the cholinergic (REM-on) cells were inhibited 
and vice versa. In support of this hypothesis, McCarley and Hobson (1975) reported 
that the induction of REM sleep is possible either by increasing cholinergic 
excitation or reducing the aminergic inhibition of REM-generating neurons. Thus, in 
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summary, the brainstem contains two populations of neurons: one population 
becomes active during REM sleep (REM-on cells-cholinergic and excitatory) 
(Marrosu et al., 1995; Lee et al., 2003), while the other becomes inactive (REM-off 
cells-noradrenergic, serotonergic and inhibitory) (Portas et al., 1998).  
 
1.1.1.2. Sleep functions 
 
Sleep is essential for optimal functioning in humans. Sleep functions include energy 
conservation (Sheldon, 2005a), body restoration and recovery (Adam & Oswald, 
1997), and learning and memory consolidation in both, adults and children (Born et  
al., 2006). Moreover it has a very important role in foetal development and structural 
development of brain in early life (Hobson, 1995). It has been reported that 
prolonged sleep deprivation in rodents, drosophila and possibly humans is fatal, 
which supports a “life sustaining” function of sleep (Rechtschaffen 1998; Cortelli et  
al. 1999; Shaw et al. 2002). 
 
One of the functions of sleep is to conserve energy. Humans consume less energy 
when during sleep. Muscular tension is reduced, heart rate is lowered, blood pressure 
and body temperature are reduced, and respiration is slower especially in SWS. The 
metabolic rate during sleep is reduced by 8-10% compared to relaxed wakefulness 
(Rosenzweig et al., 2005; Sheldon, 2005b). It has been reported that function of 
NREM sleep is restoration of body tissue and REM sleep of brain tissue (Adam & 
Oswald, 1997). The timing of growth hormone (GH) secretion which occurs during 
SWS also supports these findings (Takahashi et al., 1968). Another important 
function of sleep is its role in learning and memory consolidation (Born et al., 2006). 
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Walker and Stickgold (2004) in their review on sleep depended learning and memory 
consolidation, reported that the amount of REM sleep increases after training. Also,  
deprivation of REM, SWS or stage 2 NREM decreases subsequent memory 
performance and the overnight improvement correlates with these stages of sleep 
(Walker & Stickgold, 2004).  
 
1.1.1.3. Neurophysiological changes during sleep 
 
Several physiological changes can be observed during sleep and these include heart 
rate fluctuations, changes in respiratory rate and muscle tone. See Table 1.1. for 
detailed physiological functions amongst others during SWS and REM sleep.  
 
Property Slow-wave sleep REM sleep 
AUTONOMIC 
ACTIVITIES 
  
Heart rate  Slow decline Variable with high bursts 
Respiration Slow decline Variable with high bursts 
Thermoregulation Maintained Impaired 
Brain temperature Decreased Increased 
Cerebral blood flow Reduced High 
   
SKELETAL 
MUSCULAR SYSTEM 
  
Postural tension Progressively reduced Eliminated 
Knee jerk reflex Normal Suppressed 
Phasic twitches Reduced Increased 
Eye movements Infrequent, slow, 
uncoordinated 
Rapid, coordinated 
   
COGNITIVE STATE Vague thoughts Vivid dreams, well 
organized 
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HORMONE 
SECRETION 
Growth hormone 
secretion 
High Low 
   
NEURAL FIRING 
RATES 
 
 
 
Cerebral cortex 
(sustained) activity 
Many cells reduced and 
more phasic 
Increased firing rates; 
tonic 
   
EVENT-RELATED 
POTENTIALS 
  
Sensory-evoked Large Reduced 
 
 
Table 1.1. Properties of slow wave sleep (SWS) and rapid eye movement (REM) sleep 
(Rosenzweig et al., 2005). Table presents changes in autonomic activities, skeletal muscular 
system, cognitive state, hormone secretion, natural firing rates and event-related potentials 
between SWS and REM sleep. 
 
  
1.1.1.4. Factors modifying/influencing sleep  
 
There are several factors which modify sleep and one of those is chronological age 
(Figure 1.2.). The developmental characteristics of sleep are described in Section 
1.1.3. SWS stage decreases through life whereas sleep arousals tend to increase with 
age. In contrast to adults, infants enter sleep directly through REM sleep before 
NREM (Pegg, 2006). REM latency increases and the percentage of time spent in 
REM or active sleep gradually decreases throughout infancy and childhood to 20-
25% in adulthood (Kahn et al., 1996; Montgomery-Downs et al., 2006). 
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Figure 1.2. Age-related changes of sleep stages. Figure presents changes in time (minutes) 
for sleep latency, wake time after sleep onset (WASO), rapid eye movement (REM) sleep, 
slow wave sleep (SWS) and non-rapid eye movement sleep (NREM) sleep from 5 to 85 
years of age (adapted from Ohayon et al., 2004). It can be seen that time of SWS stage 
decreases through life whereas the occurrence of wake after sleep onset increases with age.  
 
Studies on adult sleep have shown that prior sleep history may also affect sleep, as it 
controls the homeostatic need for sleep (Franken, 2013). Also, an individual who has 
experienced sleep loss on one or more nights will show a sleep pattern that favors  
SWS during recovery in first nights, whereas REM sleep tends to recover on the 
second or subsequent recovery nights (Carskadon & Dement, 2005). The distribution 
of sleep stages can also be affected by circadian phase at which sleep occurs. It can 
be observed in the case of shift change working or travelling across many time 
zones. Thus, for instance, if sleep is delayed to early morning, when REM sleep has 
its peak, then REM may occur at the onset of sleep and will predominate in the entire 
sleep cycle (Carskadon & Dement, 2005). 
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Temperature is another factor that affects sleep, an environment that is either too hot 
or cold can cause sleep disruptions (Jhaveri et al., 2007). Bed-sharing may also 
affect sleep. It has been reported that bed-sharing children have less regular bed 
times, difficulty with sleep onset, more night-waking and seek out the parents 
following awakening during the night (Hayes et al., 2001). Another environmental 
factor affecting sleep is exposure to television (TV) prior to going to bed. Paavonen 
and colleagues (2006) examined 5-6 years old children (n=321) and reported that 
active TV viewing as well as passive TV exposure, particularly viewing adult-
targeted TV programs were strongly related to sleep disturbances in children. Similar 
findings were reported by BaHammam et al. (2006), showing significantly shorter 
sleep duration in elementary school age children (5-12 years old, n=1012) watching 
TV after 8:00 pm. Traffic noise at night may also cause sleep disturbances. The 
exposure-effect relationship between road traffic noise and sleep quality was found 
in both adults and children (Öhrström et al., 2006).  
Sleep can also be affected by drug and alcohol ingestion, as studies on adult sleep 
have shown. Several drugs, such as benzodiazepine suppress SWS, tricyclic 
antidepressants or some selective serotonin reuptake inhibitors suppress REM and 
can disrupt the distribution of sleep stages. Alcohol can also increase SWS and 
decrease REM early in the night and chronic ingestion of tetrahydrocannibol 
(marijuana) produces long term suppression of SWS (Freemon, 1982). 
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1.1.2. Clinical sleep disorders 
 
A distinction can be drawn here between sleep problems and sleep disorders. Sleep 
problems are often minor, transient annoyances that everyone experiences from time 
to time. It is important to note that sleep problems may be culturally defined and are 
often reported by parents when there is a mismatch between the child’s behaviour 
and the parents’ expectations, or when the child’s behaviour causes significant 
disruption to the parents’ sleep (Mindell & Owens, 2003). In contrast, sleep 
disorders are defined by the International Classification of Sleep Disorders 
(American Academy of Sleep Medicine, 2005) which tend to be more serious and 
may interfere with daily life. Eight categories of sleep disorders are defined: 
insomnias, sleep-related breathing disorders, hypersomnias of central origin, 
circadian rhythm disorders, parasomnias, sleep-related movement disorders, isolated 
symptoms, and other sleep disorders. Some of the most common childhood disorders 
will be discussed here in more detail.  
 
1.1.2.1. Insomnia 
 
The most commonly experienced sleep disorder is insomnia. It has been reported 
that the behavioural insomnia affects 10-30% of the child population (American 
Academy of Sleep Medicine, 2005). Individuals suffering from this disorder have 
difficulty initiating or maintaining sleep (Hobson, 1995; Wilson & Nutt, 2005). Most 
affected individuals present with one or more of the three forms of insomnia: 
difficulty with falling asleep, difficulty getting back to sleep during the night, or 
inability to return to sleep, even for a short while, after waking during the night. 
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Episodes of insomnia can last several days or weeks, or develop chronic condition 
lasting months, years or even decades. The causes of insomnia include many 
common life events such as noisy neighbours, stressful family or work events, 
depression, serious health problems and conditioned alertness (Rothenberg, 1997). 
Insomnia is associated with feelings of restlessness, irritability, anxiety, daytime 
fatigue and tiredness (American Academy of Sleep Medicine, 2001). The most 
suitable treatment for insomnia is dependant on an accurate assessment of its 
aetiology (Gillin & Byerley, 1990).  
Children can suffer from behavioural insomnia, which is characterised by bedtime 
struggles, trouble settling down and difficulty initiating and/or maintaining sleep. 
The child may refuse and resists going to bed and staying in bed. He/she will be 
unable to self-soothe to sleep and will awaken repeatedly throughout the night 
requiring parental attention, and/or require special conditions to fall asleep, such as 
certain toys, blankets, music, or the parent being in the room. This is generally 
accompanied by distress and impaired daytime functioning (Hill, 2011).  
 
1.1.2.2. Parasomnias 
 
Parasomnias are sleep disorders characterised by the occurrence of the diverse set of 
behavioural and physiological events, which intrude sleep. Parasomnias are 
manifestations of central nervous system (CNS) activation and may involve 
respiratory system, motor system or the cognitive system (Hobson, 1995; 
Rothenberg, 1997; American Academy of Sleep Medicine, 2001). These disorders 
are divided into four groups: arousal disorders (confusional arousals, sleep walking, 
sleep terror), sleep-wake transition disorders (sleep talking, night leg cramps), 
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parasomnias usually associated with REM sleep (nightmares, sleep paralysis) and 
other parasomnias (i.e. bruxism, sleep enuresis) (American Academy of Sleep 
Medicine, 2001). As parasomnias are reflection of CNS immaturity, they are more 
common in children than in adults and are generally outgrown with time (Thiedke, 
2001). It has been also found that parasomnias are associated with a higher 
prevalence of other sleep disturbances in children (n=480) aged 6 to 11 years 
(Goodwin et al., 2004). The authors also demonstrated that pre-adolescent school-
aged children with sleep-disordered breathing (SDB) experienced more parasomnias 
than those without SDB. 
 
1.1.2.3. Hypersomnia 
 
Hypersomnia has been described as uncontrollable and pathologically deep and 
prolonged sleep in both, children and adults (Kleitman, 1963). The most common 
hypersomnia is narcolepsy. It is an autosomal dominant genetic disorder of the 
neural control mechanism that regulate sleep and waking (Aldrich, 1992; 
Rothenberg, 1997). It is genetically complex disorder. Studies suggest that it results 
from a combination of genetic and environmental factors. The tight association was 
found between human leukocyte antigen (HLA) allele DQB1*0602 as well as 
DRB1*1501  (Chabas et al., 2003; Migawa et al., 2008) and the narcolepsy, 
particularly in people who also have cataplexy and loss of hypocretins. The HLA 
complex helps the immune system distinguish the body’s own proteins from proteins 
made by foreign invaders (such as viruses), thus, it has been suggest that narcolepsy 
has an autoimmune aetiology. Furthermore, it was also found that polymorphisms in 
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two immune related genes- TCRA and P2RY11 are associated with narcolepsy (Han 
et al., 2012). 
Narcolepsy is characterised by irresistible sleepiness and repeated episodes of naps 
and lapses into sleep of short duration (usually less than 1 hour) (Hobson, 1995; 
American Academy of Sleep Medicine, 2001). The excessive sleepiness observed in 
this disorder is associated with cataplexy, hypnagogic or hypnopompic 
hallucinations and sleep paralysis- so called narcoleptic tetrad. An affected 
individual may demonstrate only one of the symptoms or the full syndrome. 
Cataplexy is a sudden decrease in muscle tone while awake, which varies from mild 
weakness to inability to move. Hypnagogic and hypnopompic hallucinations are 
vivid visual images or sounds, which occur while the narcoleptic patient is awake, 
thus may be misperceived as real. Sleep paralysis occur while the person is 
awakening and for a brief period of time cannot move or speak due to the fact that 
the normal inhibition of muscle tone during REM sleep fails to end. Each of the 
symptoms from narcoleptic tetrad is caused by the failure of the neural mechanisms 
which keep REM state separate from the wake state (Rothenberg, 1997).  
 
 
1.1.2.4. Sleep-Disordered Breathing (SDB)  
 
SDB is a disorder varying from mildly disordered to severely disordered sleep 
(Strollo & Rogers, 1996). A partial decrease in airflow for 10 seconds or more is 
called hypopnoea, while complete cessation of airflow for the same period of time – 
apnoea. These events are called obstructive when the muscles and soft tissue of the 
throat collapse and impede breathing. Obstructive apnoea and hypopnea are the most 
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common sleep disorders affecting breathing (Rothenberg, 1997). Obstructive sleep 
apnoea syndrome (OSAS) is characterised by repetitive episodes of upper airway 
obstruction occurring during sleep and usually associated with a reduction in blood 
oxygen saturation. This syndrome is associated with characteristic snoring pattern, 
consisting of loud snores and brief gasps that alternate with the episodes of silence 
(American Academy of Sleep Medicine, 2001). The key feature of this disorder is 
excessive daytime sleepiness observed in affected individuals (Rothenberg, 1997). 
Prevalence of SDB estimates vary depending on the type of diagnostic tools used, 
but it is likely that snoring occurs in around 11% of children aged 4 to 11 years (Ali 
et al., 1993; Ali et al., 1994; Goodwin et al., 2003; Gozal, 2008), declining to around 
6% in adolescence (Johnson & Roth, 2006). OSAS is thought to affect around 1 to 
3% of children (Brunetti, 2001; Sogut et al., 2005). 
 
1.1.2.5. Restless Leg Syndrome 
 
Restless leg syndrome is a sleep disorder characterised by unpleasant leg sensations 
usually between knees and ankles that cause an almost irresistible urge to move legs 
(Ekbom, 1960; American Academy of Sleep Medicine, 2001). This disagreeable 
feeling can be temporarily relieved by movement. The prevalence of restless leg 
syndrome is estimated to be around 2% in children and 5-10% in adults (Allen et al., 
2005; Picchietti et al., 2007). This prevalence is much higher in children with 
Attention Deficit Hyperactivity Disorder (ADHD). It has been reported that up to 
44% of subjects with ADHD have been found to have restless leg syndrome, while 
up to 26% of subjects with restless leg syndrome have been found to have ADHD or 
ADHD symptoms (Cortese et al., 2005). The severity of this disorder range from 
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merely annoying to severely affecting sleep and quality of life (Allen et al., 2005). 
Affected individuals have difficulties falling asleep or falling back to sleep during 
the night. The aetiology of this disorder is unknown, however, dopamine agonist are 
effective in reducing its symptoms (Rothenberg, 1997). 
 
1.1.2.6. Periodic Limb Movement 
 
Periodic limb movement is another common sleep disorder of unknown aetiology. It 
is characterised by periodic episodes of repetitive limb movements occurring at 20-  
to 40-second intervals or continually throughout the night (Rothenberg, 1997; 
American Academy of Sleep Medicine, 2001). This disorder becomes increasingly 
common with age (Ancoli-Israel et al., 1991). The prevalence of periodic limb 
movement syndrome is estimated to be 4-11% in adults (Hornyak et al., 2006) and 
according to different reports 1.2-11% in children (Crabtree et al., 2003; Kirk & 
Bohn, 2004). Medical conditions, such as sleep apnoea syndrome or 
neuropsychiatric disorders may however lead to high rates of periodic limb 
movement syndrome observed in children (Hornyak et al., 2006). The most common 
symptoms of this disorder, ranging from mild to severe, include difficulty falling 
asleep and maintaining sleep, fragmented sleep architecture, daytime sleepiness and 
frequent EEG arousals. Moreover, these syndromes tend to increase with stress. As 
with restless leg syndrome, the aetiology of this disorder is unknown, however, 
benzodiazepines and dopaminergic agents have been shown to suppress muscle 
contractions and regulate muscle movements during sleep (Spriggs, 2010). 
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1.1.2.7. Daytime sleepiness 
 
Excessive sleepiness among children and adolescents has been identified as a major 
societal concern (Fallone et al., 2002). It has been suggested that children with 
increased levels of daytime sleepiness are likely to experience impairments in 
behavioural, mood and performance domains (Fallone et al., 2002). Unlike other 
sleep disorders described in the current section (Section 1.1.2), excessive daytime 
sleepiness is a secondary effect of various sleep-related problems and in infants and 
children may occur as a result of disorders leading to a sufficient loss of night-time 
sleep, such as insomnia, or persistent night waking (Stores, 2001; Kryger, 2005). 
Second most common cause of daytime sleepiness are breathing-related sleep 
disorders (i.e. sleep apnoea), because respiratory difficulties cause frequent arousals 
and awakening from sleep. In teenagers, daytime sleepiness may result from 
circadian rhythm disorders, sleep apnoea as well as narcolepsy. Some major 
psychiatric disorders, such as depression, as well as drugs used to treat them can also 
cause daytime sleepiness (Stores, 2001; Kryger, 2005). Moreover, the associations of 
excessive daytime sleepiness with obesity and anxiety have also been reported in 
school-aged children (Calhoun et al., 2011).     
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1.1.3. Sleep in children 
 
1.1.3.1. Sleep in typically developing children 
 
Sleep and circadian rhythms are different in newborns than in older infants and 
children. Circadian rhythm is not fully established at birth, thus sleep can occur at 
any time of the day and night. The infants’ pattern of sleep and wakefulness is 
irregular and is often coordinated by feeding times (Adair & Bauchner, 1993). 
Infants and young children spend majority of their time asleep, hence indicating that 
sleep is essential for a developing brain and body as well as maintaining optimal 
health (Fin Davis et al., 2004). With an increased developmental age in infancy, 
awake periods during the day become longer, daytime sleep organise into naps and 
sleep starts to consolidate during night hours (Anders et al., 1995). In general, 
infants older than 12 months show a dramatic change in sleep patterns. Total daily 
sleep tends to decrease to about 13 hours by age of 2 years, 12 hours by 3 to 4 years 
old and 11 hours by 5 years old. However, there is still considerable variability 
(Roffwarg et al., 1966). There is less remarked and more gradual decrease in 
nocturnal sleep which continues until late adolescence (Iglowstein et al., 2003). The 
gradual shift to later bedtime and sleep onset time that begins in middle childhood 
and accelerates in early to mid adolescence has also been reported (Owens, 2005; 
Ashworth et al., 2013). The characteristic of particular stages of sleep in children is 
the same as those observed in adults (see Section 1.1.1) (Fin Davis et al., 2004), 
however, the distribution of sleep stages differs. In the first year of life sleep starts 
from REM sleep (called active sleep in newborns) and the cycle is shorter than in 
adults, lasting approximately 50 to 60 min. Sleep stages develop as the brain matures 
40 
 
during first year of life. Active sleep constitutes approximately 50% of total sleep at 
birth and declines from infancy and childhood to 20-25% in adulthood (Kahn et al., 
1996; Montgomery-Downs et al., 2006).  
It has been reported that approximately 25% of all children experience some type of 
sleep problems at some point during their childhood (Owens, 2005). The type, 
relative prevalence, chronicity and severity of sleep problems can be affected by the 
number of variables associated with the child and/or parents as well as 
environmental variables. Child variables affecting sleep include temperament and 
behavioural style, individual variations in circadian preference, cognitive and 
language delays and the presence of coexisting medical and psychiatric conditions. 
Parental variables that impact sleep include parenting and discipline styles, parents’ 
level of education and knowledge of child development, quality and quantity of sleep 
of parents and all family members as well as family stress. Finally, environmental 
variables include the physical environment (space, noise, room and bed-sharing), 
family composition (i.e. number, ages) and lifestyle issues (i.e. parental work status). 
A number of studies have examined the prevalence of parent- and child- reported 
sleep complaints in children and adolescents. Sleep problems observed in childhood 
range from short-term difficulties in falling asleep and night waking to more serious 
sleep disorders such as obstructive sleep apnoea (Owens, 2005). It has been reported 
that prevalence of parent-defined sleep problems in children 4 to 10 years of age 
ranges from 3.7% (sleep disordered breathing) to 15.1% (bedtime resistance), with 
37% of the overall sample having significant sleep problems in at least one sleep 
domain (such as sleep anxiety, night waking, bedtime resistance) (Owens et al., 
2000b). Another study of over 14,000 school-aged children reported sleep problems 
in 20% of 5 year olds and 6% of 11 year olds (Rona et al., 1998). It is however 
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important to note that parental reports may over- or underestimate the prevalence of 
sleep problems in their children, as the very definition of a sleep problem is often 
highly subjective (Owens et al., 2000b).   
 
1.1.3.2. Sleep in children with developmental disabilities 
 
Sleep problems are far more common in children and adolescents with chronic 
medical or psychiatric conditions (Owens, 2005). It has been estimated that 30% to 
80% of children with severe learning difficulties and at least half of children with 
less severe cognitive impairment are affected by significant sleep disturbances 
(Stores & Wiggs, 2003). Significant sleep disturbances have been reported in 
neurodevelopmental disabilities such as Asperger’s syndrome (Allik et al., 2006), 
and Attention Deficit Hyperactivity Disorder (ADHD) (Corkum et al., 2001; 
Konofal et al., 2001; Scott et al., 2013); as well as in the syndromes of genetic 
aetiology- Smith-Magenis syndrome  (Potocki et al., 2000) and Williams syndrome 
(WS) (Bódizs et al., 2009; Goldman et al., 2009; Mason et al., 2009; Annaz et al., 
2011; Ashworth et al., 2013). These include sleep problems with initiation and 
maintenance of sleep, reduced length of sleep, irregular sleeping patterns and early 
morning waking (Owens, 2005). 
Sleep disturbances have been widely described in children with Autism Spectrum 
Disorder (ASD) which is characterised by impairment in communication, social 
interaction and difficulty to adapt to novel experiences (American Psychiatric 
Association, 1994). The prevalence of sleep problems in this population is estimated 
to be in range 44-83% (Richdale, 1999) and increases with the severity of the autistic 
spectrum disorder (Mayes & Calhoun, 2009). The most frequent sleep problems 
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observed in this group are difficulty falling asleep, restlessness during sleep (Mayes 
& Calhoun, 2009), early morning awakening and multiple night arousals (Hering et  
al., 1999) as well as frequent night waking (Williams et al., 2004). Another 
developmental disorder affected by frequent sleep disturbances is ADHD. This 
disorder is one of the most prevalent child psychiatric conditions affecting 3-7.5% 
school-aged children. It is characterised by impulsivity/ hyperactivity and inattention 
(American Psychiatric Association, 1994; Centers for Disease Control and Prevention, 
2001). Parents of children with ADHD commonly report disturbed  and restless sleep 
in their children (Corkum et al., 2001). Sleep problems observed in this population 
include high level of nocturnal activity (Konofal et al., 2001), decreased sleep time 
(Scott et al., 2013), restless leg syndrome (Cortese et al., 2005), increased bedtime 
resistance (Corkum et al., 2001), significantly shorter REM sleep and higher scores 
on insufficient sleep and sleep anxiety factors than children in the control group 
(Gruber et al., 2009).  
Sleep disorders are also common in other developmental disorders that have genetic 
aetiology, such as Down’s syndrome (DS) and Prader-Willi syndrome. Cotton and 
Richdale (2006) reported the sleep maintenance problems in DS and excessive 
daytime sleepiness in children with Prader-Willi syndrome. The study of Turner and 
Sloper (1996) also revealed that as much as 43% of children with DS aged 7 to 14 
years have problems settling at bedtime, 51% awaken at night and 38% suffer from 
night bed-wetting. Similar results were found by Carter et al. (2009) who reported 
increased bedtime resistance, sleep anxiety, night waking, parasomnias, SDB and 
daytime sleepiness in children with DS. Recently children with WS have been 
identified with sleep problems and are of interest in the current thesis (see details in 
Section 1.3.4.). 
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1.1.4. Circadian rhythm 
 
Internal clocks that control biological rhythms are called circadian, from the Latin 
circa (about) and dies (day). These clocks have periods of about 24 h (Hobson, 
1995). The circadian rhythm is generated in the suprachiasmatic nucleus (SCN) of 
the hypothalamus (Figure 1.3.), it regulates the timing and amplitude of several 
endocrinological functions, such as secretion of growth hormone, thyroid-
stimulating hormone and prolactin, via neural or neurohumoral circuits (Zeitzer et  
al., 2000). The endogenous clock located in the SCN generates other circadian 
rhythms in mammals as well, such as drinking, feeding, sleep-wake cycle, and 
temperature (Claustrat et al., 2005). 
 
 
 
Figure 1.3. Location of the hypothalamus in human brain  (The New York Times health 
Guide- Narcolepsy). 
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Markers of the circadian rhythm are the wake/sleep cycle, rest/activity cycle, 
temperature and hormones such as melatonin, cortisol and GH secretion as well as 
clock genes activity (Haffen, 2009) (Figure 1.4.). 
  
Figure 1.4. The biological rhythms controlled by circadian system. Figure presents daily 
cycles of physiology (core body temperature and urine volume) and hormone levels 
(melatonin, cortisol, growth hormone and prolactin) in human subjects with regular 
sleep/wake cycles entrained to light/dark cycles (on the left) as well as exposed to a constant 
routine (on the right). Progressive changes in physiological and endocrine status can be 
observed across day and night under normal sleep/wake routine. When exposed to constant 
routine in continuing wakefulness, physiological rhythms are maintained with slightly 
reduced amplitude. Endocrine rhythms of melatonin and cortisol secretion proved to be 
strongly circadian, while rhythm of growth hormone and prolactin are diminished due to 
their strict dependence on sleep (Czeisler & Klerman, 1999; Maywood et al., 2007). 
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Sleep has a modulatory effect on many components of the endocrine system, and 
reciprocally, hormones such as melatonin and cortisol affect sleep architecture and 
display circadian rhythmicity. The diurnal pattern of melatonin and cortisol secretion 
proved to be independent of sleep. Furthermore, these  hormones can also affect human 
daily cycle including sleep (Steiger, 2002; Reiter et al., 2010). Melatonin and cortisol 
tend to run opposite to each other, cortisol approaches its low point when melatonin 
reaches its peak (Herman, 2005).  
 
1.1.5.  Melatonin 
 
Melatonin, also known chemically as N-acetyl-5-methoxytryptamine, was first 
isolated from bovine pineal gland by Aaron Lerner (1958). It is produced mostly in 
pineal gland (Arendt, 2005) but also by the retina, lens, gastrointestinal tract, bone 
marrow and other tissues. It is also the main hormone secreted by pineal gland 
(Claustrat et al., 2005).  
 
1.1.5.1. Functions of melatonin  
 
Melatonin decreases core temperature which plays a role in the onset and duration of 
sleep (Strassmann et al., 1991; Arendt, 2005). Melatonin receptors can be found in 
peripheral blood vessels, thus the decrease of central temperature may be the result 
of peripheral vasolidation due to melatonin receptor stimulation (Van Der Helm-van 
Mil et al., 2003).  
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Melatonin displays antioxidative properties. It scavenges the oxygen centered 
radicals including highly toxic hydroxyl radical. It also demonstrates activity on 
several antioxidative enzymes (such as superoxide dismutase, glutathione peroxidase 
and glutathione reductase) by increasing their levels and inhibits pro-oxidative 
enzyme nitric oxide synthase (Claustrat et al., 2005; Berra & Rizzo, 2009).  
Melatonin also displays possible activity on the immune system, by scavenging NO 
or free radicals in lymphoid cells (Claustrat et al., 2005). Melatonin receptors were 
found in several lymphoid organs and in lymphocytes (Macchi & Bruce, 2004). 
Based on these findings, Poon and Pang (1996) suggested possible mechanisms of 
melatonin action on the immune system, including stimulation of opioid peptides by 
T lymphocytes and lymphokines, and inhibition of the immunorepressive action of 
corticosteroids.  
Melatonin is a naturally occurring oncostatic neurohormone for the prevention of 
neoplastic growth. Numerous studies demonstrate its anti- tumor activity, including 
antiproliferative actions, immunostimulatory effects on host anticancer defences and 
antioxidant activity (Hill et al., 1992; Lissoni et al., 2003).  
Melatonin has also a possible effect on circadian rhythm of blood pressure. It has 
been reported that administration of melatonin for 3 weeks in patients with essential 
hypertension reduces blood pressure without alternation of heart rate (Scheer et al., 
2004).  
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1.1.5.2. The circadian regulation of melatonin synthesis 
 
The synthesis and release of melatonin by the pineal gland is under the influence of 
the suprachiasmatic nuclei of the hypothalamus which receives information from the 
retina about the daily pattern of light and darkness (Ganong, 2005). Neuronal 
pathways from SCN distribute circadian rhythm information to different areas of the 
brain, including the pineal gland (Cardinali & Pevet, 1998). The main 
neurotransmitter regulating the pineal gland is noradrenaline, which is released at 
night in response to stimulatory signals (photic information from retina) originating in 
the SCN (Cagnacci, 1996) (Figure 1.5.). The release of melatonin is entrained to the 
dark period. The photic information is transmitted to the central pacemaker via 
retino-hypothalamic fibers (Isobe et al., 2001; Wilkinson, 2008), which originates 
from a small subset of retinal ganglion cells (Meijer & Rietveld, 1989). In the 
presence of light, the output from the retino-hypothalamic tract inhibits melatonin 
synthesis. Artificial light of sufficient intensity can also suppress melatonin 
production at night. This suppression is dose-dependent and varies with the spectral 
characteristics of the light stimulus (Lewy et al., 1980).  
 
48 
 
 
Figure 1.5. Schematic presentation of the stimulation (darkness) and inhibition (light) of 
melatonin secretion from pineal gland involving the neural pathway originating in retina and 
passing through suprachiasmatic nucleus (SCN), the main “circadian oscillator” in the brain, 
to reach pinealocytes via adrenergic nerves and adrenergic receptors at the cell membrane 
(Konturek et al., 2007). 
 
 
1.1.5.3. Biosynthesis of melatonin 
 
 
Melatonin is synthesised indirectly from L-tryptophan taken from the blood by 
pinealocytes. Hydroxylation and decarboxylation of this amino acid gives serotonin. 
The latter is then converted to N-acetyl-5-hydroxytryptamine (N-acetyl-serotonin) by 
serotonin-N-acetyl transferase (arylalkylamine N-acetyl transferase- NAT), which in 
turn is methylated to form melatonin by way of a reaction catalysed by 
hydroxyindole-O-methyl transferase (Macchi & Bruce, 2004; Vela-Bueno et al., 
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2007) (Figure 1.6.) The mRNAs encoding these enzymes are expressed with a 
day/night rhythm in the pineal gland (Bernard et al., 1999). 
The initiation of melatonin synthesis is triggered by the binding of noradrenaline to 
β-1 adrenergic receptors, which leads to the activation of pineal adenylate cyclase, 
increase in cyclic AMP (cAMP) and de novo synthesis of NAT or its activation 
(Figure 1.6.). The mechanism that limits the production of melatonin at night is 
represented by the cAMP-induced gene transcription repressor, which is activated in 
conjunction with NAT ((Stehle et al., 1993). 
 
 
 
Figure 1.6. Central nervous system pathway and mechanism controlling melatonin 
secretion in mammals. The suprachiasmatic nuclei (SCN) of the hypothalamus which 
receives information from the retina about the daily pattern of light and darkness.  The 
information from SCN goes through upper thoracic cord and superior cervical ganglion to 
pineal gland. The main neurotransmitter regulating the pineal gland is noradrenaline. 
Melatonin is synthesised indirectly from tryptophan taken from the blood by pinealocytes 
(cell of pineal gland) and then released into capillaries (Trinity University, 
http://www.trinity.edu).  
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Melatonin levels begin to increase before sleep, reach a maximum in plasma around 
3.00–4.00 am (Claustrat et al., 2005) and decrease before habitual wake up time to 
keep at a low level during the day (Ganong, 2005). Peak values of salivary melatonin 
range between 2-84 pg/ml in adults (Burgess & Fogg, 2008). Melatonin enters the 
saliva mainly via passive diffusion through the cells of the salivary glands, thus the 
saliva flow rate does not affect melatonin levels (Miles et al., 1989; Radon et al., 
2001). In the passive diffusion, the transport of the analyte from plasma to saliva is 
related to the plasma/saliva concentration gradient (Khurana, 2006). The hormone 
moves from a region of higher concentration to one of lower concentration and the 
cell does not expend energy. Thus, melatonin diffuses readily through the lipo-
protein membranes of the secretory cells in the salivary glands (Kaufman & Lamster, 
2002). In addition, as melatonin is bound to albumin in serum, its salivary levels 
represent the free hormone levels. This provides clinically useful information, since 
free serum melatonin levels are the biologically active fraction of this hormone in 
serum (Kaufman & Lamster, 2002). The saliva level of melatonin is parallel to that 
observed in plasma, and is approximately three fold lower (McIntyre et al., 1987; 
Voultsios et al., 1997; Burgess & Fogg, 2008). The ability to synthesize melatonin 
differs among individuals. There are low and high secretors of melatonin. Normal 
daytime serum levels in healthy adults range from 0-20 pg/ml, whereas the night 
levels, when melatonin reaches its peak, vary between 50-200 pg/ml (Wetterberg, 
1978; Waldhauser & Dietzel, 1985). However, within the same individual melatonin 
rhythm and its amplitude remains constant representing one of the most robust 
circadian rhythms (Arato, 1985; Bojkowski et al., 1987). It should be noted that 
levels of melatonin change with age (Figure 1.7). The circadian rhythm of melatonin 
appears at the end of the neonatal period (Ardura et al. 2003) and melatonin reaches 
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highest nocturnal levels between 1 to 3 years of age (Waldhauser et al., 1993). 
During childhood melatonin levels drop by approximately 80% until adult levels are 
reached (Figure 1.7.). Kennaway and collegues (1999) have shown that changes in 
melatonin with age were essentially complete before the age of 30 and further 
analyses of melatonin levels in 5-year age spans did not show any significance.  
 
 
 
Figure 1.7 . Age variations of melatonin levels. Peak of melatonin secretion occur in early 
childhood and it gradually decreases from puberty through the life (Grivas &  Savvidou, 
2007). 
  
Melatonin is highly lypophylic and somewhat hydrophilic as well, which facilitates 
passage across cell membranes. As no pineal storage of melatonin is available, upon 
biosynthesis it is released into capillaries, where up to 70% is bound to albumin in 
order to be transported through the blood and eventually reach the liver (Cardinali et  
al., 1972; Pardridge & Mietus, 1980). Albumin is the most abundant protein in 
plasma and binds melatonin non-selectively (Borer, 2003). Transport of hormones in 
bound form extends their period of availability and action by preventing their rapid 
clearance from plasma. There is a dynamic equilibrium between the bound and free 
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fraction of melatonin (Nussey & Whitehead, 2001; Borer, 2003). The fraction bound 
to albumin is called weakly bound hormone (Kovacs & Ojeda, 2012). Melatonin can 
readily bind and dissociate from albumin. The free fraction of melatonin is 
biologically active and it is free to cross capillary walls and bind selectively with 
target cell receptors to exert an effect (Sherwood, 2010). Melatonin can be found in 
various fluids, tissues and cellular compartments (saliva, urine, cerebrospinal fluid, 
preovulatory follicle, semen, amniotic fluid and milk) (Claustrat et al., 2005). 
 
1.1.5.4. Catabolism of melatonin 
 
The biological half- life of melatonin is short and according to different sources it 
ranges between 30 min (Brown et al., 1997) and 1 h (Claustrat et al., 1986; Mallo et 
al., 1990). Melatonin is metabolised primarily in the liver, but also to much lesser 
extent in the kidneys. In the first step it is hydroxylated and then conjugated with 
sulphate and glucuronide. In humans the main metabolite of melatonin is 6-
sulfatoxymelatonin (MT6s). Its urinary concentrations account for up to 90% of 
melatonin and closely parallels the plasma melatonin profile , as seen in administered 
melatonin studies (Arendt et al., 1985; Macchi & Bruce, 2004). Liver and renal 
pathologies can alter clearance rates (Lane & Moss, 1985; Viljoen et al., 1992) (See 
Section 1.1.6.5. for more details).  
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1.1.5.5. Melatonin and sleep 
 
It is generally accepted that melatonin can serve as an endogenous synchroniser able 
to stabilize and reinforce circadian rhythms and maintain their mutual phase-
relationship (Armstrong, 1989). Melatonin reinforces nocturnal decrease of core 
body temperature, which in turn facilitates sleep propensity (Strassmann et al., 1991; 
Arendt, 2005). Melatonin excretion coincides with sleepiness and temperature nadir 
(Claustrat et al., 2005). There is a clear relationship between the duration of sleep 
and melatonin secretion. Long-sleepers have a longer biological night than the short-
sleepers. Long sleepers have longer nocturnal intervals of high plasma melatonin 
levels, increasing cortisol levels, low body temperature and increasing sleepiness 
(Aeschbach et al., 2003). A study by Van Den Heuvel and colleagues (1997)  
examined the physiological role of melatonin in relation to sleep.  Nocturnal sleep 
was recorded in 8 young men over 4 nights (aged 21.3 ± 0.9 years). Participants 
received Atenolol (medication suppressing melatonin secretion) on one of the last 2 
nights and showed significantly increased total wake time and wakefulness after 
sleep onset, as well as decreased REM sleep and SWS. When melatonin (total 5 mg) 
was given after Atenolol on the next night, the changes in these parameters were 
reversed. These studies indicate that high levels of melatonin through the night 
promote sleep consolidation and that low melatonin levels are casual factor in some 
types of insomnia (Van Den Heuvel et al., 1997; Macchi & Bruce, 2004). Another 
important fact is that the imbalance in sleep distribution between night and day in  
infants becomes more distinguished around 3-4 months of life, which correlates with 
the maturation of melatonin rhythm (Rivkees, 2003). 
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As described previously, the evening rise of melatonin secretion correlated with a 
fall in body temperature, facilitates sleep. From the other side, cortisol, which 
secretion increases before dawn, prepares us for physical and mental demands of 
awaking, by increasing heart rate, blood pressure and releasing glucose to our blood 
stream. If these mechanisms are disturbed, sleep disorders may occur.  
 
1.1.6.  Cortisol 
 
Cortisol (hydrocortisone) is one of the major glucocorticoid hormones secreted by 
the adrenal cortex (Aron et al., 2007).  
 
1.1.6.1. Functions of cortisol 
 
Cortisol is often referred to as a stress hormone, as it is involved in response to stress 
and anxiety. It supplies our body in fuel and energy, by such actions as increasing 
heart rate and releasing glucose to the blood stream (Seaward, 2006). Thus, the main 
actions of glucocorticoids include increasing the circulating levels of energy 
providing compounds such as glucose, through gluconeogenesis and glycogenolysis; 
free fatty acids, by selective lipolysis, with loss of body fat in the limbs and its 
accumulation over the lower face and trunk; as well as free amino acids, by 
increased breakdown of proteins (Loriaux, 2001). The other important function of 
cortisol is increasing cardiac output and response to catecholamines, thus increasing 
heart rate and blood pressure (Loriaux, 2001; Seifter et al., 2005). 
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Another function of cortisol is direct inhibition of natural killer cells activity, 
reduction of the sytnthesis of prostacyclins, thus suppression of inflammation and 
immune system, and also sequestration of eosinophils (Zhou et al., 1997). The 
abnormal pattern of cortisol secretion, such as flattened diurnal cortisol, has been 
linked to a poor prognosis for women with breast cancer, thus cortisol can be a 
predictor of breast cancer survival (Sephton et al., 2000). 
Cortisol acts on calcium metabolism and bone formation by decreasing serum levels 
of this ion and accelerating osteoporosis.  
There are also several studies indicating that cortisol modulates hippocampus-
dependent declarative memory functions. It affects cognitive, as well as emotional 
networks of the CNS (Het et al., 2005). 
Another function of this hormone is increasing free water clearance and inhibition of 
vasopressin (Loriaux, 2001). 
In the case of the glucocorticoid deficiency, effects such as increased sensitivity to 
insulin, thus tendency to hypoglycaemia, and reduced gluconeogenesis can be 
observed (Silbernagl, 2000). Overexposure/abnormally high levels of cortisol can 
lead to health problems such as sleep disorders, hyperglycaemia (De Feo et al., 
1989) and memory impairment (Newcomer et al., 1999; Lupien et al., 1997). 
 
1.1.6.2. Circadian regulation of cortisol synthesis 
 
Cortisol, in addition to that seen in the stress response, is secreted in a pulsatile 
fashion that displays a circadian rhythm. This distinct 24-h rhythm of cortisol 
secretion occurs as a result of the hypothalamus-pituitary-adrenal (HPA) axis 
regulation by circadian oscillators (Gallagher et al., 1973). It has been reported that 
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the SCN influences HPA activity via projections to the paraventricular nucleus 
(PVN) as well as by direct autonomic innervation of the zona fasciculate (Buijs et  
al., 1999). At the time of awakening, direct innervations by the SCN acts as a 
zeitgeber (synchroniser) to the adrenal cortex (Scheer & Buijs, 1999). Similarly to 
melatonin production, information about the light/dark cycle is transmitted by the 
retina to the SCN in the hypothalamus. This occurs in spite of the negative feedback 
effects of cortisol on the hypothalamus and pituitary. The first few hours of sleep 
have an inhibitory effect on cortisol secretion (Weitzman et al., 1983) and morning 
exposition to bright light induces elevation of cortisol level (Leproult et al., 2001). 
Cortisol levels are the highest in early morning (McVicar et al., 2007), they increase 
dynamically in the first 45 min after awakening, decline throughout afternoon and 
the evening (Plat et al., 1996; Van Cauter, 2000; Clow et al., 2010)  with nadir early 
in the sleep period (New, et al., 1989). This pattern of cortisol secretion proved to be 
stable across days and weeks among individuals with wide age range (Pruessner et  
al., 1997). Salivary cortisol levels correlate well with the amount of free cortisol in 
blood (r ≥ 0.90). This agreement is caused by the fact that, as in the case of 
melatonin (Section 1.1.5.3.),  cortisol enters the cell and the oral cavity mainly by 
passive diffusion, thus its salivary levels are independent of saliva flow rate 
(Kirschbaum & Hellhammer, 2000). In blood, the majority of cortisol is bind to 
cortisol binding globulin (CBG). The unbound fraction of steroid is considered the 
free, bioavailable fraction, which enters the salivary gland and salivary duct by 
passive diffusion along the gradient without expenditure of any energy (Zava, 2004; 
Khurana, 2006). Hence, saliva provides a convenient diagnostic fluid from which to 
monitor non- invasively, the bioavailable fraction of steroid hormones circulating in 
the blood stream and entering the tissues (Zava, 2004).  The normal values of salivary 
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cortisol range from 10 to 27 nmol/l at 8.00 am and 2 to 4 nmol/l at 8.00 pm (Laudat 
et al., 1988). Small elevations of daytime levels can be associated with high-protein 
meals (especially at lunch time), drinks containing caffeine and stressful events 
(New, et al., 1989; Gibson et al., 1999). It is suggested that high levels of cortisol in 
the morning are linked with a stress-related preparation in regard to the upcoming 
day (Wilhelm et al., 2007, Clow et al., 2010). It has also been reported that the 
rhythmicity of cortisol secretion is unrelated to such factors as age, weight, smoking 
status and alcohol consumption during the previous night, as well as duration of 
sleep, physical activity and morning routines (Edwards et al., 2001). There is also 
significant individual variation, although a given person tends to have consistent 
rhythms (Stone et al., 2001). 
 
1.1.6.3. Biosynthesis and metabolism of cortisol 
 
Cortisol is synthesized from cholesterol under the control of adrenocorticotropic 
hormone (ACTH) secreted by the anterior pituitary gland in the zona fasciculate, the 
second of three layers comprising the outer adrenal cortex (New et al., 1989). 
Cholesterol is imported to mitochondria and converted to pregnenolone by 
cholesterol desmolase. Pregnenolone in turn, is converted to 17-hydroxypregnolone 
by 17α- hydroxylase after its transfer from mitochondria to endoplasmic reticulum. 
17-hydroxypregnolone undergoes conversion to 17-hydroxyprogesteron by 3β-
hydroxysteroid dehydrogenase/Δ5-Δ4 isomarase enzyme complex. There is also an 
alternative pathway in zona fasciculate and reticularis, which leads from 
pregnenolone to 17α-hydroxyprogesteron via conversion to progesterone. This 
pathway however, is of less importance. In the next step, which is microsomal, 17α-
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hydroxyprogesteron is hydroxylated to 11-deoxycortisol by 21α-hydroxylase. The 
final step takes place in mitochondria and involves hydroxylation of 11-
deoxycortisol by 11β-hydroxylase, what forms cortisol (Loriaux, 2001; Yadav, 
2004) (Figure 1.8.). 
 
Figure 1.8. Major human steroidogenic pathways. Key enzymes are shown near arrows 
indicating chemical reactions. The red/green colour of the boxes represents cellular location 
of enzymes with red indicating mitochondria and green- smooth endoplasmic reticulum. 
(www.citizendia.org). 
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1.1.6.4. Negative feedback loop regulation of cortisol synthesis 
 
The secretion of cortisol is ultimately controlled by the CNS which stimulates 
hypothalamus to release corticotropin releasing hormone (CRH) into the portal vein.  
CRH from the hypothalamus stimulates the secretion of ACTH in the pituitary gland 
by binding the receptors on corticotrophs in the anterior pituitary (New et al., 1989; 
Rinne et al., 2002). ACTH in turn acts on the adrenal cortex causing the synthesis of 
cortisol. High levels of this glucocorticoid travel through the blood stream back to 
the hypothalamus and pituitary suppressing CRH and ACTH production and also 
target tissues (liver, skeletal muscle and adipose tissue) through the body to mediate 
stress response (Figure 1.9.) (Besser & Thorner, 1994; Holt & Hanley, 2007; 
MacLaren & Morton, 2012). ACTH probably controls cortisol by controlling the 
movement of calcium into the cortisol-secreting target cells (Davies et al., 1985). It 
has been reported that ACTH can activate calcium ions, that leads to their entry 
through calcium channels. This mechanism is essential for ACTH-induced cortisol 
production (Enyeart et al., 1993; Omura et al., 2007).  
 
60 
 
 
Figure 1.9. Negative feedback loop of cortisol secretion. In response to stimuli from 
central nervous system (e.g. stress) the hypothalamus releases corticotropin releasing 
hormone (CRH), that stimulates pituitary gland to release adrenocorticotropic hormone 
(ACTH). ACTH in turn acts on the adrenal cortex causing the synthesis of cortisol, 
which is then released into the blood circulation. High levels of this glucocorticoid 
travel through the blood stream back to the hypothalamus and pituitary suppressing 
CRH and ACTH production (adapted and modified from Campos-Rodriguez et al., 2013). 
 
 
Arginine vasopressin (AVP) also exerts an important influence on ACTH secretion 
by augmenting the response to CRH (Goodman, 2003). It also appears that there is 
positive reciprocal interaction between CRH and AVP at the level of hypothalamus, 
with each neuropeptide stimulating the secretion of the other (Bernardini et al., 
1994). The most important function of AVP in the human organism is however 
inhibition of diuresis and thus, regulation of body’s water retention (Schrier & 
Abraham, 2007).   
Thus, as it has been described, cortisol acts in negative feedback loop on the HPA 
axis (McVicar et al., 2007), which is one of the primary biological pathways linking 
61 
 
psychological factors and the immune system (Kirschbaum & Hellhammer, 1994). 
Cortisol suppression of CRH and ACTH prevents overproduction of cortisol. 
Breakdown of this feedback system leads to severe problems due to uncontrolled 
production this major glucocorticoid (Aron et al., 2007). 
 
1.1.6.5. Metabolism and excretion of cortisol 
 
The primary site of cortisol metabolism is liver, whereas kidneys are the main site of 
the excretion of this glucocorticoid. The main task of hepatic metabolism is to 
decrease the biologic activity of the hormone and to increase its water solubility 
through the conversion to hydrophilic form which can easily be excreted in the urine. 
Cortisol is bound in plasma with very high affinity. Approximately 5-10% is bound 
to albumin, and the majority is bound to CBG, that protects this hormone from 
degradation. CBG provides plasma storage of bound steroid, while the free fraction 
of cortisol passes freely across cell membranes to initiate hormone action by binding 
to the glucocorticoid receptor within the cytoplasm of the target cells (Murphy 2000; 
Sherwood, 2010). The binding to CBG is rapidly reversible, thus, cortisol may 
quickly be transferred from the bound to the free state. The free fraction of cortisol is 
in constant equilibrium with bound form. It has also been found that during 
inflammatory process and due to exposure to serine protease from granulocytes, 
CBG is cleaved and releases all or most of its bound steroid. This process enhances 
the delivery of cortisol to the sites of inflammation (Murphy 2000). The major 
metabolic reactions of cortisol include the irreversible reduction of C4-5 bond 
producing dihydrocortisol, which is metabolised to tetrahydrocortisol by the 
reduction of the C3 ketone group. Tetrahydrocortisol is further conjugated with 
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glucuronic acid or sulphuric acid that yields a highly water soluble form and can also 
undergo reduction to cortol (Brownie, 1992; Yadav, 2004) (Figure 1.10.). 
 
 
Figure 1.10. Major metabolic pathways for cortisol. Reduction of the double bond at C4 
produces urinary metabolites with both the 5β and 5α orientations (Loriaux, 2001). 
 
 
Another pathway of cortisol metabolism that can be distinguished includes the 
oxidation of hydroxyl group on carbon 11 of active cortisol to form inactive 
cortisone, that lowers the affinity for adrenal steroid hormone receptors. Cortisol 
differs from cortisone only by the presence of a hydroxyl group at carbon 17. 
Cortisone circulates in blood at about one-fifth the concentration of cortisol. Cortisol 
(hydrocortisone) can be converted to cortisone in mineralocorticoid target cells and 
cortisone can be reduced to cortisol in the liver and other glucocorticoid target cells. 
These reactions are carried out by the 11β-hydroxysteroid dehydrogenase system 
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(HSD I and HSD II) at extraadrenal sites. HSD I can catalyze the reaction in both 
directions, thus may activate or inactivate the hormone. HSD II catalyzes only the 
conversion of cortisol to cortisone (Figure 1.11.) (Goodman, 2003).    
 
 
Figure 1.11. The cortisol/cortisone shuttle. HSD I can catalyze the reaction in both 
directions, thus may activate or inactivate the hormone. HSD II catalyzes only the 
conversion of cortisol to cortisone (Goodman, 2003). 
 
Cortisone may be then metabolised following the same steps as in the cortisol 
metabolic pathway producing tetrahydrocortisone, cortolone and conjugated 
products of each (Figure 1.10). The half- life of cortisol is relatively long compared 
to other steroids and it equals 60 to 100 min (Loriaux, 2001). The majority of 
unconjugated cortisol that is filtered through the kidney is reabsorbed. Most of the 
cortisol which is excreted in urine is in the form of conjugates with sulphate and 
glucuronide. However, due to the fact that urinary free cortisol is derived from the 
unbound or bioactive cortisol by glomerular filtration, and its concentration increases 
rapidly as the binding capacity of CBG is exceeded, the urinary free cortisol levels 
directly reflects the bioactive plasma concentration (Brownie, 1992; Loriaux, 2001). 
As stated in the Section 1.1.5.4. liver pathologies can alter clearance rates of 
hormones (Lane & Moss, 1985; Viljoen et al., 1992). The reduced rate of hormonal 
metabolism has been reported in liver diseases (e.g. hepatitis, cirrhosis), what might 
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be related to a decrease in hepatic blood flow (Marshall & Bangert, 2008; 
McCornick, 2011). The changes in urinary excretion pattern may be subsequently 
observed. In addition, any failure in hormone metabolism results in a rise in blood 
hormone levels, what affects the balance between secretion rates of hormones and 
their utilisation. However, there is a feedback mechanism between plasma hormone 
levels and hormone secretion, what prevents any but temporary increase in 
circulating levels (McCornick, 2011). It has also been reported that there seems to be 
little difficulty in the hormonal conjugation process, even in the presence of 
hepatocellular disease. In addition, liver synthesises many plasma proteins including 
albumin and CBG (Murphy, 2000; Farkas & Farkas, 2009). Thus, liver dysfunction 
may result in reduced levels of these carrier proteins, which in turn may affect 
transport of cortisol and melatonin through the circulation and cause the increase of 
levels of free, biologically active fractions of these hormones (Farkas & Farkas, 
2009; Jones, 2013). 
 
1.1.6.6. Cortisol and sleep 
 
Wilhelm and others (2007) suggested that since the HPA axis is a vital part of the 
human stress response system, cortisol responses to psychological or physiological 
stimuli can superimpose the circadian rhythm. The central circadian clock, a function 
of the SCN of the hypothalamus, regulates awakening at the end of normal nocturnal 
sleep, and is also responsible for circadian regulation of pituitary and adrenal activity 
(Czeisler et al., 1980; Van Cauter & Turek, 1995). The human SCN has direct 
projections to PVN which secretes CRH. As it is well understood, CRH acts on 
anterior pituitary leading to release of ACTH, what results in secretion of cortisol by 
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the adrenal glands (Buijs et al., 2003). It has been reported that not only circadian 
rhythmicity in ACTH and cortisol secretion is closely associated with patterns of 
sleep and wakefulness, but also circulating ACTH and cortisol are at lowest levels 
during SWS and secretory activity is markedly enhanced during REM sleep (Born & 
Fehm, 1998). As it has been already described (Section 1.1.1.), the REM sleep 
occurs more often during late sleep. It has been hypothesised that the increase in 
cortisol and ACTH levels occurring during the final cycles of REM sleep may play a 
role in the process of spontaneous awakening (Follenius et al., 1985; Spath-
Schwalbe et al., 1991; Born et al., 1999). The studies of Born and colleagues (1989) 
have shown that cortisol infusion during sleep influences sleep patterns, by 
increasing the time spent in wakeful episodes during stage I sleep and decreasing 
time spent in REM sleep. Another evidence for a close association between the SCN 
influence on sleep/wake cycle and HPA activity is the cortisol awakening response, 
when the concentration of cortisol is rapidly increasing (Clow et al., 2010). As in the 
case of melatonin, there is a relationship between chronotype and the concentration 
of cortisol. Bailey and Heitkemper (1991) analysed early-morning cortisol in saliva 
of 20 healthy participants 23-39 years of age. Each participant collected seven saliva 
samples at 20-minutes intervals over the period of 2 h beginning with the wake up 
time. Cortisol levels were determined using radioimmunoassay (RIA) method. These 
studies demonstrated that morning-active individuals awaken early show more 
marked elevation of salivary free cortisol in the morning than evening-active 
individuals. It has also been reported that lower cortisol levels immediately after 
awakening were found to be related to poor sleep quality in patients with pr imary 
insomnia (Backhaus et al., 2004).  
 
66 
 
1.1.7. Clock genes 
 
Clock genes are transcriptional regulators underlying circadian rhythm generation at 
the cellular level (Franken & Dijk, 2009). The core feedback loop of these molecular 
oscillations contains positive and negative elements. The positive elements are basic 
helix- loop-helix transcription factors: CLOCK, BMAL1, NPAS2, which all contain 
PAS domains. BMAL1 can form active heterodimers either with CLOCK or NPAS2, 
that can enable the transcription of Cryptochrome (Cry) and Period (Per) genes. The 
translation outcome: Cry and Per suppresses CLOCK:BMAL1 and NPAS2:BMAL1 
dimers leading to the production of negative elements in the feedback loop (Franken 
& Dijk, 2009). As reported, the clock gene expression has been observed in saliva, 
skin samples and peripheral blood mononuclear cells (PBMCs) (James et al., 2007). 
Reinitiation of the cycle occurs when the proteins in the nucleus break down and the 
genes are released from inhibition to become active again. The whole cycle takes 
about 24 hours (Hastings, 1998). This molecular circadian cycle is not only active in 
SCN but it is expressed in most peripheral tissues. Previous examination 
demonstrates that light exposure affect the phase in SCN and also the functional 
activity of peripheral organs (Cailotto et al., 2009). Thus, in conclusion light can be 
considered as the most important synchronizer for the SCN which causes the 
changes in melatonin and cortisol secretion as well as in clock genes expression.  
Several studies suggest that human clock gene variants contribute to phenotypic 
differences observed in various behavioral and physiological processes and can have 
an impact on circadian rhythm (Albrecht, 2002; Viola et al., 2007; Lee et al., 2010; 
Franken, 2013; Zhang et al., 2013). Table 1.2. presents type of clock genes and their 
functions. Oster et al. (2006) have found clock gene expression in the adrenal cortex, 
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prefiguring a role of the clock in regulating glucocorticoid and mineralocorticoid 
biogenesis. The authors reported that in Per2/Cry1 double mutant mouse lacking a 
circadian clock, HPA axis regulating cortisol secretion was defective. In addition, it 
has been also reported that mutation in Per2 is responsible for familial advanced 
sleep phase syndrome (Toh et al., 2001; Ebisawa, 2007). Another investigation of 
clock gene mutation in mice have shown that sleep duration is reduced by 1-2 hrs in 
Clock mutant mice (Naylor et al., 2000). In addition it has been reported that the 
Per3 polymorphism correlates with diurnal preference. The longer allele was 
associated with diurnal preference for morning activity, while the shorter allele with 
evening diurnal preference (Archer et al., 2003). Moreover, the authors have shown 
that the shorter allele was strongly associated with the delayed sleep phase 
syndrome. 
It has also been reported that expression of clock genes (such as Per1, Cry1, Npas4) 
can be influenced by secretion of both, melatonin and cortisol (Yamamoto et al., 
2005; Imbesi et al., 2009; Mavroudis et al., 2012; Zeman & Herichová, 2013). 
Experiments in human PBMCs and fibroblasts established that glucocorticoids, after 
binding to glucocorticoid receptors, induce the expression of the clock gene Per1 
(Balsalobre, 2002; Burioka et al., 2005). In line with these findings Yamamoto et al., 
(2005) examined the expression of clock genes in response to corticosterone 
injection in mice and found the elevation of the expression of Per1 in peripheral 
organs. On the other hand, studies by Imbesi et al. (2009) indicated that melatonin 
receptor 1 is involved in the regulatory action of melatonin on neurona l clock gene 
expression. Von Gall et al. (2006) reported that in the pars tuberalis (part of anterior 
lobe of the pituitary gland) of the melatonin receptor 1 knock-out mouse, the 
expression of Per1, Cry1, Clock and Bmal1 was dramatically reduced. Thus, 
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melatonin receptor 1 may control clock gene expression and in turn generation of 
circadian rhythm. 
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Gene  Organism Characteristics of protein product Clock function 
Input genes 
Cry D. melanogaster Similar to DNA photolyases Conveys photic information to PER-TIM 
Per1, Per2 Mammals PAS domain Induced by light in the SCN, Per1 important for photic entrainment 
OPT4 Mammals Melanopsin Photoreceptor, mediates light input signals to the SCN oscillator  
Pdfr D. melanogaster G protein-coupled receptor Neuronal clock synchroniser in the brain 
VIP Mammals Neuropeptide  Neuronal clock synchroniser in the SCN 
VIPR2 Mammals G protein-coupled receptor Neuronal clock synchroniser in the SCN 
Nocte D. melanogaster Large glutamine-rich protein Temperature synchroniser of behavioural activity  
ID2 Mammals 
bHLH-containing transcriptional 
repressor 
Regulates photic entrainment 
DEXRAS1 Mammals RAS-like G protein Potentiates photic and supresses non-photic entrainment 
cGKII Mammals cGMP-dependent protein kinase II Mediates light entrainment by regulating Per1 and Per2 expression 
GR Mammals Glucocorticoid receptor Resets circadian phase in peripheral tissues 
Pacemakers 
Clock 
Mammals, birds, 
fish, amphibians 
bHLH-PAS factor 
Dimerises with Bmal1 and activates clock and clock-controlled gene 
expression 
 
Per 
Mammals (3genes), 
fish, insects 
PAS domain 
Negatively regulates CLOCK-BMAL1-driven transcription, positively 
regulates Bmal (mammals) or Clock  (Drosophila) expression 
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Tim 
Mammals, fish,  
D. melanogaster 
 
In Drosophila dimerises with PER to express CLOCK- BMAL1-driven 
transcription and activate clock expression 
Bmal1 
Mammals, fish,  
D. melanogaster 
bHLH-PAS factor 
Dimerises with CLOCK and activates CLOCK and CLOCK controlled 
gene expression  
Cry 
Mammals,  
D. melanogaster 
Similar to DNA photolyases 
In Drosophila, binds TIM and inhibits PER-TIM dimer. In mammals, 
negatively regulates CLOCK-BMAL1-driven transcription; 
translocates PER to the nucleus 
Npas2 Mammals 
bHLH-PAS domain containing 
transcription factor 
Paralogue of CLOCK, dimerises with BMAL1 
Dec1, Dec2 Mammals bHLH-containing transcription factor Repress CLOCK-BMAL1-mediated transcription 
Output genes 
Pdf D. melanogaster Neuropeptide Links the molecular clock to behaviour 
Avp Mammals Vasopressin peptide Controls the activity of various output pathways 
Takeout D. melanogaster Similarity to ligand-binding proteins Involved in output pathways that link the clock to feeding 
TGFA Mammals Cytokine Regulates cell proliferation 
EGFR Mammals Receptor Tyr kinase Regulates cell proliferation 
gprk2 D. melanogaster G protein-couples receptor kinase Regulates clock-dependent rhythmic olfactory responses 
  
Table 1.2. The most important clock genes in animal and fungi, their protein products and function (adapted and modified from Cermakian 
& Sassone-Corsi, 2000 and Zhand & Kay, 2008). Abbreviations: bHLH- basic helix- loop-helix, SCN- suprachiasmatic nucleus.
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1.1.8. Measurements of endocrine markers of sleep in children 
 
Sleep architecture and/or patterns have been widely studied both in adults and 
children using such methods as questionnaires, actigraphy and polysomnography 
(PSG) measurements (see Section 1.2.1) (Owens et al., 2000b; Sadeh & Acebo, 
2002; Wiggs et al., 2005). However, thus far, very few studies analysed endocrine 
sleep markers such as cortisol and melatonin and none of them included individuals 
with WS. Salti and others (2000) analysed nocturnal pattern of melatonin in blood of 
16 healthy school-aged children (8 boys and 8 girls; 8.7 to 16.8 years of age) using 
RIA. Samples were collected in 30-minutes intervals between 7 pm and 7 am at the 
research ward. The results of these studies demonstrated significant circadian 
rhythmicity of melatonin with peak at approximately 2.30 am. In another study, 
Kohyama (2002) examined melatonin levels in saliva (n = 42) and urine (n = 14) of 
healthy 3-year old children, collected in the morning just after awakening. The aim 
of this study was to analyse the relationship between the nocturnal sleep habits and 
the melatonin levels in youngsters. The authors hypothesised that children who fall 
into sleep late in the night receive higher amounts of light, than those who fall into 
sleep early in the night, what may suppress melatonin secretion. In this study, the 
potential negative physiological consequence of light exposure at night time during 
early stage of life was confirmed by finding lower melatonin levels in late sleepers.  
Melatonin levels in saliva appeared to be significantly higher in children with sleep 
onset times of earlier than 10 pm (6.3 pg/ml) than in the samples of children with 
later sleep onset times (4.8 pg/ml). Respectively, the average urinary concentration 
of melatonin metabolite, was higher in samples with earlier sleep onset times 
(255.0ng/mg creatinine), than with later sleep onset (178.5 ng/mg creatinine). Both 
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of these studies included samples collected from healthy children. It has been 
reported that the morning levels of melatonin in plasma range between 0-20 pg/ml in 
children and adolescents (1-11 years of age) (Waldhauser et al. 1984), however, it 
has also been shown that melatonin reaches highest nocturnal levels between 1 to 3 
years of age (Waldhauser et al., 1993). 
 
Several studies examined sleep problems and altered circadian rhythms in children 
with ASD as well as other developmental disabilities, such as DS, ADHD and 
Smith-Magenis syndrome (Potocki et al., 2000; Corkum et al., 2001; Tordjman et  
al., 2005; Corbett et al., 2006; Cotton & Richdale, 2006; Mayes & Calhoun, 2009). 
For example Tordjman and colleagues (2005) analysed nocturnal urinary excretion 
of MT6s by RIA in groups of children and adolescents with ASD (n = 49) and 
healthy control individuals, age and gender matched (n = 88). The findings of this 
study clearly indicate that nocturnal production of melatonin was significantly 
reduced in children with ASD and also significantly negatively correlated with 
severity of autism. Another study examining difference in melatonin levels were 
based on measurements of salivary melatonin in children with enuresis (n = 14) 
compared to healthy controls (n = 11). Saliva samples were collected in 4-hr 
intervals from 8 am to 4 am the next day and analysed using a commercial RIA. The 
highest reported values were always detected at 4 am, however, there were no 
significant difference overall in melatonin levels between children with enuresis and 
controls (Ardura-Fernandez et al., 2007). Levels of melatonin has been analysed in 
other neurodevelopmental disabilities as well. Potocki and others (2000) measured 
MT6s in urine of 28 patients with Smith-Magenis syndrome. All but one patient 
demonstrated inverted circadian rhythm of this metabolite. The Smith-Magenis 
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syndrome is caused by an interstitial deletion of chromosome 17p11.2. It is 
characterised as a multisystem disorder with distinctive craniofacial appearance 
(deep-set eyes, square jaw, full and everted upper lip) as well as complex pattern of 
physical, developmental, and behavioral features including speech delay, high 
prevalence of individuals with hearing loss, learning difficulties, short statue, but 
also sleep disturbances, such as daytime sleepiness, difficulty falling asleep at night 
and nocturnal awakening (Smith et al., 1998; Smith & Gropman, 2005).  
 
Unlike melatonin, cortisol has not been studied as a sleep marker in children with 
developmental disabilities caused by various genetic disorders, such as WS or DS. 
However, there are studies examining this hormone in healthy children and children 
with autism. Kiess and colleagues (1995) examined salivary cortisol levels in 
samples from 138 healthy infants, children and adolescents, as well as 14 adults. 
Saliva samples were collected at home using cotton swabs at 8 am, 1 pm, and 6 pm 
before meals. Cortisol was measured using fluorescent immunoassay. The aim of 
this study was to examine the relationship between cortisol levels and age, pubertal 
stage, weight and gender. No sex difference was found, however, after the age of 6 
years old, cortisol levels correlated positively with pubertal stages regardless of 
sampling time (morning, midday, evening). These findings were not however 
confirmed by other studies, reporting that cortisol levels were relatively stable across 
pubertal maturation (Matchock et al., 2007) and no correlation between age (2-18 
years old) and cortisol was found (Knutsson et al., 2007). Several studies reported 
decrease in sleep time during adolescence (Karacan et al., 1975; Carskadon, 1990; 
Iglowstein et al., 2003), however, there is no evidence of association between 
cortisol and sleep time through puberty. The relationship between age and cortisol 
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levels was also studied by Price and others  (1983). The focus of this study was to 
determine the age of appearance of circadian rhythmicity of cortisol. The group of 
participants consisted of 8 healthy infants. Their saliva was collected by mothers (4 
samples in 24 h time) at monthly intervals for the first 6 months of life and analysed 
by RIA. This study concluded that circadian rhythmicity of cortisol appeared by the 
age of 3 months (Price et al., 1983). One of the studies examining circadian rhythms 
of cortisol secretion in children with autism was performed by Corbett and 
colleagues (2006). Saliva samples were collected from boys aged 6 to 11 with (n = 
12) and without autism (n = 10) in the afternoon, evening and morning and assayed 
using RIA. In this study, both groups showed circadian variation of cortisol, 
however, children with autism demonstrated statistically significant elevations of 
cortisol levels following exposure to novel, non-social stimulus. Another study, by 
Richdale and Prior (1992) investigated the basal urinary cortisol rhythm in a group 
of high-functioning children with autism (4-14 years of age) and matched controls. 
All participants were asked to collect 7 samples during the day, however, when the 
participant provided a urine sample during the night, it was included within morning 
sample. Urinary cortisol was analysed using a standard RIA kit. The circadian 
rhythm of cortisol in children with autism was normal, however, the tendency 
towards cortisol hypersecretion in this group was observed. This tendency may 
indicate an environmental stress response in children with autism. To date, there are 
no studies investigating cortisol as possible factor for sleep disorders in children, 
neither has this hormone been studied in genetic disorders. Cortisol plays a 
significant role in our circadian rhythm and sleep/wake cycle, therefore it is 
necessary to examine closely this endocrine marker in individuals with sleep 
problems. 
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1.2. Analyses of sleep and circadian rhythm 
 
1.2.1. Methods of sleep analyses  
 
There are several methods of analysing sleep properties. These include pulse 
oximetry, actigraphy and questionnaires, which are used in current studies as well as 
PSG.  
 
1.2.1.1. Polysomnography (PSG) 
 
PSG is a gold standard multi-parametric study of sleep consisting of continuous 
nocturnal monitoring of electrencephalogram (EEG), electro-oculogram (EOG), 
electromyogram (EMG), electrocardiogram (ECG), nasal/oral airflow by 
capnography and pressure transduction, end-tidal CO2 trend by capnometry, chest 
and abdominal wall respiratory movement by piezocrystal belts, body position, 
sonography measuring upper respiratory tract sound, finger plethysomnography 
measuring pulse volume and pulse oximetry. After the test is completed, the records 
are scored and evaluated in usually 20 to 30-seconds epochs (Sheldon, 2005c; Snasel 
et al., 2011). The weak points of this method are that it is expensive and labour-
intensive and the measurement needs to be undertaken in an unfamiliar environment, 
which is a sleep laboratory (Portier et al., 2000). It usually requires two nights stay, 
as the first night is necessary for acclimatisation (Kingshott & Douglas, 2000).  
Electroencephalogram (electro- electrical, encephalon- brain, gram- record) is the 
recording of the electrical activity of the brain measured by conductors attached to 
the scalp (Webb, 1975; Niedermeyer & da Silva, 2004). The EEG machine amplifies 
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the small electrical potential changes and converts them to a mechanical write-out on 
continuously running paper belt. The EEG measurement of sleeping person allow to 
differentiate particular stages of sleep (Figure 1.12.) (Rosenzweig et al., 2005). The 
main diagnostic applications of EEG are epilepsy, coma, encephalopathies and brain 
death (Niedermeyer & da Silva, 2004). 
 
Figure 1.12. EEG pattern of different stages of human sleep. Awake: low voltage, fast 
alpha and beta activity. Stage 1: 4-7 Hz theta activity. Stage 2: 11-15 Hz sleep spindles and 
K complexes. Stage 3 and 4: High voltage delta activity. REM: low voltage fast theta 
activity similar to the awake state (Horne, 1988). 
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Electro-oculography and electromyography usually supplement the EEG recording  
of the brain. EOG is the recording of eye movements and EMG is the recording of 
electrical activity of the muscle (muscle tension). In order to get the EMG recording, 
electrodes are placed on the skin over a muscle. For the PSG measurements, EMG 
electrodes are placed on the chin and left and right anterior tibial muscle. These 
positions allow researchers to study different sleep disorders, such as bruxism, REM 
sleep behaviour disorder, which may present with unusual muscle activity, that can 
be recorded by EMG measured on the chin (Rosenzweig et al., 2005; Sheldon, 
2005c). The EOG recording can provide important information in regard to 
differentiation between particular stages of sleep, especially REM sleep. The 
electrodes are placed at the outer canthus of each eye (Sheldon, 2005c). 
ECG is a measurement of patient’s cardiac activity including heart rate and rhythm. 
Heart rate change through the sleep stages, declining from stage 1 to stage 4 NREM 
and increasing in REM sleep, however the general heart rate in sleep is about 4-8 
beats per minute slower than during quiet wakefulness (Willis et al., 1990). The 
polysomnographic measurements use the lead II ECG, which continuous recordings 
are assessed for rhythm, rate and abnormalities that may be associated with central or 
obstructive respiratory problems (Sheldon, 2005c). 
 
1.2.1.2. Actigraphy  
 
Actigraph is a computerised wristwatch-like device that monitors a persons’ activity. 
This method can be used for sleep-wake identification, as well as calculating the 
sleep efficiency, sleep latency, fragmentation index, immobile and mobile minutes 
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during sleep. The actigraphs (actiwatches) have an analogue system detecting 
movement in two or three axis by piezoelectric beam. The detected movements are 
further translated into digital counts accumulated across certain intervals (e.g. 1 
minute). The actigraphs have an internal memory and can record data continuously 
over certain period of time (e.g. 1 week) (Sadeh & Acebo, 2002; Sazonov et al., 
2004). Computer software, used to read the data from actigraphs, can calculate levels 
of activity/inactivity, and sleep/wake parameters (such as total sleep time, percentage 
of time spent asleep, number of awakenings) (Ancoli-Israel et al., 2003). The 
actigraphy has been validated against PSG and it proved total sleep time, sleep 
efficiency and the number of awakenings to be in line with PSG both in adults and 
children (85 to 90% agreement between the two methods) (Corkum et al., 2001; 
Kushida et al., 2001; Gay et al., 2004). Several other studies reported that wrist 
actigraphy can successfully differentiate between sleep and wake state, and monitor 
circadian sleep/wake disturbances (Broughton et al., 1996), however, based on this 
method, one cannot characterise clinical sleep disorders nor sleep stages (Thorpy et  
al., 1995). Also, actigraphy may not always be appropriate for certain groups, for 
example insomniac patients who may be awake but remain still for long periods of 
time. American Academy of Sleep Medicine Standards of Practice Committee 
developed guidelines on the clinical use of this technology. One of these guidelines 
indicate that actigraphy is particularly useful in studying infants and children, as well 
as in special paediatric population as PSG can be difficult to perform and/or interpret 
(Morgenthaler et al., 2007). Actigraphy also demonstrates high accuracy, simplicity 
of use and low intrusiveness (Sazonov et al., 2004). 
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1.2.1.3. Pulse oximetry 
 
Pulse oximetry is non-invasive method monitoring the pulse rate and arterial oxygen 
saturation. The pulse oximetry sensor consisting of light source and a detector is 
placed on the both sides of any pulsating arterial vascular bed, such as earlobe, 
finger, toe or in the younger infants on the foot. The pulse oximetry method is based 
on the difference of the light absorbance between reduced and oxygenated 
haemoglobin, and the pulsating blood between the source and the detector (Tremper 
& Barker, 1989). Thus, the pulse of the vessel and the oxygen saturation of the 
arterial haemoglobin cause the changes of the light path length that modifies the 
amount of light detected. Pulse oximeter calculates the arterial haemoglobin oxygen 
saturation with no interference from surrounding venous blood, skin, connective 
tissue or bone (Yelderman & New, 1983; Sheldon, 2005c). Pulse oximeters are 
increasingly used for the evaluation of SDB (Netzer et al., 2001). These monitors are 
easy to use in a home environment and provide accurate information on oxygen 
levels (Urschitz, 2003).   
 
1.2.1.4. Questionnaires 
 
The use of questionnaires is an efficient and cost-effective method for gathering a 
large amount of data. In the developmental literature a widely used questionnaire is 
the Children’s Sleep Habits Questionnaire (CSHQ; Owens et al., 2000a), a 33- item 
parent-report questionnaire covering the major clinical symptoms of childhood sleep 
problems. Its scores can consistently differentiate between children with sleep 
disorders and children without, though it has not yet been quantified for atypical 
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populations, such as children with developmental disorders. Although the CSHQ 
provides an excellent measure for assessing sleep, parent reporting is not always 
entirely accurate as parents are not always aware of their children’s sleep problems. 
Large inconsistencies have been found between sleep diaries, questionnaires and 
actigraphy data. Generally, parents are able to be relatively accurate when reporting 
bedtime, wake time and assumed sleep time, but their reports are less consistent than 
actigraphy when recording actual sleep time, night wakings and sleep quality, 
especially if the child does not cry out for parental attention when they wake during 
the night. However, questionnaires are usually used as a first step to characterize 
sleep patterns in a child. Therefore it is recommended that objective methods such as 
PSG or actigraphy ought to be used in conjunction with parent reports to gain 
reliable information about children’s sleep (Sadeh et al., 2000; Corkum et al. 2001; 
Shott et al., 2006; Werner et al. 2008; Holley et al., 2010).  
 
1.2.2. Laboratory measurements of endocrine markers of sleep 
 
Several bioanalytical methods for determination of melatonin, cortisol and their 
metabolites have been reported using various laboratory techniques. The most 
common methods used for analysis of these hormones in children as well as for 
research studies on sleep disorders are radio- and enzyme based immunoassays using 
saliva, plasma and urine as matrices (Table 1.3.) (Salti et al., 2000; Van Cauter et al., 
2000; Kunz et al., 2004; Corbett et al., 2006). More recently, however, these methods 
are being replaced by more sensitive and faster liquid chromatography - mass 
spectrometry (LC-MS) based methods (Taylor et al., 2002; Eriksson et al., 2003; Barrett 
et al., 2005; Jensen et al., 2011). General clinical analysis of melatonin and cortisol are 
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mostly based on the use of immunoassay based methods, mainly because of the 
convenience and limited number of clinical laboratories with liquid chromatography 
tandem mass spectrometry (LC-MS/MS) equipment (Inder et al., 2012).  
 
Hormone Type of analysis Medium Method References 
M
e
la
to
n
in
 
Research studies 
on sleep disorders 
Saliva RIA 
Ardura-Fernandez et al., 
2007 
Urine 
RIA 
Tordjman et al., 2005; 
Potocki et al., 2000 
ELISA Kunz et al., 2004 
Analysis in 
children 
Plasma RIA Salti et al., 2000 
Saliva RIA Kohyama et al., 2002 
Urine ELISA Lee et al., 2012 
Methods 
publications 
Plasma  LC-MS Hartter et al., 2001 
Saliva 
HPLC-FLD Romsing et al., 2006 
LC-MS/MS 
Eriksson et al., 2003; 
Jensen et al., 2011 
Urine HPLC-FLD Minami et al., 2008 
C
o
rt
is
o
l 
Research studies 
on sleep disorders 
Plasma RIA Van Cauter et al., 2000 
Urine  RIA  Prinz et al., 2000 
Analysis in 
children 
Saliva 
FIA Kiess et al., 1995  
RIA 
Price et al., 1983; 
Corbett et al., 2006 
ELISA Shimada et al., 1995 
Urine RIA Richdale & Prior, 1992 
Methods 
publications 
Saliva  LC-MS/MS Jensen et al., 2011 
Urine LC-MS/MS 
Machacek et al., 2001; 
Nassar et al., 2001; 
Taylor et al., 2002; 
Barrett et al., 2005 
 
Table 1.3. The most common method of analysis of melatonin and cortisol used 
in the research studies on sleep disorders, the analysis in children as well as 
method development publications. It can be seen that immunoassay based methods 
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are the main methods used in research and analysis of melatonin and cortisol in 
children in plasma, saliva and urine. More recently, however, the number of 
publication regarding new methods using liquid chromatography and/or mass 
spectrometry based methods is increasing. Abbreviations: ELISA- enzyme- linked 
immunosorbent assay, HPLC-FLD- high performance liquid chromatography-  
fluorescence detection, LC-MS- liquid chromatography- mass spectrometry, LC-
MS/MS- liquid chromatography tandem mass spectrometry, RIA- 
radioimmunoassay. 
 
Radio- and enzyme based immunoassays are widely used for the determination of 
these compounds in plasma, saliva and urine (Zhiri et al., 1986; Chegini et al., 1995; 
Kovács et al., 2000; Jerjes et al., 2006; Lee et al., 2012). Both approaches are based 
on the formation of antigen-antibody complex. The immunoassay techniques are 
divided into competitive and non-competitive. In competitive assays the microtiter 
plate is coated with a known amount of antibody. The antigen in the sample (e.g.  
melatonin) competes with the labelled antigen for a fixed number of antibody 
binding sites. Enzymes (enzyme immunoassays) or radioisotopes (RIAs) can be used 
as labels (Estridge et al., 2000). The most common isotopes used for RIA analysis 
are 125I, 3H and 57Co (Nuclear Energy Agency, 2004). Non-competitive 
immunoassays may be used to detect the presence of either antigen or antibody in a 
sample. In this type of assays, labelled antibody and antigen interact without 
deliberate introduction of competing molecules (Stanley, 2002). In enzyme based 
immunoassays an enzyme catalyses colourimetric reaction after adding the substrate. 
In RIA, the signal of radioactivity is measured (Moore, 2002). Intensity of 
colour/radioactivity is inversely (competitive assay) or directly (non-competitive 
assay) proportional to the amount of antigen in the sample (Elgert, 2009; Iles & 
Roitt, 2012).  
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Although RIA is a very sensitive method (detection limit of 10-9 to 10-12 mol/L) 
(Wybranska et al., 2002; Saha, 2010), it is tedious, requires book-keeping and the 
use of radioactive isotopes is potentially hazardous and produces radioactive waste 
(Elgert, 2009). Another disadvantage of RIA is a short shelf life (Mahlen, 1998). To 
overcome these drawbacks, it has been replaced by enzyme linked immunosorbent 
assay (ELISA) in many clinical and basic science laboratories (Elgert, 2009). 
Theoretically sensitivity of ELISA is around 10-14 mol/L which meets the sensitivity 
requirement for many clinical analyses (Diamandis et al., 1996; Moore, 2002). 
Another advantage of enzyme immunoassays over RIA is that the enzyme 
preparations are stable with long shelf life and they represent a minimal hazard to 
laboratory staff (Moore, 2002).  
Despite the wide use of immunoassays, there are a number of limitations of these 
methods; (i) lack of an internal standard to monitor routine variation in the response 
of the measuring system/analyte; (ii) a limited number of samples can be analysed at 
a time; and  (iii) antibody cross-reactivity with other structurally similar compounds 
that may be present in the sample (Nahoul et al., 1982).  
Other analytical techniques used for analysis of melatonin and cortisol are based on 
chromatographic methods. These include high performance- liquid chromatography 
(HPLC) with fluorescence detection (Romsing et al., 2006) or ultra violet (UV) 
detection (Taylor et al., 2002), gas chromatography-mass spectrometry (GC-MS) 
(Nùñez-Vergara et al., 2001) and LC-MS/MS (Machacek et al., 2001; Nassar et al., 
2001; Eriksson et al., 2003; Barrett et al., 2005). It has been reported that 
chromatographic methods provide a means of separating cortisol from any 
interferents in the matrix and allow quantification of cortisone (Taylor et al., 2002). 
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It has also been shown that LC-MS/MS offer better specificity and accuracy than 
immunoassay based methods (Tiosano et al., 2003). 
Gas chromatography (GC) is an analytical technique used for the separation of 
volatile mixtures. Gas chromatographs consist of a gaseous mobile phase, an 
injection port, a separation column containing the stationary phase, a detector and a 
data recording system. Samples are vaporised and injected onto the head of the 
chromatographic column. The inert flowing mobile phase transports the sample to 
the column (Prasad, 2010). The compounds are separated due to differences in their 
partitioning behaviour between the mobile gas phase and the stationary phase in the 
column (Sheehan, 2009). In GC-MS, the mass spectrometer acts as a detector for the 
gas chromatograph. Mass spectrometry (MS) is one of the most sensitive detection 
technique of molecular analysis (Vogeser & Seger, 2008; Loos et al., 2011) and will 
be described on the next page.  
There are some disadvantages to using GC. It is limited to separation of volatile 
samples and not suitable for thermally labile samples. It is also fairly difficult to 
utilise for preparative purposes and requires elaborate instrumentation, such as a 
mass spectrometer to confirm identity of an analyte peak (McNair & Miller, 1997). 
Liquid chromatography (LC) is another technique that is used for separation of range 
of molecules, it utilises high pressure for pumping liquids through columns packed 
with a stationary phase (Ahuja, 2003). An HPLC system consists of solvent 
reservoirs to hold the LC solvents necessary for continuous operation of the system; 
the pumps providing constant flow of the mobile phase through the system and 
allowing controlled mixing of different solvents from different solvent reservoirs. An 
injector is used to introduce an aliquot of a sample into the stream of mobile phase 
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prior to its entering the column (Sherwood, 2005; Kazakevich & LoBrutto, 2007). 
Separation is carried out using the LC column which comprises of a narrow stainless 
steel tube packed with fine, chemically modified silica or polymer based particles 
(Niessen, 2006). Compounds are separated on the basis of their relative interaction 
with the chemical coating on these particles and the solvent/mobile phase eluting 
through the column. In the next step, analytes are ionised. The two most common 
ionisation interfaces that are used for LC-MS are the atmospheric pressure chemical 
ionisation (APCI) and electrospray ionisation (ESI) interfaces. In ESI interface, the 
eluent from the LC column is forced through a narrow capillary that has a high 
potential applied to it. This results in the generation of a very fine mist of charged 
droplets carrying ions surrounded by solvent molecules. Further, as the droplets 
move towards the entrance of mass analyser, the solvent evaporates and the charge 
concentration results in the droplets dividing into even finer droplets. The 
evaporation process occurs due to the presence of a nebulising gas, usually nitrogen 
and the interface being heated to temperatures of 200ºC or more. The process results 
in formation of isolated gas-phase ions (Niessen, 2006; Hacker et al., 2009). APCI is 
also based on ionising sample at atmospheric pressure. However, this mode of 
ionisation is used for non-polar compounds that have some volatility (Loos et al., 
2011). Once the eluent stream is desolvated and gas phase ions have been formed, 
the beam of ions is introduced into the mass analyser. The basic function of a mass 
analyser is to measure the mass to charge ratio (m/z) of ions and this provides means 
of separating the ions. There are several types of mass analysers that can be used 
which include magnetic sector, quadrupole, ion trap, time-of- flight and fourier 
transform ion cyclotron resonance instruments (Kazakevich & LoBrutto, 2007). The 
quadrupole mass spectrometer was previously used for analysis of cortisol and 
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melatonin (Taylor & Singh, 2002; Kushnir et al., 2003; Eriksson et al., 2003; Jensen 
et al., 2011). This type of mass analyser consists of four cylindrical or parabolicaly 
shaped rods in a parallel configuration (Figure 1.13.). Both positive and negative 
electric fields are applied to the rods and adjusted by a current voltage such that only 
the ion of given corresponding frequency (resonant ion) can successfully pass down 
the axis between the rods and reach the detector. This frequency is related to the m/z 
ratio of the ion; hence its measurement gives the molecular weight. Other ions have 
unstable trajectories and collide with the rods (Hacker et al., 2009; Loos et al., 
2011).  
 
Figure 1.13. The mass analyser of the mass spectrometer (http://www.chm.bris.ac.uk/). 
 
LC-MS/MS is the HPLC system coupled with MS detector. It is an analytical 
technique that combines separation of compounds using chromatography with mass 
analysis of a mass spectrometer. The liquid chromatography component is used to 
physically separate compounds and the mass spectrometer is used to detect the 
compounds on the basis of their m/z ratio. Tandem MS (MS/MS) as opposed to 
single-stage MS involves at least two stages of mass analysis. In the most common 
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MS/MS systems a first analyser is used to isolate a precursor ion, which then 
undergoes fragmentation to product ions measured by second mass spectrometer (de 
Hoffmann & Stroobant, 2007). Thus, the specificity and sensitivity is significantly 
improved (March & Todd, 2005). MS/MS analysis also offer enhanced speed in 
comparison to a single quadrupole instruments. There are several advantages to 
using this technique over GC-MS and LC-MS assays; (i) the sample preparation time 
is lower, which increases the speed of analysis; (ii) it enables direct screening of a 
complex mixture for a specific target compound; and (iii) it provides the highest 
degree of certainty in analyte identification (Bart, 2005). The sensitivity of MS/MS 
is typically in the sub-pg range (Bart, 2005). 
Although MS is the most sensitive detection technique, several other detectors, such 
as, fluorescence and UV detectors may be used. Maximum sensitivity reached by 
fluorescence detection is 10-9 to 10-11 mg/ml, while by the UV detectors 
approximately 10-8 to 10-9 mg/ml (Kazakevich & LoBrutto, 2007). The drawback of 
fluorescence detection technique is that it requires compounds to have native 
fluorescence or to be chemically modified to induce fluorescence. Also, its response 
is only linear over small concentration range, usually two orders of magnitude 
(Sherwood, 2005). On the other hand, UV detectors can be only used for the 
compounds that absorb in the UV range of wavelengths of interest (Scott, 1977).  
HPLC offers a number of advantages over GC. One of them is that polar compounds 
such as drug metabolites can be analysed directly (Kwong, 2002). Also, the majority 
of difficult separations are often more readily achieved using HPLC. There are 
several reasons for this. In HPLC systems, both phases participate in 
chromatographic separation process. This separation is achieved by the particular 
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interactions between sample molecules and the stationary and mobile phase(s), thus 
more selective interactions are possible with the sample molecule. This provides an 
additional variable for regulating and improving separation. As GC system consists 
of only one phase (flowing gas), these interactions are absent. Also, in HPLC, a wide 
range of selectivity is provided by a large variety of unique column packings 
(stationary phases). Another advantage of HPLC is the lower temperature used in 
this separation technique, what increases the effectiveness of intermolecular 
interaction and in turn improves chromatographic separation (Ahuja, 2003). 
It has been reported that methods based on LC- UV detection for the measurement of 
urinary free cortisol and cortisone, requires an analysis time longer than 20 min in 
order to obtain good resolution of these analytes from interferents (Taylor et al., 
2002). The use of liquid chromatography- tandem mass spectrometry (LC-MS/MS) 
has overcome these limitations (Machacek et al., 2001; Nassar et al., 2001).  
The latest separation technology is ultra-high performance liquid chromatography 
(UHPLC), however, to date it has not been used for the analysis of melatonin and 
cortisol. UHPLC retains the practicality and principles of HPLC, while increasing 
the attributes of speed, sensitivity and resolution (Swartz, 2005; Prathap et al., 2013). 
It is using reversed phase columns with smaller particles and/or higher flow rates for 
increased speed with superior peak resolution and sensitivity. Due to hardware 
adjustments it is also possible to work at extreme pressures (approximately 12,000 
psi) that gives marked improvement of chromatographic performance for complex 
mixture separation (Lindon, 2007; Hyotylainen & Kivilompolo, 2011). Compared to 
HPLC system, UHPLC gives more than doubling of peak capacity. Also,  almost 10-
fold increase in speed, as well as 3- to 5-fold increase in sensitivity can be obtained 
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in comparison with a conventional stationary phase depending on the detection 
technique (Swartz, 2005; Lindon, 2007). MS detection is significantly enhanced by 
UHPLC, as the increased peak concentrations with reduced chromatographic 
dispersion at lower flow rates promotes increased source ionization efficiencies 
(reduced ion suppression) (Swartz, 2005; Lindon, 2007).   
 
1.3. Williams syndrome (WS) 
 
WS was first described in the early 1960s, by Williams and colleagues (1961) who 
reported the case of four patients having the same clinical symptoms: supravalvular 
aortic stenosis (SVAS), mental “subnormality” and unusual facial features. Shortly 
after, Beuren and others (1962) reported the syndrome independently including 
dental anomalies, peripheral pulmonary aortic stenosis and a friendly personality. As 
a result, this condition is called Williams syndrome or Williams-Beuren syndrome. 
 
WS is an autosomal dominant genetic disorder caused by a microdeletion of 28 
genes (Shubert, 2009) on chromosome 7q11.23 including the ELASTIN gene (ELN) 
(Chen, 2006; Ewart et al., 1993). This ssyndrome affects boys and girls equally 
(American Academy Of Pediatrics, 2001) and occurs at approximately 1 in 7500 to 1 
in 20000 live births in the UK and worldwide (Tassabehji et al., 1999; Stromme et  
al., 2002).  
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1.3.1. Clinical symptoms 
 
Individuals with WS have characteristic “elfin” facial appearance, which can be 
easily recognised by an experienced observer due to their distinctiveness (Figure 
1.14.) (Semel & Rosner, 2003; Smoot et al., 2005; Morris, 2006). The extent of 
dysmorphology varies over the time in the same individual as well as among 
different individuals (Burn, 1986; Morris et al., 1988).  Characteristic facial features 
include: flat facial profile, broad forehead, prominent eyes, full cheeks, macrostomia 
(wide mouth), small jaw/small chin, short-upturned nose with full nasal tips, flat 
bridge of the nose, large ears, full lips, epicanthal folds, bitemporal narrowness and 
periorbital fullness. Distinctive features include as well malocclusion, small widely 
spaced teeth, long philtrum, malar hypoplasia, strabismus and stellate or lacy irides 
among blue-eyed individuals (Semel & Rosner, 2003; Smoot et al., 2005; Morris, 
2006).   
 
Figure 1.14. Characteristic facial features in WS (Semel & Rosner, 2003; 
http://dailypostal.com/2010/04/13/williams-syndrome-removes-racial-bias/). 
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WS has been described as a multisystem disorder with leading cardiovascular 
problems. The most common and the most significant clinically is SVAS, which 
may be present in isolation or in conjunction with other vascular stenoses and it 
occurs in approximately 75% of individuals (Morris, 2006; Ergul et al., 2012). 
SVAS causes narrowing of the aorta and is a result of the deletion of one copy of 
ELN (haploinsufficiency for ELN) (Smoot et al., 2005). This pathology often forms 
the basis for the diagnosis of WS particularly in infancy when other signs may be 
lacking (Smoot et al., 2005). Other common cardiovascular findings are peripheral 
pulmonic stenosis, which occurs mostly in infancy (Morris, 2006) and hypertension 
affecting approximately 50% of individuals (Zalzstein et al., 1991; Wessel et al., 
1997; Eronen, 2002). There is a likelihood that mild to moderate pulmonary stenoses 
can improve spontaneously with time, but the reason for that is not known (Giddins 
et al., 1989). It is reported that approximately 22% of all individuals with WS 
require surgical intervention due to cardiovascular lesions (Smoot et al., 2005). 
Connective tissue abnormalities lead to several symptoms observed in the 
individuals with WS, such as: hoarse, low-pitched voice, inguinal/umbilical hernia, 
bowel/bladder diverticulae, rectal prolapse, joint limitation or laxity, and soft and lax 
skin (Morris, 2006). 
 
Also, growth abnormalities are present in most individuals with WS (Morris et al., 
1988; Pankau et al., 1992). The growth pattern is characterized by intrauterine 
growth retardation, failure to thrive in infancy (70%), poor weight gain and linear 
growth in the first four years. A rate of linear growth is 75% of normal in childhood 
with a brief pubertal growth spurt. However final adult height typically falls in the 
low range of normal adult height (Pankau et al., 1992; Morris, 2006). 
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Renal malformations are quite common among individuals with WS. It is reported 
that 35-50% of these individuals have structural abnormalities of urinary tract, from 
which 15-20% are abnormalities of kidneys, such as solitary, duplicated, hypoplasic 
or scarred kidney (Pober et al., 1993; Pankau et al., 1996). Enuresis, weak bladder 
and frequent voiding affects as many as 50% of individuals with WS. These 
conditions may be caused by bladder diverticuli (40%) (Morris et al., 1988) as well 
as reduced bladder capacity and detrusor overactivity, both observed in 60% of the 
WS population (Sammour et al., 2006). All these abnormalities may contribute to 
recurrent urinary tract infections affecting approximately 30% of adults with WS  
(Morris et al., 1990; Pober et al., 1993). Another abnormality of the urinary tract is 
renal artery stenosis in 50% and nephrocalcinosis in less than 5% of individuals with 
WS (Pankau et al., 1996; Sforzini et al., 2002). Renal dysplasia, recurrent infections, 
renal artery stenosis and nephrocalcinosis, can all contribute to renal failure 
occasionally reported in WS (Steiger et al., 1988; Ichinose et al., 1996). 
 
Endocrine problems in WS are mainly associated with calcium, glucose and thyroid 
abnormalities as well as early puberty (in 50% of WS individuals) (Morris, 2006; 
Pober & Morris, 2007). 
The most common abnormalities of calcium metabolism are hypercalcaemia (15%) 
and hypercalciuria (30% of WS population) (Morris, 2006), but their aetiology is 
unknown (Kruse et al., 1992). Hypercalcaemia occurs usually in infancy but may 
recur in adult life producing symptoms like poor feeding, vomiting, failure to thrive, 
constipation and irritability (Martin et al., 1984; Morris et al., 1990). Hypercalciuria 
can occur independently from hypercalcaemia and it increases the risk of 
nephrocalcinosis (Morris et al., 1988).  
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The most common thyroid abnormality is hypothyroidism. Early onset of this 
condition has been reported in children with WS and the frequency of subclinical 
hypothyroidism increases in adulthood affecting approximately 20% of WS 
individuals (Pober et al., 2000; Morris, 2006).  
 
Abnormal glucose metabolism affects the majority of WS population (Pober et al., 
2001; Masserini et al., 2013). Cherniske and others (2004) observed extremely high 
frequency of abnormal glucose tolerance in adults with WS compared to adults in the 
general population with similar body mass index’s (BMIs). Diabetes mellitus affects 
15% of adults with WS (Morris et al., 1988; Morris et al., 1990). 
Several gastrointestinal problems occur both in children and adults with WS. The 
most common problems in infants are gastroesophageal reflux, constipation (both 
found in almost 50% of infants), disordered suck and swallow, textural aversion, 
vomiting and colic (Morris et al., 1988). Prolonged colic (over 4 months) may be 
related to gastroesophageal reflux, chronic constipation and idiopathic 
hypercalcaemia (Morris, 2006). Chronic abdominal pain occurs commonly in 
children and adults with WS. The possible causes of this condition include 
gastroesophageal reflux, hiatal hernia, peptic ulcer disease, cholelithiasis, 
diverticulitis, ischemic bowel disease, chronic constipation, and somatisation of 
anxiety (Morris, 2006). It has been also reported that the occurrence of coeliac 
disease is increased in children with WS (9.6%) in comparison with the general 
population (0.5%) (Giannotti et al., 2001). 
 
Infants and young children with WS are often affected by hypotonia and lax joints, 
while older children and adults demonstrate hypertonia and hyperreflexia together 
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with fine motor disturbances leading to difficulty with tool use and handwriting at all 
ages (Chapman et al., 1996; Morris, 2006). The gradual tightening of heel cords and 
hamstrings results in a stiff gait, lordosis and kyphosis by adolescence (Morris et al., 
1988; Kaplan et al., 1989). Progressive joint limitation affects coordination and 
motor skills, thus the impairment of oculomotor control, dysmetria, limb and gait 
ataxia are frequently found in WS population (Pober & Szekely, 1999).  
 
Another neurological abnormality among individuals with WS is Chiari 
malformation type I found in both children and adults. It is the malformation of the 
brain caused by displacement of the cerebellar tonsils below the level of the foramen 
magnum (Kaplan et al., 1989; Pober & Filiano, 1995) and gives such symptoms as 
headache, neck and arm pain, upper extremity weakness, difficulty swallowing, 
nausea and impaired coordination (Jacob & Rhoton, 1997). In addition, it has been 
reported that sleep disordered breathing problems are highly prevelant in all age 
groups of patients suffring from Chiari malformation (Dauvilliers et al., 2006; 
Murray et al., 2006). Using high-resolution imaging, it has also been found that the 
corpus collosum, which is the largest inter-hemispheric commissure in the brain, as 
well as the whole brain size is reduced in individuals with WS (Schmitt et al., 2001; 
Chiang et al., 2007). There is a reduction in volume of both, white matter (by 18 %) 
and grey matter (11 %) with posterior regions showing greater reduction in 
comparison to frontal ones. The volume of cerebellum is however relatively 
preserved (Reiss et al., 2000; Reiss et al., 2004; Chiang et al., 2007). In addition, 
altered neuronal packing density, as well as abnormal folding patterns of cerebral 
cortex have been reported (Galaburda et al., 2002; Van Essen et al., 2006). 
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Relationship between brain abnormalities and cognition in WS is discussed in 
Section 1.3.3) 
 
WS is diagnosed clinically (Morris, 2006) and confirmed by the detection of 
hemizygosity at the elastin locus using fluorescence in situ hybridization (FISH) 
analysis (Figure 1.15.) or other molecular techniques, such as microsatellite analyses, 
microarrays and multiplex ligation-dependent probe amplification (Borg et al., 1995; 
Smoot et al., 2005, Rees et al., 2012). These methods detect the deletion in 95-99% 
of patients with clinical diagnosis and allow an approximate estimation of the 
deletion size (Smoot et al., 2005; Morris, 2006; Shubert, 2009). Individuals with 
clinical features of WS, whose FISH test did not detect the deletion in WS critical 
region (WSCR) are referred for further diagnosis involving atypical deletion or other 
diagnoses (Smoot et al., 2005).  
 
 
Figure 1.15. FISH test using elastin probe (red) from chromosome 7q11.23 and a control 
probe (green) from chromosome 7q31 showing the absence of elastin gene from the 
individual with WS  (http://www.dnalabsindia.com/neonatologist_pediatrician.php). 
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1.3.2. Genetics 
 
WS is an autosomal genetic disorder caused by microdeletion of 28 coding genes, 
which have been identified so far (Shubert, 2009)  on the long arm of chromosome 7 
(7q11.23) including ELN (Ewart et al., 1993; Chen, 2006). The mutation is 
spontaneous, however, the transmission from parent to child can occasionally occur 
(Morris, 2006). The common deletion of 1.5 to 1.8 mega base pairs (Mb) of DNA is 
referred to as the WSCR and occurs with equal frequency on the maternally or 
paternally inherited chromosome 7 (Perez Jurado et al., 1996; Chen, 2006). The 
WSCR includes a single copy gene region of approximately 1.2 Mb flanked by three 
large low-copy-repeat sequences (LCR), set up in LCR blocks A, B and C. These 
LCR blocks are arranged in different complexes located on centromeric (C-A-B 
cen), medial (C-B-A mid) and telomeric (B-A-C tel) part of WS locus. Each of these 
complexes has a size of approximately 320 kb and includes one of each block (Chen, 
2006) (Figure 1.16.). As seen in the case of other microdeletion syndromes, the 
deletions in the WSCR develop due to high similarity of LCR blocks, especially 
block B. These highly homologous sequences predispose to unequal crossing-over 
and misalignment of gametes during meiosis (Francke, 1999; Smoot et al., 2005; 
Chen, 2006).  
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Figure 1.16. Graphical view of Williams syndrome critical region (WSCR) and the 
density of Alu-repeats in the section of low-copy repeat (LCR) blocks. Alu-repeats are 
thought to predispose regions for homologous recombination, causing genetic exchanges 
such as duplications, deletions and translocations. The horizontal arrows show the common 
deletion sizes of ~1.5 Mb and ~1.8Mb (Chen, 2006). 
 
Another, much rarer consequence of these homologous duplications is an inversion 
of WSCR found in approximately 7% of the general population (Osborne et al., 
2001). In almost all cases the inversion carrier is clinically normal, however, the risk 
of conceiving a child with typical WS is increased by 4 (Morris et al., 2004).  
The minimal critical region (MCR) for WS, as well as genotype-phenotype 
associations have been defined studying individuals with atypical deletions (Botta et 
al., 1999; Tassabehji et al., 1999; Karmiloff-Smith et al., 2003; Tassabehji et al., 
2005; Edelman et al., 2007) (Figure 1.17.). The MCR defines nine genes from ELN  
to GTF2I. It has been reported that loss of one copy of the genes from MCR is both, 
sufficient and necessary to cause full WS (Wu et al., 1998).  
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Figure 1.17. Summary of deletion mapping of WS classical and atypical patients . A schematic representation of the genes mapping at 7.11.23  
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critical region is shown below the human chromosome pictogram. The thick horizontal 
arrows represent the three large blocks of low-copy repeats, labeled as A, B and C, with 
centromeric (c), medial (m) and telomeric (t) sequence indicated. The typical 1.54 Mb WS 
deletion interval is depicted below as a solid like, whereas the dotted lines represents 
extended boundaries of the rarer 1.84 Mb deletion. The solid lines below show deletion 
mapping of WS atypical patients reported in the literature. Gray bars represent deletions of 
WS patients reported by authors with typical and well-documented WS cognitive profile, 
while black bars represent deletions of WS patients with absent or not well-defined WS 
cognitive profile. Deletion mapping of WS atypical cases defined a critical region for the 
visual-spatial construction, cognition and soc ial behaviour in WS (depicted by a gray 
vertical rectangle). The minimal critical region for WS consisting of nine genes is depicted 
in a red rectangle. (Ferrero et al., 2010).  
 
 
For a few genes, genotype/phenotype correlation have been established. Details of 
the genes in the WSCR as well as their proposed function and role in WS phenotype 
are summarized in Table 1.4. Numerous studies demonstrate that the deletion of ELN  
causes the WS cardiovascular phenotype (SVAS) (Metcalfe et al., 2000; Micale et 
al. 2010). ELN encodes tropoelastin. Multiple molecules of this protein bind together 
forming mature elastin protein. Elastin is the major component of elastic fibers, that 
provide strength and flexibility to  connective tissue (Brooke et al., 2003; Harvey & 
Ferrier, 2011). In WS, production of tropoelastin is reduced by half, what reduces the 
amount of mature elastin protein and consequently disrupts the normal structure of 
elastic fibers in many connective tissues. As a result, elastic fibers that make up large 
blood vessels are thinner than normal. To compensate, the smooth muscle cells that 
line the large blood vessels, e.g. aorta, increase in number, making the vessel 
thicken, narrower and as a result less flexible and resilient than normal. These 
vessels can narrow, increasing the resistance to normal blood flow and leading to 
serious medical problems (Tassabehji at al., 1998; Metcalfe et al., 2000; Harvey & 
Ferrier, 2011). Haploinsufficiency for another gene found in the WSCR- LIMK1, 
encoding LIM-kinase1 protein, was proposed to be responsible for hyperacusis and 
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progressive hearing loss (Matsumoto et al., 2011). LIM-kinase1 protein is highly 
expressed in neurons and plays role in regulating cytoskeletal structure via actin 
filaments (Smoot et al., 2005). Several findings report that the most telomeric genes 
in the WSCR (CYLN2, GTF2IRD1, GTF2-I) may be responsible for learning 
difficulties in WS (Francke, 1999; Hoogenraad et al., 2002; Hakimi et al., 2003). 
Individuals with WS, who have a deletion excluding some of these three genes or all 
of them, have borderline to normal intelligence and varying degrees of impairment 
of visuospatial functioning (Morris et al., 2003). In addition, GTF2-I 
haploinsufficiency could be a contributor to the hypersociability in WS individuals  
(Sakurai et al., 2011). Furthermore, there are studies suggesting association of 
GTF2IRD1 and BAZ1B (Tassabehji et al., 2005; Ashe et al., 2008) with craniofacial 
features as well as STX1A with diabetes mellitus (Lam et al., 2005). It has been also 
reported that the haploinsufficiency of BAZ1B and TFII-I may contribute to 
hypercalcaemia in WS (Osborne, 2010; Letavernier et al., 2012).  
 
Direct linkage between structural brain abnormalities and neurobehavioral profile in 
children with WS has also been suggested (Wang et al., 1992; Volterra et al., 1996; 
Fahim et al., 2012). In addition, some of the genes deleted in WS, such as STX1A 
and LIMK1 are expressed in brain prenatally and/or postnatally (Frangiskakis et al., 
1996; Osborne et al., 1997), while others, such as the gene for replication factor C 
subunit 2 (RFC2), may be involved in brain development (Peoples et al., 1996). The 
protein product of RFC2 is a part of multimeric complex involved in DNA 
elongation during replication (Chen et al., 1992). Thus, it has been suggested that a 
gene in the deletion region may contribute to the sleep disorders in individuals with 
WS (Arens et al., 1998). However, none of the studies reported so far confirmed the 
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association between genes in WS deletion region and sleep problems as well as/or 
levels of endocrine markers of circadian rhythm and sleep.  
 
Gene Protein Function 
Proposed role in WS 
phenotype 
Reference 
ELN 
Plays an essential role 
in a structure of 
connective tissue 
Cardiovascular and 
connective tissue 
abnormalities 
Metcalfe et al., 2000; 
Micale et al., 2010 
LIMK1 
Involved in the normal 
development of the 
central nervous system, 
as well as regulation of 
cytoskeletal structure 
Possible role in cognition 
Frangiskakis et al., 
1996;  
Tassabehji et al., 1996; 
Smoot et al., 2005 
 
CYLN2 
Role in attaching 
endosomes to 
microtubules 
Possible role in learning 
difficulties, involved in 
normal cognitive and brain 
development 
Francke, 1999; 
Hoogenraad et al., 
2002 
GTF2IRD1 
Transcription factor 
involved regulation of 
tissue development and 
differentiation 
Possible role in learning 
difficulties, involved in 
normal cognitive and brain 
development, also possible 
associations with 
craniofacial features as 
well as maintaining normal 
circadian locomotor 
activity and 
endocrinological response 
to stress 
Francke, 1999; Franke 
et al.,1999; 
Tassabehji et al., 2005; 
Schneider et al., 2012 
GTF2-I 
Transcription factor 
involved regulation of 
tissue development and 
differentiation 
Possible role in learning 
difficulties, involved in 
normal cognitive and brain 
development 
Danoff et al., 2004; 
Dai et al., 2009 
 
GTF2IRD2 
Involved in 
development of facial 
features and tooth 
formation 
Unknown 
Tipney et al., 2004 
 
BAZ1B 
Part of protein complex 
involved in replication, 
transcription and 
chromatin maintaince 
Abnormal vitamin D 
metabolism and 
hypercalcaemia, also 
possible associations with 
craniofacial features 
Kitagawa et al., 2003;  
Ashe et al., 2008 
 
STX1A 
Plays a vital role in 
neurotransmitter release 
Proposed role in normal 
cognitive development and 
intelligence. Associations 
with diabetes have also 
been found 
Nakayama et al., 1998; 
Lam et al., 2005;  
Gao et al., 2010 
EIF4H 
Positive regulator of 
protein synthesis at the 
level of translation 
initiation 
Unknown 
Francke, 1999;  
Majka et al., 2004 
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LAT2 
Membrane-associated 
adaptor molecule  
Unknown Martindale et al., 2000 
RFC2 
Part of multimeric 
complex involved in 
DNA elongation 
during replication 
Possible role in brain 
development 
Peoples et al., 1996;  
Majka et al., 2004 
 
NCF1 
Plays a role in the 
immune system and 
electron transport 
Role in hypertension Del Campo et al., 2006 
ABHD11 
Expressed ubiquitously 
in body although 
biological function 
unknown 
Unknown Merla et al., 2002 
BCL7B Unknown Unknown Francke, 1999 
CLDN3/ 
CLDN4 
Involved in formation 
and function of tight-
junctions of epithelial 
cells 
Unknown 
Francke, 1999; 
Bagherie-Lachidan et 
al., 2009 
FKBP6 
Highly expressed in 
human testes, essential 
role in homologous 
pairing in meiosis and 
in male fertility 
Unknown Crackower et al., 2003 
MLXIPL 
Transcription factor that 
activates expression of 
glucose-regulated and 
lipogenic genes 
Unknown Li et al., 2010 
NSUN5 
Putative 
methyltransferase 
Unknown Shubert et al., 2009 
TBL2 
Gene product unclear, 
may play a role in 
tumour suppression 
Unknown Perez-Jurado et al., 
1999 
TRIM50 
Possible role in 
ubiquitin-mediated 
proteasome pathway 
Unknown Micale et al., 2008 
VPS37D 
Role in regulation of a 
vesicular trafficking 
process, it is a part of 
endosomal sorting 
complex required for 
transport 
Unknown Shubert et al., 2009 
WBSCR22 
Strongly expressed in 
testes, protein function 
unknown 
Unknown 
Doll & Grzeschik, 
2011 
 
Table 1.4 Genes within the Williams syndrome critical region (WSCR) and their 
proposed protein function as well as proposed role in the WS phenotype. 
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1.3.2.1. Mouse models 
 
The WS mouse models play an important role in defining genotype/phenotype 
correlations. Due to the fact that atypical WS patients are very rare, the statistical 
significance as well as conclusive evidence is difficult, often impossible to obtain. 
Creating animal models with targeted single or multiple gene knockouts and then 
carrying out testing in controlled environment helps to overcome these issues. Mice 
are ideal candidates to model human genetic disorder, due to the fact that 99 % of a 
mouse genome sequence has direct counterparts in humans, thus, genomic 
alternations should affect the same biological pathways throughout development and 
result in similar phenotypes (Gunter & Dhand, 2002) . Figure 1.18 presents the 
organisation of human and mouse WS regions. 
 
 
Figure 1.18. Long-range organisation of human and mouse Williams syndrome regions . 
Figure presents a physical map of the WS regions on human chromosome 7q and mouse 
chromosome 5G. The position of the known genes residing within and flanking the interval 
commonly deleted in WS is emphasised. Bold dashed lines indicate human  WS region of 
∼1.6 Mb interval, which is flanked by duplicated blocks of DNA of near-identical sequence 
(estimated at ∼300 kb in size; indicated by dark rectangles). The relative positions of the 
centromere (CEN) and telomere (TEL) are also  indicated. The inverted orientation of the 
two discontiguous segments of human chromosome 7 relative to the single contiguous 
segment of mouse chromosome 5G are also shown (DeSilva et al., 2002). 
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In order to determine how the genes within WSCR contribute to WS phenotype, Li 
et al. (2009) created knockout mouse models: proximal deletion mice lacking Gtf2i 
to Limk1, distal deletion mice lacking Limk1 to Fkbp6 and the double heterozygotes 
model with complete human deletion. It has been found that increased sociability, 
but also higher level anxiety as well as growth retardation was associated with 
proximal deletion, while cognitive defects and deficits in locomotor activity with 
distal deletion. Findings of this study have also suggested that genes within both, the 
proximal and distal deletion are involved in craniofacial and brain development. In 
line with these findings, Tassabehji et al., (2005) reported craniofacial abnormalities 
in mouse model of  Gt2ird1 located in proximal deletion region, while Ashe et al. 
(2008) reported similar findings, but using Baz1b mouse model located in distal 
deletion region.  Several other studies have created single-gene knockout mouse 
models of WS and these are summarised in Table 1.5. The study of Schneider et al., 
(2012) is of particular interest for the current work. The authors examined Gt2ird1 
knock-out mice and reported that Gt2ird1 null mice showed decreased circadian 
locomotor activity, increased anxiety and elevated endocrinological response to 
stress, while Gt2ird1 heterozygous mice displayed decreased circadian activity.  
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Gene Phenotype Reference 
FKBP6 Fertile with no phenotype observed Crackower et al., 2003 
FZD9 Diminished seizure threshold, abnormal 
hippocampal structure 
Zhao et al., 2005;  
Ranheim et al., 2005 
BAZ1B Mild craniofacial abnormalities, low 
frequency of cardiac malformations 
Ashe et al., 2008; 
 
STX1A no deficits in learning and memory, anxiety 
or locomotor activity observed (small 
number of mice tested) 
Fujiwara et al., 2006;  
McRory et al., 2008 
ELN Hypertension, decreased aortic compliance 
and mild cardiac atrophy 
Li et al., 1998;  
 Faury et al., 2003;  
 Goergen et al., 2011 
CLIP2 Mild growth deficiency, hyppocampal 
dysfunction, deficits in motor coordination 
Hoogenrad et al., 2002 
GTF2IRD1 Mild growth deficiency, hypersociability, 
learning and memory deficits, craniofacial 
abnormalities, decreased circadian activity 
Tassabehji et al., 2005; 
Young et al., 2008;  
Palmer et al., 2010; 
Schneider et al., 2012 
 
Table 1.5.  Phenotypic features of single gene heterozygous mouse models of WS 
(with haploinsufficiency of one copy of genes listed on the left hand side of the 
table) (adopted and modified from Osborne et al., 2010).  
 
 
1.3.3. Behavioural and cognitive profile 
 
The behavioral phenotype for WS is characterised by a distinctive cognitive profile 
with a characteristic pattern of strengths and weaknesses and unique personality 
profile (Semel & Rosner, 2003). Most individuals with WS have mild to moderate 
learning difficulties with mean IQ between 50-60  (Karmiloff-Smith et al., 2003; 
Smoot et al., 2005). Some of the relative strength abilities in WS cognitive profile 
include language skills, face recognition, auditory rote memory and musical skills 
106 
 
(Morris & Mervis, 2000; Smoot et al., 2005; Mervis & Velleman, 2011). Although 
speech is usually delayed with the first words at about 2 years and first sentences at 
about 3 years, older children and adolescents have a language rich in affect, prosody 
and narrative enrichment (Bellugi et al., 1994). Several studies reported that children 
with WS have better auditory rote memory abilities than children with learning 
difficulties of mixed aetiologies, matched by chronological age (Bellugi et al., 1994; 
Jarrold et al., 1998; Klein & Mervis, 1999). Face recognition in WS is good albeit 
atypical mechanism of recognition has been noted (Karmiloff-Smith, 1998; 
Karmiloff-Smith et al., 2004;  Annaz et al., 2009). Some significant weaknesses are 
within the domain of visuospatial functioning (Mervis & Klein-Tasman, 2000). 
Many individuals with WS have great problems with hand writing, perceptual 
planning and drawing objects in a disjointed manner (Bellugi et al., 1988; Bellugi et  
al., 1992; Wang et al., 1995; Bertrand et al., 1997; Klein & Mervis, 1999). As no 
correlation has been observed between visuospatial cognition and severity o f ocular 
problems in WS, it was suggested that this deficit has its origins in the brain (van der 
Geest et al., 2004). Abnormal frontoparietal circuitry is thought to underlie the 
visuospatial weekness (Galaburda et al., 2002, Atkinson et al., 2003; Meyer-
Lindenberg & Zink, 2007). Meyer-Linderberg et al. (2004) have shown 
hypoactivation in the parietal portion of the dorsal stream, which is one of the 
sensory pathways of primary visual cortex, when participants focused on the spatial 
location of objects and faces. Moreover, the volume of grey matter in a region 
neighbouring the dorsal stream was also found to be reduced. Thus, the authors 
suggested that lack of neuronal integrity in this region may prevent information 
coming from primary visual cortex from further dorsal stream processing (Meyer-
Linderberg et al., 2004). It has aslo been found that adult WS patients have reduced 
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activation in the visual and parietal cortices in comparison to age and gender-  
matched healthy controls, during a global processing task (Mobbs et al., 2007). Both 
studies were performed using functional magnetic resonance imaging (fMRI). 
Difficulties with reading, spelling and especially mathematics are also observed and 
WS individuals often reach only about 7 to 8 year level in these areas (Howlin et al., 
1998).  
 
The behavioural phenotype for WS is characterised by their unusual personality 
profile. Hypersociability is the most noticeable behavioural feature (Carrasco et al., 
2005; Jones et al., 2000) as people with WS are often described as overly friendly 
(Gosch & Pankau, 1997), outgoing (Beuren et al., 1962), approachable (Tomc et al., 
1990), never going unnoticed in a group (Dykens & Rosner, 1999) and highly 
empathic (Gosch & Pankau, 1994), but also as lacking social judgment skills 
(Einfeld et al., 1997). On the other hand, high level of anxiety, worries and fears has 
also been reported (Dykens, 2003), however, the degree and intensity of anxiety may 
vary over time (Smoot et al., 2005). Dykens (2003) examined anxiety and phobia in 
120 children and adults with WS (age 6 - 48 years) compared to 70 IQ, age and 
gender-matched individuals with learning difficulties of mixed or nonspecific 
aetiologies. It was found that 96 % of WS participants showed persistent anxiety 
producing fears for at least 6 months and 35 % met all criteria for clinical phobia  
with half of them having more than one subtype of phobia. Sub-clinical phobia was 
found in 84 % of WS individuals, meeting all criteria for phobia apart of impaired 
adaptive functioning. The natural environment subtype was seen in 94 % (72 % of 
these had fears of thunderstorms and 55 % of high places), 44 % showed other types 
(e.g. afraid of being alone), and 22 % showed the animal subtype. The least amount 
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of fears were found in boys and girls aged 6 to 12 years. Fears generally increased 
with advancing age, often peaking in the adult years. Longitudinal course of anxiety 
in children and adolescents with WS (n = 45, aged 4 – 13 years) was also examined 
for a period of at least 1 year (Woodruff-Borden et al., 2010). Of the entire study 
sample, 51.1 % was diagnosed with anxiety. Developmental trajectories have shown 
persistence of anxiety over time and suggested that the odds of a positive diagnos is 
did not change with time. Moreover, chronic, persistent anxiety within the period of 
5 years after initial diagnosis was shown in 62.2 % of those WS individuals with 
anxiety diagnosis. Another study has also examined anxiety in 132 children with WS 
(4 – 16 years old) (Leyfer et al., 2009). Children with WS showed significantly 
greater prevalence of specific phobia, generalised anxiety disorder and separation 
anxiety in comparison to children in general population. Both studies showed that 
anxiety is highly prevalence in all ages in the WS population. Furthermore, Lense et 
al., (2013) reported elevated cortisol levels in response to the novel settings 
(residential summer camp), what could be a result of increased anxiety.  
The anxiety profile in WS may be explained by abnormal activity in the amygdala,  
that is a complex brain structure, which is activated when the senses perceive 
something of special significance. It plays a crucial role in processing, controlling 
and memorising the emotional reactions (Ono et al., 1995; Talarovicova et al., 2007) 
as well as in the development and expression of fear (Davis, 1992). It has been 
shown that lesions of the amygdala directly linked to its cortical regions, can cause 
disinhibition and impaired social function (Bauman et al., 2004; Willis et al., 2010). 
In 13 adults with WS, Meyer-Lindenberg et al. (2005) found significantly 
diminished amygdala activation when viewing images of threatening or angry faces, 
relative to age and gender-matched healthy control participants. This reduction in the 
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responsiveness to social danger may contribute to the social disinhibition and 
diminished fear of strangers that is characteristic of WS. Conversely, participants 
with WS showed abnormally increased activation when viewing threatening non-
social scenes, suggesting a likely neural basis for the high levels of non-social 
anxiety in WS (Figure 1.19).  
 
 
Figure 1.19. Abnormal regulation of the amygdala in participants with WS (right) 
compared to controls (left). The amygdala activates more for threatening scenes (bottom), 
but less for threatening faces(top) (Meyer-Lindenberg et al., 2005). 
 
There are also studies suggesting the link between activation of amygdala and the 
regulation of REM sleep (Benca et al., 2000; Sanford et al., 2002). Amygdala is 
heavily interconnected with brainstem nuclei known to be involved in sleep control,  
however, it has received little attention from sleep researchers (Morrison et al., 2000; 
Jha et al., 2005). It has been shown that electrical activation of central nucleus of the 
amygdala can increase the occurrence of REM sleep (Sanford et al., 2002). Benca et  
al. (2000) examined the effects of amygdala lesions on sleep in rhesus monkey in 
comparison to normal controls. It was found that sleep was least disrupted in animals 
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with large bilateral lesions of the amygdala. These animals had more sleep and 
higher proportion of REM sleep than did animals with smaller lesions and control 
group. Based on these results, the authors suggested that the amygdala plays a role in 
sleep regulation in primates and may be important in mediating the effects of 
emotions and/or stress on sleep.  
In addition, recent study of Schneider et al., (2012) on WS mouse models, suggested 
possible links between the loss of Gtf2ird1 function and a loss of hypothalamic-
pituitary function, that could result in an increased anxiety.  
Problems with attention are also very common in WS and they manifest as 
hyperactivity or ADHD (Udwin & Yule, 1991).  
The area of weakness of adaptive behaviour profile in WS includes self-care and 
daily living skills (Mervis & Klein-Tasman, 2000). Individuals with this syndrome 
usually achieve approximately 6 year old levels for personal self-care (Plissart et al., 
1994). 
 
1.3.4. Characteristics of sleep in Williams syndrome 
 
Parents of children with WS often report sleep-related problems, including difficulty 
falling asleep and frequent and prolonged awakenings, however, it is still an aspect 
of WS phenotype that has yet to be adequately characterised (Arens et al., 1998; 
Annaz et al., 2011; Gombos et al., 2011; Mason et al., 2011; Ashworth et al., 2013). 
Thus far, very few studies were carried out to look specifically at sleep problems in 
WS and all of them were based on data collected through questionnaires and PSG 
(Arens et al., 1998; Annaz et al., 2011; Gombos et al., 2011; Mason et al., 2011; 
Ashworth et al., 2013). At the start of the current PhD, two studies reporting sleep 
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problems in individuals with WS were published (Arens et al., 1998; Goldman et al., 
2009), however, several others were published during the course of the work  (Annaz 
et al., 2011; Gombos et al., 2011; Mason et al., 2011; Ashworth et al., 2013). In one 
of the studies, parents of 28 children were questioned about the possible sleep 
problems with their children (Arens et al., 1998). The results of that examination 
showed that 57% of these children had symptoms compatible with sleep disorders. 
Of the 16 children screened for possible movement arousal sleep disorder, 7 agreed 
to have PSG measurements, that revealed that WS children also have a disorder of 
periodic limb movement in sleep (Arens et al., 1998). Another study examined sleep 
patterns in adolescents and adults with WS (n = 23) aged 17 to 35 years, using 
structured interviews, sleep questionnaire and actigraphy. The results showed that 
36.4 % had trouble sleeping, 65 % reported two or more awakenings per night and as 
much as 95.2 % of the participants felt tired during the day (Goldman et al., 2009). 
In one of the largest questionnaire based studies (n = 64), Annaz and colleagues 
(2011) reported sleep problems in school-aged children with WS. Based on 
Children’s Sleep Habit Questionnaire (CSHQ) parents reported significantly greater 
bedtime resistance, sleep anxiety, night walking and daytime sleepiness compared 
with typically developing controls. One of the most recent studies by Gombos and 
colleagues (2011) examined sleep architecture, leg movements and the EEG using 
PSG in adolescents and young adults with WS (n = 9) aged from 14 to 28 years. The 
data were compared with age- and gender- matched healthy controls (n = 9, 14 to 29 
years of age). Obtained data have shown atypical sleep patterns in WS individuals 
with decreased sleep time, sleep efficiency and REM sleep percentage, and increased 
wake time after sleep onset, NREM sleep percentage and SWS. The number of leg 
movements was also higher in WS and the sleep cycles appeared to be irregular 
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compared to healthy controls. Similar results were obtained by Mason and 
colleagues (2011) who used a larger number of participants including 35 WS and 35 
TD children (age 2-18 years). The study was based on an overnight PSG and 
questionnaires regarding the participants’ sleep and behaviour, which were 
completed by parents. Obtained results confirmed previous findings that individuals 
with WS also have decreased sleep efficiency, increased SWS, greater difficulty to 
fall asleep, higher level of restlessness and arousals from sleep in comparison to the 
TD control group. The most recent study by Ashworth and colleagues (2013) 
examined sleep problems and syndromic specificity. The authors compared  6 to 12 
years old children in two clinical groups, namely DS (n=22) and WS (n=24). The 
results showed that children with WS have significant problems initiating sleep, for 
example bed-wetting and body pains were also reported by parents.  
Lastly, based on the hypothesis that sleep problems may affect sleep-dependent 
learning, Dimitriou and colleagues (2013) investigated the impact of sleep on a 
motor memory task. The authors examined 12 children with WS and 15 TD children 
(age range 6 to 12 years, mean = 8.6) on the finger tapping task. Children were 
trained on the task in the evening and retested the following morning and afternoon. 
Following sleep period, the control group dramatically improved in performance 
accuracy but there was no evidence of sleep-related learning in WS. However, the 
lack of improvement in the WS group cannot be attributed to sleep problems per se 
before more studies can confirm this finding.  
 
To date, there has been no study analysing biological properties of sleep problems in 
WS. As sleep problems in children with WS can adversely affect daytime activity 
and the quality of life, as well as social, emotional, health and economic functioning 
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of the entire family, it is important to address this issue as it will affect the quality of 
life of the child and family. 
 
 
Summary 
This chapter has discussed sleep characteristics as well as physiological and 
cognitive phenotypes of individuals with WS and techniques used for sleep 
monitoring and analysis of endocrine markers of sleep. The effects of sleep problems 
in WS children are wide-ranging, yet precious little research has focused on the 
causal mechanism of sleep problems in children with disorders. Sleep problems, 
behavioural problems, and having a child with a disability all contribute to maternal 
stress and depression. Chronic sleep disruption may also negatively impact parental 
perception of the child (Hayes et al. 2001). Sleep and its consequences is an area that 
requires thorough investigation in children with WS as these groups clearly 
experience significant sleep problems. As has been shown, sleep problems are often 
amenable to treatment, so alleviating these problems could have a beneficial effect 
on daytime functioning and a knock-on effect on children’s families and maternal 
well-being. It is hence vital to assess sleep problems in disorder groups in more 
depth using multidisciplinary approaches. 
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AIMS OF THE STUDY 
As described previously, the evening rise of melatonin secretion and correlated with 
that fall in body temperature, facilitate sleep. In direct contrast, cortisol whose 
secretion increases before dawn, prepares us for physical and mental demands of 
awaking, by increasing heart rate, blood pressure and releasing glucose to our blood 
stream (Seaward, 2006). If these mechanisms are disturbed, sleep disorders/problems 
may occur. 
The aims of this study are: 
1. To define sleep quality and quantity using actigraphy and compare the results 
to parent-reported sleep data for school-aged TD children and WS. 
2. To quantify nocturnal oxyhaemoglobin saturation and indices that can predict 
OSAS in these groups. 
3. To quantify and compare levels of melatonin in children with WS and TD.  
4. To quantify and compare levels of cortisol in children with WS and TD.  
5. To examine if sleep quality and quantity are related to melatonin and cortisol 
levels. 
6. To assess whether age, gender and environmental factors have an influence 
on sleep patterns and secretion of melatonin and cortisol. 
It is predicted that children with WS have worse sleep quality than age- and gender-
matched healthy controls (Gombos et al., 2011; Mason et al., 2011; Ashworth et al., 
2013). As problems with settling down by WS individuals have been reported, 
abnormal levels of cortisol and/or melatonin before night time sleep may be 
observed as well.   
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2. METHODOLOGY- ANALYSES OF SLEEP QUALITY AND 
QUANTITY 
 
In this chapter participants’ characteristics and the procedures of objective and 
subjective sleep analysis are presented. Sleep measurements described in this chapter 
include actigraphy for monitoring a persons’ activity, pulse oximetry for the 
measurement of pulse rate and oxygen saturation in order to determine whether there 
are problems related to breathing that may obstruct sleep. This chapter also outlines 
the standard sleep questionnaire as well as medical questionnaire used to assess 
whether there are any medical conditions which may have an impact on sleep in 
study participants.   
 
2.1. Participants 
 
2.1.1. Ethical approval 
 
All studies were approved by the Middlesex University Natural Sciences Ethics sub-
Committee (Approval Letter 524) prior to recruitment of participants. In the case of 
participants with WS, a formal research proposal was submitted and accepted by the 
WS Professional Advisory Panel. Each parent was sent detailed information about 
the studies (Appendix 1). Parents then returned a slip indicating whether or not they 
would like their children to take part in the studies. Each child was also verbally 
asked if s/he would like to take part in the study.  
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2.1.2. Participants 
 
2.1.2.1. Children with WS 
 
Primary school-aged children with WS (13 male, 14 female; four to eleven years of 
age) were identified from the database provided by the Williams Syndrome 
Foundation, UK. Parents of 35 children were contacted and of these 27 agreed to 
take part in the studies, yielding an overall response rate of 77%. This number 
represents approximately 30% of all school-aged children with WS in the United 
Kingdom. All children with WS were diagnosed clinically and tested positive on the 
FISH method for detecting hyploinsufficiency for ELN.  
 
2.1.2.2. Typically developing control group 
 
The control group consists of 27 typically developing (TD) children (12 male, 15 
female) age- and gender- matched with WS group and selected from mainstream 
schools of Greater London and South-East UK.  
 
2.1.3. Exclusion criteria 
 
Due to the nature of the studies, children were not included in the study if they had 
co-morbid medical or psychiatric disorders such as ADHD or autism or if they were 
taking prescribed medication for sleep problems. Upon analysis it was noted that two 
children with WS were taking melatonin for their sleep problems, thus, the data 
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obtained for these children were excluded from statistical analysis and analysed 
separately from the rest of the group. The age range of the participants was 4 to 11 
years. This range was chosen in order to avoid puberty.  
 
2.1.4. Challenges with testing young children and children with 
developmental disorders 
 
Given the rarity of WS, and difficulty in gaining access to young children it is often 
challenging to recruit large groups, especially if the study is focusing on a relatively 
narrow age range. However, it is important to employ sufficient participant numbers 
to disentangle systematic variation between groups from random noise, particularly 
if the tests involved produce only a small range of scores (e.g. CSHQ having 3-point 
scale range). Also, travel to collect the samples was critically important and required 
very careful logistical planning since children were living far away from each other 
(See Figure 2.1.). 
 
Figure 2.1. Map presenting families visited during the course of this study. Blue 
dots represent families having a child with Williams syndrome, while red dots 
represent typically developing children.  
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2.2.  Actigraphy 
 
Each child was given an Actiwatch Mini (CamNTech, Cambridge, UK) (Figure 2.2.) 
to objectively assess their sleep patterns. This was worn around the non-dominant 
wrist, as if wearing a watch, and children were asked to wear it continuously for 3 
consecutive days and nights. As described in the introduction (Section 1.2.1.2), the 
actiwatch contains accelerometer measuring activity and movements of an 
individual. The Actiwatch Activity & Sleep Analysis 7 software (CamNTech, 
Cambridge, UK) was used to download data from the actiwatch at the default 
‘medium’ sensitivity level. The programme uses an algorithm to score each one-
minute epoch as sleep or wake based on movement during that minute, as well as the 
two preceding and two successive minutes. The activity scores from adjacent 
minutes influence the total score in the following way: within 1 min of the scored 
epoch activity levels are reduced by a factor of 5 and this value is added to the 
scored value; within 2 min of the scored activity epoch, activity values are reduced 
by a factor of 25 and this value is added to the scored value. A total score of 40 or 
more determines the epoch as being “Awake”. For the determination of “Sleep start” 
the algorithm looks for a period of at least 10 min of consecutive immobility with no 
more than 1 epoch of movement within that time, following the “Bed time”. The 
start of this period is classified as “Sleep start”. The “Sleep end” is determined by the 
last epoch from consecutive 6 min period of activity below the threshold. Within this 
period two epochs above the threshold are allowed. The threshold necessary to 
equate to “Sleep end” is determined by 6 or less activity counts per minute. During 
the night, there are at least low activity recordings visible on the actigram, whereas, 
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in case when actiwatch is removed by a user, no activity recordings (flat line) can be 
observed (The Actiwatch Mini user guide, Cambridge Neurotechnology Ltd.). 
 
 
Figure 2.2. Actiwatch Mini (CamNTech, Cambridge, UK). 
 
Several actigraphy variables were computed from the data including: 
 Time in bed: the total elapsed time between the “Bed Time” and “Get Up” 
times.  
 Sleep latency: time from bed time to sleep start. 
 Assumed sleep time: time from sleep onset to offset.  
 Actual sleep time: assumed time asleep minus any period(s) awake. 
 Actual sleep (%): actual sleep time expressed as a percentage of the 
assumed sleep time. 
 Actual wake time: the total time spent awake after sleep onset 
 Actual wake (%): actual wake time expressed as a percentage of the 
assumed sleep time. 
 Night wakings : number of night wake bouts. 
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 Mean sleep bout time: average duration of periods of sleep.  
 Mean wake bout time: average duration of periods of intermittent 
wakefulness. 
 Sleep efficiency: actual sleep time expressed as a percentage of time in bed.  
 Moving minutes: the total number of minutes during sleep where the child is 
moving. 
 Moving time (%): percentage of time spent moving from sleep onset to 
offset. 
 Immobile minutes: the total number of minutes spent immobile from sleep 
onset to offset. 
 Immobile time (%): percentage of time spent immobile from sleep onset to 
offset. 
 Number of immobile phases: the number of contiguous sections categorised 
as immobile in the epoch-by-epoch mobile/immobile categorisation.  
 Mean length immobility: the average length of each of the immobile bouts.  
 One minute immobility phases: the number of immobile bouts which were 
less than or equal to one minute in length. 
 One minute immobility (%): the number of immobile bouts less than or 
equal to one minute expressed as a percentage of the total number of 
immobile bouts. 
 Fragmentation index: The sum of the moving time (%) and the immobile 
bouts  ≤ 1min (%). This is an indication of the degree of fragmentation of the 
sleep period and restlessness, and can be used as an indication of sleep 
quality (or the lack of it). A higher figure denotes increased restlessness.  
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 Total activity score: the total of all the activity counts during the assumed 
sleep period. 
 Mean activity score: the total activity score divided by the number of epochs 
in the assumed sleep period. 
 Average wake movement: average activity counts per epoch for the wake 
period (The Actiwatch Mini user guide, Cambridge Neurotechnology Ltd.).  
 
 
2.3.  Pulse oximetry 
 
Pulse oximeters used in the current study were Masimo Rad-8 monitors (Figure 
2.3.). Pulse oximetry was used to measure the pulse rate and oxygen saturation over 
the same period of three consecutive nights as used for the actigraphy measurements, 
by an infrared sensor attached to a finger or toe. These monitors are increasingly 
used for the evaluation of sleep disordered breathing (Netzer et al., 2001). Thus, it is 
expected that data obtained from pulse oximetry will allow us to determine whether 
there are any problems related to breathing, such as sleep apnoea that may obstruct 
sleep. Pulse rate was also monitored. The pulse oximetry variables of interest were: 
mean and median oxygen saturation (SpO2), mean pulse rate, number of over-4% 
dips in SpO2 per hour, delta index 12s (an index of SpO2 variability over each 12-
second epoch where a higher figure indicates increased variability) and the time 
spent with SpO2 under 90% calculated in hh:mm:ss as well as the percentage of 
analysis interval. 
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Figure 2.3. Masimo Rad-8 monitor (http://masimo.co.uk/). 
 
 
2.4.  Questionnaires 
 
Parents of all participants were asked to complete the CSHQ (Owens et al., 2000a) 
(Appendix 2), Medical Questionnaire (Appendix 3), sleep diary (Appendix 4) and 
asses their child puberty stage using Tanner’s scale (Appendix 5). 
 
2.4.1. Children’s Sleep Habit Questionnaire  
 
Due to the fact that spontaneous parental reports are prone to bias, CSHQ (Owens et  
al., 2000a) was used in this study. The CSHQ is standard 45- item parent 
questionnaire that has been used in a number of studies to examine sleep behaviour 
in school-age children (Liu et al., 2005; Annaz et al., 2011). Parents answer on a 
three-point scale, which is: “usually” if the sleep behaviour occurred 5-7 times per 
week; “sometimes” for 2-4 times per week; and “rarely” for 0-1 time per week. 
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Thirty-three items from the questionnaire (indicated by starts in Appendix 2) are 
used to calculate total sleep disturbance score, as well as scores in 8 sub-scales: 
bedtime resistance, sleep onset delay, sleep duration, sleep anxiety, night waking, 
parasomnias, sleep disordered breathing and daytime sleep iness. The higher the 
score obtained on this questionnaire, the greater the sleep problems. It has been 
reported that psychometric properties of CSHQ are satisfactory, showing good 
internal consistency, validity and test-retest reliability (Owens et al., 2000a). No 
norms were established for total score and subscale scores for this questionnaire, 
however, Owens et al. (2000a) reported that using 41 as a cut-off score produce the 
best diagnostic confidence by correctly identifying 80% of the clinical sample.  
 
2.4.2. Medical Questionnaire 
 
Medical Questionnaire, designed for these studies, consists of 45 items divided into 
four parts. The first section has questions about the demographic data of the family. 
Sections second and third are the “medical history” and “health habits” sections of 
the Pediatric Sleep Clinic Questionnaire for children aged 4 to 12 (Owens, 
http://www.kidzzzsleep.org). Health habits section also includes questions related to 
child’s sport activity. The last section of this questionnaire consists of questions 
about child’s diet, such as amount of caffeinated drinks, main meals and snacks that 
a child consumes per day. For most of the questions, the care giver must circle one of 
the options, i.e. “Yes”, “No”, “Don’t know”; some questions were rated on a five-
point scale: “None”, “Up to 2 hours”, “2-4 hours”, “4-6 hours”, “More than 6 hours”, 
for instance those  regarding the time spent on the TV or computer per day. There 
are also several open-ended questions, such as those on medications or sport activity.  
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2.4.3. Tanner’s scale of puberty  
 
Tanner scale is a scale of physical maturity of children, adolescents and adults based 
on the development of primary and secondary sexual characteristics, such as the 
development of pubic and axillary hair, the testicular volume and the size of genitalia 
and breasts (see Appendix 5 for detailed description of Tanner’s stages)  (Marshall & 
Tanner, 1969; Marshall & Tanner, 1970). 
 
 
2.4.4.  Sleep diary 
 
Parents were requested to complete a sleep diary recording their child’s bed time and 
getting up time for the duration of the study. These were used to support analyses of 
actigraphy data.  
Actigraphy, pulse oximetry and CSHQ were all obtained within the same time and 
during the weekdays to ensure normal routine.  
 
2.5. Statistical analyses 
 
Unless otherwise stated, the data were analysed using SPSS Version 19 (SPSS Inc., 
Chicago, IL). In other cases the software used was Minitab Version 16 (Minitab Inc., 
State College, PA). For the group comparison the independent-samples t-test or 
Mann-Whitney test were used. The application of adequate test was based on the 
results from the Shapiro-Wilk test of normality. T-test was used for normally 
distributed data (p > 0.05 on Shapiro-Wilk test) and Mann-Whitney for non-normal 
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distributions (p < 0.05 on Shapiro-Wilk test of normality). If the data are normally 
distributed (t-test) they are appropriately described with mean and standard deviation 
(SD), while the median and interquartile range (IQR) (the range between 25th and 
75th percentiles) are appropriate for non-normal distributions (Lang & Secic, 2006).  
Analysis of covariance (ANCOVA) were used to control for the age effect while 
analysing sleep scores and sleep parameters of children with WS and TD group. The 
outliers of over 3 SD from the mean were excluded.  
 
Summary 
This chapter outlined the methodology of sleep analysis including widely used 
actigraphy for objective sleep measurement as well as standard CSHQ, a more 
subjective parental report on their children’s sleep. Although PSG is a gold standard 
technique for sleep analysis, it has been reported that actigraphic measurements, 
such as sleep efficiency and number of awakenings during the night are in agreement 
with PSG measurements in both adults and children (Corkum et al., 2001; Kushida 
et al., 2001; Gay et al., 2004). Furthermore, it has been reported that actigraphy is 
particularly useful in studying infants and children, as well as in special paediatric 
population as PSG can be difficult to perform (Morgenthaler et al., 2007). The pulse 
oximetry and medical questionnaire were also presented in this chapter in order to 
determine whether there are any conditions/factors which may obstruct sleep in these 
children. 
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3. RESULTS – ANALYSIS OF QUALITY AND QUANTITY OF 
SLEEP 
 
The previous chapter focused on methodology of sleep analysis. Based on these 
methods, this chapter provides a detailed account of sleep characteristics in WS 
children and the TD controls. The results of qualitative and quantitative sleep 
analyses including data collected through actigraphy and pulse oximetry as well as 
questionnaires are reported here.  
 
3.1. Participants’ characteristics 
 
The children with WS ranged in age from 4.48 years to 11 years (mean age 7.34 
years) and were attending mainstream schools. The healthy control group for 
comparison of sleep and physiological measures, ranged from 4.04 years to 10.80 
years (mean age 7.47 years). Demographic data (Appendix 3) was obtained for each 
individual. Series of statistical analyses were conducted in order to determine 
whether groups differed in age, gender, parents’ socioeconomic status and puberty 
stage (Table 3.1.). Age difference between WS children and TD controls as well as 
BMI was tested using independent samples t-test. No age difference between these 
two groups was found (t(50) = -0.240 p = 0.81). In order to assess whether the two 
groups had any differences on categorical variables such as gender and ethnicity, a 
Chi-square analyses were conducted. The two groups did not differ on gender (χ2 (1) 
= 0.074, p = 0.79), ethnicity (χ2 (2) = 3.031, p = 0.22) and parent occupation 
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(professional, clerical, manual and other occupation) (mother’s occupation: χ2 (6) = 
6.349, p = 0.39; father’s occupation: χ2 (6) = 5.843, p = 0.44). Eighty eight percent of 
children with WS and 94 % of controls indicated to be in prepubertal stage using 
Tanner puberty scale. Using chi-square analyses, it was found that both groups 
scored similar on this scale (χ2 (1) = 1.236, p = 0.27).   
 
 WS (n=25) TD (n=27) 
Age, years (SD) 7.34 (1.87) 7.47 (2.00) 
Age range 4.48 – 11.00 4.04 – 10.80 
Gender (M/F %) 48/52 44/56 
Ethnicity (%White) 92 78 
Ethnicity (% Black) 0 0 
Ethnicity (% Other) 8 22 
Parents’ occupation:   
Professional (%) 33 46 
Clerical (%) 20 22 
Manual and other (%) 47 32 
 
Table 3.1. Detailed characteristics of groups of study participants. N value for WS group 
accounts for the differences from N=27, as two children were excluded from the studies due 
to taking sleep medication.  
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3.2. Actigraphy 
 
Actigraphs were well tolerated by the children, and data were available for 43 (83 %) 
of the 52 children involved in the studies. Five children with WS and four TD either 
refused to wear the actigraphs at all or removed them during the night. These 
children were not excluded from the rest of the study. The child’s bedtime (time the 
child is in bed with lights off) and get-up time were obtained from sleep diary 
recorded by parents. Mean night bedtime for children with WS was 20:40 pm (SD = 
45 min) and for TD group 21:01 pm (SD = 44 min).  
 
   
Figure 3.1. Example of actigrams for WS and TD children during three consecutive 
days and nights. The black bands indicate the level of the child’s activity per minute during 
the 24h cycle. It can be seen that child with WS has a greater level of activity during the 
night  in comparison to TD child, whose nocturnal activity levels are low, as recorded by 
actigraphy.   
 
In order to investigate if there were any differences between the WS and TD control 
group on actigraphy scores, analyses of group comparison were performed using t-
test (unless otherwise noted). As shown in Table 3.2., children in the WS group were 
significantly affected by several types of sleep problems.  
TD WS 
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Category of actigraphic scores 
TD (n=22) 
Mean (SD)/ 
Median (IQR) 
WS (n=21) 
Mean (SD)/ Median 
(IQR) 
95% CI p 
Bed time (hh:mm) 21:01 (00:44)  20:40 (00:45)  -0.82, 0.10 0.12 
Time in bed (hh:mm) 10:24 (00:31)  10:27 (00:50)  -0.34, 0.56 0.62 
Sleep latency (hh:mm) 00:34 (00:25)  00:53 (00:29)  1.82, 35.17 0.03 
Assumed sleep time (hh:mm) 09:37 (00:40)  09:36 (00:51)  -0.49, 0.47 0.98 
Actual sleep time (hh:mm) 
Actual sleep (%) 
Actual wake time (hh:mm) 
Actual wake (%) 
08:34 (00:38)  
89.63 (3.07) 
01:02 (00:19)  
10.65 (3.07) 
08:21 (00:50)  
86.10 (5.70) 
01:16 (00:27)  
13.10 (4.37) 
-0.70, 0.24 
-6.16,-0.37 
-0.2, 0.48 
0.05, 4.85 
0.32 
0.03 
0.06 
0.04 
Night waking 
Mean sleep bout time (mm:ss)* 
Mean wake bout time (mm:ss)* 
29.02 (6.51) 
17.23 (15.03-20.02) 
2.07 (2.07-2.28) 
28.52 (8.73) 
16.98 (13.81-21.69) 
2.53 (2.20-3.16) 
-5.47, 4.47 
-2.93,3.55 
0.20,0.93 
0.84 
1.00 
0.02 
Sleep efficiency (%) 
Moving minutes 
82.55 (5.60) 
78.53 (19.55) 
78.92 (6.40) 
110.88 (59.00) 
-7.47, 0.23 
3.59, 61.11 
0.06 
0.03 
Moving time (%) 
Immobile minutes 
Immobile time (%) 
Number of immobile phases 
Mean length immobility 
One minute immobility phases 
One minute immobility (%) 
13.59 (2.98) 
496.86 (34.73) 
86.23 (2.90) 
49.51 (11.62) 
10.67 (3.28) 
8.73 (3.72) 
17.32 (3.98) 
17.45 (5.71) 
465.13 (63.32) 
80.92 (9.30) 
50.46 (11.56) 
10.03 (3.66) 
11.27 (5.22) 
20.84 (6.07) 
0.89, 6.85 
-64.92, 1.45 
-9.82,-0.80 
-6.37, 8.27 
-2.84,1.56 
-0.33,5.41 
0.19, 6.84 
0.01 
0.06 
0.02 
0.79 
0.56 
0.08 
0.04 
Fragmentation index 
Total activity score* 
Mean activity score* 
Mean score in active periods* 
Average wake movement 
30.05 (6.71) 
7269 (5116-9641) 
12.56 (9.16-15.27) 
91.05 (72.53-
114.83) 
546.18 (156.36) 
39.75 (13.59) 
7720 (6221-15966) 
14.09 (10.92- 25.10) 
90.28 (66.31-115.94) 
447.12 (232.29) 
2.74, 16.64 
-426,5683 
-0.37,9.37 
-
17.52,26.47 
-228.9, 
30.83 
0.01 
0.13 
0.06 
0.83 
0.13 
* group comparison performed on Mann-Whitney 
Table 3.2. Comparison of actigraphic scores in WS and TD children using t-test and 
Mann-Whitney. Table includes mean and standard deviation (SD)/median corresponding to 
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categories of actigraphic scores on left hand column; 95% confidence interval (95% CI) and 
p value for determination of significance (p < 0.05) are also shown. Statistically significant 
results are shown in bold.   
 
 
3.3. Pulse oximetry 
 
Ten children with WS and 9 TD children refused to wear a sensor on their finger or 
toe. For the additional 3 WS children and 2 TD insufficient data was collected. Thus, 
the pulse oximetry data were available for 28 children out of 52 involved in the study 
(54%). Pulseoximetric measures included mean and median saturation of oxygen 
(SpO2), mean pulse rate, number of dips of SpO2 per hour over 4%, delta 12 s index 
(index of SpO2 variability over each 12-second epoch, where a higher figure 
indicates increased variability), time spent under 90% of SpO2 calculated in mm:ss, 
as well as in a percentage of analysis interval.  
In order to investigate if there were any differences between the WS and TD control 
group on pulse oximetry scores, Mann-Whitney/t-test for group comparison was 
performed. The Mann-Whitney test was used for the data that did not demonstrate 
normal distribution (p < 0.05 on Shapiro-Wilk test of normality), while t-test for 
normally distributed data (p > 0.05 on Shapiro-Wilk test). As shown in Table 3.3. 
children with WS had significantly higher levels of pulse rate compared to TD 
controls. No difference was observed between both groups in mean and median 
SpO2, as well as on the rest of the pulseoximetric scores.  
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Pulse oximetry parameters 
TD (n=16) 
Median (IQR)/ 
Mean (SD) 
WS (n=12) 
Median (IQR)/ 
Mean (SD) 
95% CI 
p 
value 
Mean Sp02* 96.37 (2.37) 95.22 (2.73) -2.38,0.43 0.13 
Median Sp02* 97.06 (1.73) 96.08 (2.35) -2.00,0.00 0.12 
Mean pulse rate** 74.33 (6.92) 87.49 (7.49) 6.03,16.99 
<0.00
1 
Dips/hr > 4%** 4.26 (3.55) 5.22 (3.81) -1.80,3.71 0.48 
Delta index 12 s** 0.51 (0.16) 0.59 (0.19) -0.05,0.21 0.22 
Time spent <90% SpO2 
(mm:ss)* 
14.38 (31.17) 22.38 (32.14) -16.2, 66.0 0.60 
Time spent <90% SpO2 
(% of analysis interval)* 
3.36 (6.84) 3.38 (3.94) -7.80, 4.07 0.50 
*   group comparison performed using Mann-Whitney 
** group comparison performed using t-test 
 
Table 3.3. Comparison of pulse oximetry scores in WS and TD children using Mann-
Whitney and t-test. Table includes median and IQR/ mean and SD corresponding to 
categories of actigraphic scores on left hand column; 95% confidence interval (95% CI) 
values and p value for determination of significance are also shown. 
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3.4. Children’s Sleep Habit Questionnaire 
3.4.1. Detailed characteristics of sleep disturbances in children with WS 
 
In the answer for question “Does your child have a sleep problem or have they had a 
sleep problem in the past?” 15% of the children with WS were reported as having a 
sleep problem in the past and 65% were reported as having a current problem from 
which 23% demonstrate phases of sleep problems. The sleep problems described by 
parents were: difficulty to relax and settle down during bed time, thus taking a long 
time to fall asleep, and difficulty to go back to sleep after night awakening. As 
shown in Table 3.4., 41% of parents reported that their children never or rare ly fall 
asleep within 20 min, 30% do it sometimes and as little as 33% usually sleeps the 
right amount each night. Restlessness during sleep was reported in 48% of WS 
children and up to 59% have trouble falling asleep when they are away from home 
(33%- to demonstrate this problem sometimes; 26%- often). Other frequently 
reported sleep problems included enuresis in 48% of the WS sample. A relatively 
large number of parents (53%) reported their children to be tired during the day 
(42%- sometimes; 11% often). However, despite appearing tired, none of children 
were reported to nap during the day and only 4% fall asleep spontaneously during 
daytime activities. Bruxism was a rare problem occurring in less than 5% of WS 
group (3.8%). Parents reported bruxism, sleeptalking, restlessness, sleepwalking and 
breathing problems by passively observing their children. The mean amount of 
reported sleep for WS children was 9.5 h (SD = 1.3), similar to TD group with the 
average amount of sleep 10.2 h (SD = 0.5) per night.  
 
133 
 
  Sleep problems reported in 
CSHQ 
WS children TD children 
 % U % S % R/N % U % S % R/N 
BEDTIME RESISTANCE AND 
ANXIETY: 
Going to bed at same times 
Falling asleep within 20 min 
Falling asleep in other’s bed 
Needing parent in the room to sleep 
Resisting to go to bed 
Struggling at bed time 
Trouble sleeping away 
Afraid to sleep alone 
Afraid to sleep in the dark 
 
 
85.2 
29.6 
14.8 
7.4 
3.7 
7.4 
25.9 
11.1 
22.2 
 
 
11.1 
29.6 
14.8 
0 
37.0 
40.7 
33.3 
14.8 
18.5 
 
 
3.7 
40.7 
70.4 
92.6 
59.3 
51.9 
40.7 
74.1 
59.3 
 
 
100.0 
56.5 
0 
4.3 
17.4 
0 
4.3 
4.3 
17.4 
 
 
0 
21.7 
13.6 
0 
39.1 
0 
8.7 
4.3 
4.3 
 
 
0 
21.7 
86.4 
95.7 
43.5 
100.0 
87.0 
91.3 
78.3 
NIGHT WAKINGS AND SLEEP 
DURATION: 
Moving to other’s bed  
Awaking once during the night 
Awaking more than once 
Sleeping too little 
Sufficient sleep 
Consistent sleep 
 
 
14.8 
37.0 
7.7 
33.3 
33.3 
63.0 
 
 
18.5 
25.9 
30.8 
37.0 
40.7 
33.3 
 
 
66.7 
37.0 
61.5 
29.6 
25.9 
3.7 
 
 
0 
9.1 
0 
0 
95.7 
91.3 
 
 
21.7 
40.9 
0 
26.1 
4.3 
8.7 
 
 
78.3 
50.0 
100.0 
73.9 
0 
0 
SLEEP DISORDERED 
BREATHING: 
Snoring loudly 
Holding breath during sleep 
Snorting and gasping 
 
 
0 
0 
0 
 
 
29.6 
7.7 
11.1 
 
 
70.4 
92.3 
88.9 
 
 
4.3 
0 
0 
 
 
8.7 
0 
4.3 
 
 
87.0 
100.0 
95.7 
PARASOMNIAS: 
Wetting the bed 
Sleeptalking 
Restlessness 
Sleepwalking 
Grinding teeth during sleep 
Awaken screaming, sweating 
Awaken by frightening dream 
 
48.1 
3.7 
48.1 
0 
0 
0 
0 
 
14.8 
18.5 
22.2 
0 
3.8 
11.1 
25.9 
 
37.0 
77.8 
29.6 
100.0 
96.2 
88.9 
74.1 
 
4.3 
0 
4.5 
0 
0 
0 
0 
 
4.3 
34.8 
27.3 
0 
8.7 
0 
18.2 
 
91.3 
65.2 
72.7 
100.0 
91.3 
100.0 
81.8 
DAYTIME SLEEPINESS 
Awakening by others in the morning 
Waking up in a bad mood 
Hard time getting out of bed 
Taking a long time to be alert 
Seeming tired during the day 
Falling asleep while watching TV 
Falling asleep in a car  
Falling asleep during daytime  
Napping during the day 
 
22.2 
7.4 
11.1 
0 
11.5 
7.7 
11.5 
0 
0 
 
18.5 
22.2 
14.8 
18.5 
42.3 
7.7 
7.7 
3.8 
0 
 
59.3 
70.4 
74.1 
81.5 
46.2 
84.6 
80.8 
96.2 
100.0 
 
26.1 
0 
9.1 
0 
0 
0 
0 
0 
0 
 
56.6 
22.7 
27.3 
18.2 
17.4 
0 
0 
0 
0 
 
17.4 
77.3 
63.6 
81.8 
78.3 
100.0 
100.0 
100.0 
100.0 
Table 3.4. The percentage of specific sleep problems in WS and TD children reported 
by parents in CSHQ. U indicates usually (5-7 nights/week), S- sometimes (2-4 
nights/week) and R/N- rarely/never (0-1 nights/week).  
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3.4.2. Comparison of WS and TD groups 
 
In order to investigate whether there were any differences between the WS and TD 
control groups on the total scores and subscales of CSHQ scores, one-way between-
groups Mann-Whitney test was applied. As shown in Figure 3.2 children with WS 
compared to TD controls had significantly elevated scores on bedtime resistance (p < 
0.01), sleep onset delay (p = 0.03), sleep duration (<0.001), sleep anxiety (p < 0.01), 
excessive night waking (p = 0.04) and parasomnias (p < 0.01), as well as on total 
CSHQ score (<0.001).  
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Figure 3.2. Comparison of CSHQ scores in WS and TD children using Mann-Whitney. Figure represents median and IQR of all scores. 95% confidence 
interval (95% CI) and p values for determination of significance are also shown.                                                                                                                             
* p < 0.05, ** p < 0.01, *** p < 0.001
** 
* 
** 
*** 
 * 
** 
*** 
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Lastly, sleep scores and parameters of children with WS and TD group were also 
analysed using ANCOVA with age as the covariate to control for the age effects. 
There was an expected general trend for a decrease in sleep time with increasing 
chronological age. This trend was significant for time in bed in WS group (F(1,22) = 
11.36, p < 0.01) but not TD group (F(1,20) = 0.29, p = 0.60). Similar situation was 
observed for assumed sleep time (WS: F(1,21) = 14.78, p = 0.001; TD: F(1,20) = 
0.60, p = 0.45), and the actual sleep time (WS: F(1,21) =  7.85, p = 0.01; TD: F(1,20) 
= 0.41, p = 0.53).  
 
3.5. Medical questionnaire 
 
Parents of one child from the TD group failed to return completed medical 
questionnaire, thus the data were available for 53 children out of 54 involved in the 
study (98 %). See Tables 3.5. and 3.6. for percentage of children who were reported 
with specific problems.  
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Specific health problems (%) 
TD 
(n=26) 
WS 
(n=25) 
χ2 p  
Allergies 11 4 1.00 0.32 
Asthma 11 0 3.06 0.08 
Frequent sinus infections  0 4 0.98 0.32 
Frequent colds/respiratory infections 22 20 0.02 0.88 
Frequent strep throats/tonsillitis 
Pain due to chronic medical condition 
Difficulty breathing by nose  
Frequent complain of heartburn 
8 
0 
4 
0 
4 
4 
8 
4 
0.31 
1.06 
0.31 
1.06 
0.58 
0.30 
0.58 
0.30 
Gastroesophageal reflux 
Abnormal glucose levels 
Thyroid problems 
0 
0 
0 
14 
4 
12 
2.19 
1.06 
3.31 
0.14 
0.30 
0.07 
 
Table 3.5. Percentages of specific health problems which may affect sleep and/or levels 
of melatonin and cortisol in WS and TD children. The outcome of the Chi-square 
analyses are also shown in the table. No significant difference was found between WS and 
TD children in any of these parameters. 
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Medical questionnaire variables (%) 
TD 
(n=26) 
WS 
(n=25) 
χ2 p  
Extracurricular sport activities 72 52 2.01 0.16 
TV in bedroom 12 29 2.42 0.12 
PC/game console in bedroom 23 12 1.08 0.30 
Shared bedroom 50 33 1.42 0.23 
Bedroom on the main road 8 16 0.85 0.36 
 
Table 3.6. Percentages of specific medical questionnaire parameters which may affect 
sleep patterns and/or levels of melatonin and cortisol. The outcome of the Chi-square 
analyses are also shown in the table. No significant difference was found between WS and 
TD children in any of these parameters. 
 
Further questions related to the amount of time spent watching TV/playing on the 
computer each school day and during the weekend. Parents answered on the six-
point scale: “none”, “up to 2 hrs”, “2-4 hrs per day”, “4-6 hrs per day”, “more than 6 
hrs per day” and “don’t know”. In the WS group, 72% of children spend up to 2 hrs 
and 28% between 2 and 4 hrs watching TV on school days, while for TD group these 
numbers are 65% and 31% respectively. One TD child did not watch TV at all on 
school days. Regarding playing computer/game console during the school days, in 
WS group 40% of children do not use it at all, while 60% spent up to 2 hrs playing 
games. In TD control group, 31% of children did not spent any time on the computer 
on school days, 65% did it for up to 2 hrs daily and one child spent between 2-4 hrs 
playing games. During the weekend, 24% of children with WS spent up to 2 hrs  
watching TV, 48% 2-4 hrs, 24% 4-6 hrs and 1 child over 6 hrs. For the TD group 
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these numbers are respectively: 15%, 73%, 8% and 1 child watching TV for over 6 
hrs. Twenty-four % of children with WS did not use a computer on the weekend 
days at all, 56% did it up to 2 hrs, 16% between 2-4 hrs and 1 child over 6 hrs. In TD 
group, 23% of children do not spent any time on computer/game consoles during the 
weekend, 54% spent up to 2 hrs per day and a further 23% between 2-4 hrs. Next 
question related to watching TV and/or videos in 30 min before falling sleep. Parents 
answered on a five-point scale: “every night”, “5-6 nights per week”, “3-4 nights per 
week”, “1-2 nights per week” and “not at all”. It was noted that 42% of WS children 
did not watch TV in 30 min before sleep at all, while 17% did it every night. For the 
TD children, these numbers are 38% and 23% respectively. Due to the fact that data 
were not normally distributed (p < 0.05 on Shapiro-Wilk test of normality) Mann-
Whitney analyses were conducted to determine whether there are any differences 
between both groups in any of these variables (Table 3.7.).    
 
 
 
 
 
 
 
 
140 
 
Medical questionnaire variables 95% CI
 P value 
TV on school days 0.00, 0.0001 1.00 
PC/game console on school days 0.00, 0.0001 0.40 
TV on weekend days -0.0001, 0.0002 0.69 
PC/game console on weekend days  0.00, 0.0002 0.88 
TV 30 min before sleep -0.99, 1.00 0.79 
 
Table 3.7. Comparison of specific variables from medical questionnaire between WS 
and TD children using Mann-Whitney test. Table presents 95% confidence interval 
values (95% CI) and p value for the determination of significance. It is shown that there are 
no significant differences in these parameters between both study groups (p > 0.05).  
 
Analyses of the dietary habits of the WS and TD groups showed that  88% of WS 
children and 89% of TD controls did not drink any caffeinated drinks at all ((χ2(2) = 
1.20, p = 0.55) and  there was no difference in the number of main meals consumed 
(χ2(2) = 1.29, p = 0.52). However, the WS children had significantly more snacks 
daily compared to TD controls (χ2(2) = 6.00, p = 0.05). The consumption of food 
prior bedtime (time from last meal to bedtime) has not been analysed.  
This data from Medical questionnaire was used for the analysis of covariance to 
estimate its effect on sleep and endocrine markers of sleep in both study groups (see 
Section 5.9.). 
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3.6. Comparison of actigraphy and CSHQ measures 
 
Pearson’s product-moment correlations were used to investigate the similarity 
between parent report and actigraphy, where analogous variables existed. This was 
conducted for the variables: sleep onset delay, bedtime resistance, sleep duration and 
night wakings from CSHQ, and sleep latency, assumed and actual sleep times, time 
in bed, number and duration of night wakings as well as sleep fragmentation from 
actigraphy (see Table 3.8.).  
Sleep latency was likely to correlate with parentally reported sleep onset delay. The 
significant correlation was observed for the WS (r(21) = 0.439, p = 0.05) (Figure 
3.3.), but not TD group (r(22) = 0.328, p = 0.13). Significant positive correlation was 
also observed between parentally reported night wakings and the mean wake bout 
time computed from actigraphs, however, only in TD children (r(22) = 0.441, p = 
0.04) and not in the WS group (r(21) = 0.141, p = 0.55). 
 
Figure 3.3. Comparison of sleep onset delay scores of Children’s sleep habit 
questionnaire (CSHQ) and sleep latency (min) measured by actigraphy in children 
with WS. The higher sleep latency score demonstrates more pronounced problems with 
sleep onset in children. Positive relationship can be observed between the scores on time 
taken to fall asleep measured by both methods, CSHQ and actigraphy.  
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No significant relationships were found between night wakings and sleep 
fragmentation (WS: r(22) = -0.006, p = 0.98; TD: r(19) = 0.133, p = 0.59), bedtime 
resistance and sleep latency (WS: r(21) = 0.314, p = 0.18; TD: r(22) = -0.147, p = 
0.51), sleep duration and assumed sleep time (WS: r(21) = -0.017, p = 0.94; TD: 
r(20) = -0.430, p = 0.06), sleep duration and actual sleep time (hr) (WS: r(21) = 
0.120, p = 0.61; TD: r(20) = -0.359, p = 0.12), sleep duration and the percentage of 
actual sleep time in the night (WS: r(22) = 0.106, p = 0.65; TD: r(20) = 0.095,           
p = 0.69), sleep duration and time in bed (WS: r(22) = 0.034, p = 0.88; TD: r(20) =          
-0.415, p = 0.07) and for the number of night wakings reported by parents in CSHQ 
as well as computed by actigraphy (WS: r(21) = -0.239, p = 0.31; TD: r(19) = -0.228, 
p = 0.35). Many of the correlations were negative, especially in TD group (nearly 50 
% of negative correlations), indicating that parents’ knowledge of their children’s 
sleep is limited. Due to the nature of parental questionnaire as well as the 
subjectivity and inaccuracy of CSHQ for reporting sleep characteristics, it should not 
be used as a substitute for objective measures, such as actigraphy and PSG. 
However, many of the CSHQ parameters, such as child waking up in negative mood, 
pain reports or appetite cannot be measured by actigraphy, and in addition, sleep 
diary is necessary for analysis of actigraphy data, thus, parent report should still be 
valued. 
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Parental report 
(CSHQ) 
Actigraphy parameters Group r value P value 
Sleep onset delay Sleep latency 
TD(22) 0.33 0.13 
WS(21) 0.44 0.05 
Night wakings 
Mean wake bout time 
TD(22) 0.44 0.04 
WS(21) 0.14 0.55 
Sleep fragmentation 
TD(19) 0.13 0.59 
WS(22) -0.01 0.98 
Bedtime resistance Sleep latency 
TD(22) -0.15 0.51 
WS(21) 0.31 0.18 
Sleep duration 
Assumed sleep time 
TD(20) -0.43 0.06 
WS(21) -0.02 0.94 
Actual sleep time 
TD(20) -0.36 0.12 
WS(21) 0.12 0.61 
The percentage of actual 
sleep time in the night 
TD(20) 0.10 0.69 
WS(22) 0.11 0.65 
Time in bed 
TD(20) 0.415 0.07 
 WS(22) 0.03 0.88 
Night waking Number of wakings 
TD(19) -0.23 0.35 
WS(21) -0.24 0.31 
 
Table 3.8. Pearson’s product moment correlation analysis between parental report 
(Children’s Sleep Habit Questionnaire- CSHQ) and actigraphy. Only two significant 
correlations can be observed and are indicated in bold. Many of the correlations were 
negative, especially in TD group (nearly 50 % of negative correlations), indicating that 
parents’ knowledge of their children’s sleep is limited and parental reports are not reliable 
methods of sleep analysis in children.  
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Summary 
This chapter outlines the results obtained from the measurements undertaken at 
participant’s home environment including questionnaires, actigraphy and pulse 
oximetry. It has been shown, that children with WS demonstrate significant sleep 
disturbances including increased sleep latency, moving time during the night and 
fragmentation index, which is the indication of restlessness as well as bedtime 
resistance and sleep anxiety. Furthermore, no breathing-related problems, which 
could affect sleep, were found in any of the study groups.   
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4. METHODOLOGY- LABORATORY ANALYSES OF 
BIOMEDICAL MARKERS OF CIRCADIAN RHYTHM AND 
SLEEP 
 
Previous chapters focused on the analysis of sleep patterns in WS and TD children. 
However, as stated in the aims, the current work focused on the analysis of endocrine 
markers of circadian rhythm, namely melatonin and cortisol. Thus, the following 
section outlines a detailed description of sample collection from participants as well 
as the enzyme based immunoassay techniques used for analysis of salivary 
melatonin and cortisol as well as urinary MT6s. Lastly, the development and 
application of a ultra-high performance liquid chromatography- tandem mass 
spectrometry (UHPLC-MS/MS) method for simultaneous measurement of MT6s, 
cortisol and cortisone in urine is described. 
 
4.1. Sample collection 
 
Given compliance and ethical concerns regarding repeated sample collection from 
children, salivary levels of cortisol and melatonin as well as urinary levels of 
cortisol, cortisone and MT6s were measured. The environmental conditions, such as 
stress, cause a physiologic increase in cortisol levels, thus, parents of all the children 
were instructed to ensure normal night routine for each child and were further asked 
whether anything abnormal happened in a day/night of collection. Saliva and urine 
samples were all obtained within the same time as actigraphy, pulse oximetry and 
CSHQ measurements and during the weekdays to ensure normal routine. Samples 
146 
 
were collected over the period of one year through all the seasons. The reports 
regarding seasonal changes of melatonin and cortisol are inconclusive. The delay of 
the time of maximum excretion was found for both melatonin and cortisol during 
Winter in comparison to samples collected in Summer (Kennaway & Royles, 1986). 
On the other hand, it has also been reported that the excretion of 6-
sulfatoxymelatonin and amplitude of cortisol excretion is remarkably stable between 
summer and winter solstices (Kennaway & Royles, 1986) and in addition, no  
influence of season of the year on levels of melatonin was found (Sack et al., 1986). 
 
4.1.1. Saliva 
 
Due to circadian rhythmicity of melatonin and cortisol, saliva samples were obtained 
at three time points: afternoon between 4-6 pm, evening before bedtime, and 
morning immediately after awakening. Sample collection at these three time points 
provided a means of determining whether sleep hormones in WS follow similar or 
different pattern compared to TD control group. In order to ensure that the time 
between first collection and bedtime sample did not vary strongly across study 
participants, parents were instructed, that the time difference between these 
collection points should fall within 3-4 h. Several studies have reported high stability 
and intra-day reproducibility of melatonin (Benloucif et al., 2008; Mirick & Davis, 
2008) and cortisol (Kudielka & Kirschbaum, 2003; Stone et al., 2001) in the same 
individual. Thus, in the current work, samples were collected over the period of one 
day. It has also been established that salivary levels of melatonin and cortisol closely 
parallel those found in corresponding blood samples (Voultsios et al. 1997; Dorn et  
al. 2007). 
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Parents of all the participants were trained in how to collect saliva samples and the 
collection protocol was given to each parent (Appendix 6 and 7). Parents were asked 
to collect samples in a dimly lit room as high intensity of light is known to suppress 
level of melatonin. Saliva was collected using saliva collection devices including 
inert polymer swab (Salimetrics Europe, UK). On the day of collection every child 
was asked to avoid caffeinated drinks, chocolate and bananas, as these can affect 
levels of hormonal markers of sleep. Every child was asked to, avoid any food or 
drink for at least 15 min and to rinse their mouth with water before sampling. A 
swab was placed in the mouth for 3 to 5 min until it was thoroughly wet, and then 
placed into a storage tube. If this method of sampling caused any discomfort to the 
child, they could instead spit directly into the tube. Every sample was labelled with 
the time and date of collection and then stored in a household fridge for maximum of 
24 h before they were transported in ice to a laboratory freezer. In cases when it was 
not feasible to transport the samples within 24 h, parents were asked to freeze the 
specimens. In these cases when the samples collected from parents were already 
frozen, they have been placed directly to the laboratory freezer, then thawed and 
centrifuged on the day of analysis. Samples were transported to the laboratory in ice 
box and centrifuged for 10 min at 1500 g in order to extract saliva. Volume capacity 
of thoroughly saturated swab was 1 ml. Saliva collected at the bottom of the 
centrifuge tubes was subsequently divided into 2-3 aliquots and stored at -20°C until 
assayed. It has been reported that salivary melatonin is stable for at least 3 days even 
when kept at room temperature, and for months (probably years) when kept frozen 
(at -20°C or lower) (Weber et al., 1999). It has also been reported that storage of 
uncentrifuged swabs for 24 h at 4°C or for 2 months in a freezer does not affect the 
recovery of melatonin from the swab. Thus, there is no need to centrifuge samples 
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within short period of time after collection (Bagci et al., 2009). Cortisol levels also 
demonstrate good stability, salivary cortisol is stable for at least a year at -20°C 
(Garde & Hansen, 2005).  
 
4.1.2.  Urine 
 
First void urine samples were collected into 200 ml storage pots which were labelled 
with the date and time of collection. No food or drink was given prior to collection. 
As in the case of saliva samples, urine specimens were stored by parents of 
participating children in the household fridge for maximum of 24 h before they were 
transported to a laboratory freezer. In cases where it was not possible to transport the 
samples within 24 h of collection then they were stored in a freezer. Following 
transfer to the laboratory, uncentrifuged urine samples were divided into 4-5 aliquots 
and stored at -20°C. In cases where the samples collected were already frozen, they 
were transported in ice to a laboratory freezer. They were thawed and centrifuged on 
the day of analysis. Bojkowski et al. (1987) stored urine samples without 
preservative at room temperature for 5 days, and at -20°C for 2 years and found that 
urinary metabolite of melatonin (MT6s) is stable under both conditions. Cortisol 
levels also demonstrate good stability in the urine, the samples can be stored in a 
freezer for at least 9 months (Barrett et al., 2005). 
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4.2. Analyses of salivary melatonin 
 
Salivary melatonin was analysed in duplicates using a competitive ELISA kit from 
IBL International (Germany).  The assay is based on the competition between 
biotinylated melatonin and melatonin in the sample for a fixed number of antibody 
biding sites (Figure 4.1.).  
Prior to analyses, each sample was thawed, mixed and centrifuged for 10 min at 
3500 rpm. An aliquot (100 µl) of each sample, control and standards were added to 
wells coated with anti-rabbit IgG polyclonal antibodies. In the next step 50 µl of 
antiserum was added to each well, except blank wells. Plates were then incubated 
overnight for 16-20 h at 4 °C. After each incubation process, plates were washed five 
times with ‘wash buffer’ and excess solution was removed by inverting the plate 
onto a paper towel and tapping it. In the next step biotin solution (100 µL) was added 
to each well and the plate was incubated for 2 h at room temperature. After this 
incubation step and plate washing, 100 µl of enzyme conjugate (streptavidin 
conjugated to horseradish peroxide) was added to each well and the plate was 
incubated for additional 1 h at room temperature. Following the last wash step, 100 
μl of tetramethylbenzidine (TMB) substrate was added to each well and the plate 
was incubated for 15 min at room temperature. TMB chromophore (blue) was 
formed in each well. Directly after this incubation step 100 µl of TMB stop solution 
(1M sulphuric acid) was added to each well, which produced a yellow colour. In the 
last step, the plate was shaken briefly and the absorbance was measured using a 
FLUOstar OPTIMA plate reader (BMG LABTECH) set at wavelength of 450 nm 
within 15 min after pipetting stop solution. Final results were calculated from 4 
Parameter Logistic fit, using OPTIMA MARS data analysing software (BMG 
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LABTECH). The concentration of analyte in the sample was determined using a  
standard curve. The amount of biotinylated antigen bound to the antibody, as 
measured by the intensity of colour, is inversely proportional to the analyte 
concentration of the sample. Samples with melatonin levels exceeding highest level 
of standard curve were diluted with standard A, reassayed and the results were 
multiplied by the corresponding dilution factor.  The sensitivity of the assay was 0.3 
pg/ml. The assay was carried out according to manufacturer’s instructions with 
modification in washing steps (five washing steps instead of four) (Melatonin direct 
saliva ELISA instruction of use, http://www.ibl- international.com).  
 
Figure 4.1. Principle of competitive ELISA method. 
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4.3. Analyses of salivary cortisol 
 
Salivary cortisol was assayed in duplicates using competitive enzyme immunoassay 
kit from Salimetrics Europe (Suffolk, UK). On the day of analysis, saliva samples 
were thawed, vortexed and centrifuged at 3000 rpm for 15 min. Multiple freeze-thaw 
cycles were avoided. Samples were allowed to reach room temperature before they 
were transferred to an assay plate. This assay was based on the competition between 
standards and unknowns with cortisol linked to horseradish peroxide for the antibody 
biding sites. In the first step an aliquot of each sample, standard or control (25 µL) 
was added to a microtiter plate coated with monoclonal anti-cortisol antibodies. 
Next, 200 µl of cortisol conjugated to horseradish peroxide was added to each well  
and the plate was incubated for 55 min at room temperature. The plate was then 
washed five times with washing buffer. An aliquot (200 µL) of the substrate TMB 
was added to each well. The plate was then placed on a plate rotator for 5 min at 500 
rpm and incubated for additional 25 min at room temperature. Bound cortisol 
peroxidase was measured by the reaction of peroxidase enzyme on the TMB 
substrate. This reaction produced a blue colour. A yellow colour was formed after 
stopping the reaction with 50 µl of stop solution (3 M sulphuric acid). Following 3 
min of mixing on the plate rotator at 500 rpm, the optical density was determined 
using a standard FLUOstar OPTIMA plate reader (BMG LABTECH) set at a 
wavelength of 450 nm. Final results were calculated from 4 Parameter Logistic fit 
using OPTIMA MARS data analysing software (BMG LABTECH). The 
concentration of analyte in the sample was determined using a standard curve. The 
amount of cortisol peroxidase detected, as measured by the intensity of colour, was 
inversely proportional to the amount of cortisol present. Samples with cortisol levels 
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exceeding highest level used to generate a standard curve were diluted with assay 
diluent and reassayed. The sensitivity of the assay was 30 pg/ml. The assay was 
carried out according to manufacturer’s instructions with modification in washing 
steps (five washing steps instead of four) (High sensitivity salivary cortisol enzyme 
immunoassay kit protocol, http://www.salimetrics.com). 
 
4.4. Analyses of MT6s using ELISA 
 
Urinary Mt6s was analysed using competitive ELISA kit from IBL International 
(Germany). The assay is based on the competition between unknown amount of 
antigen present in the sample with a fixed amount of enzyme labelled antigen for the 
biding sites of the antibodies coated onto the wells.  
Prior to analyses, each sample was thawed, mixed and centrifuged for 10 min at 
3500 rpm. A small volume (10 µl) of each standard, control and urine sample was 
transferred to an eppendorf tube, mixed with 500 µL of assay buffer and vortexed. 
Further, 50 µl of each diluted standard, control and samples were transferred into the 
respective walls of the microtiter plate. Next, 50 µl of enzyme conjugate was added 
to each well, followed by 50 µl of melatonin sulphate antiserum. The plate was 
further incubated for 2 h at room temperature on orbital shaker (500 rpm). The plate 
was then washed five times with washing buffer and 100 µl of the TMB substrate 
solution was added to each well. The plate was then incubated for 30 min at room on 
a plate rotator at 500 rpm. Chromophore was formed in inverse proportion to the 
amount of MT6s. This reaction produced a blue colour. Directly after this incubation 
step 100 µl of TMB stop solution (1M sulphuric acid) was added to each well, which 
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produced a yellow colour. In the last step, the plate was shaken briefly on a shaker 
and the absorbance was measured using a FLUOstar OPTIMA plate reader (BMG 
LABTECH) set at a wavelength of 450 nm. Final results were calculated from 4 
Parameter Logistic fit, using OPTIMA MARS data analysing software (BMG 
LABTECH). The absorbance reading was used to determine level of analyte present 
in a sample. The concentration of analyte in the sample was determined using a  
standard curve. The intensity of colour was inversely proportional to the analyte 
concentration in the urine sample. The sensitivity of the assay was 1 ng/ml. The 
assay was carried out according to manufacturer’s instructions with modification in 
washing steps (five washing steps instead of four) (Melatonin sulfate ELISA 
instruction of use, http://www.ibl- international.com).  
For the analysis of salivary melatonin and cortisol as well as urinary MT6s using 
immunoassays, each sample was run in duplicate and average value was calculated 
and used for further data analyses. In these cases when the results of duplicate 
samples did not agree within 10 % (van Emmon, 2006), samples were re-run and the 
concentrations that were within 10 % were taken for further analysis.  
 
 
4.5. Analyses of urinary levels of MT6s, cortisol and cortisone using 
UHPLC-MS/MS 
 
UHPLC-MS/MS is an analytical technique that combines separation of compounds 
using chromatography with detection using a mass spectrometer. The liquid 
chromatography component is used to physically separate compounds and the mass 
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spectrometer is used to detect the compounds on the basis of their m/z ratio. In the 
current work a UHPLC-MS/MS method (described in details in Section 1.2.2.) was 
developed for the measurement of cortisol, cortisone and MT6s in urine of children 
with WS and a TD control group. In order to account for the dilution of urine, 
creatinine was analysed separately using UHPLC-MS/MS method as well and the 
levels of cortisol, cortisone and MT6s were divided by creatinine levels.   
 
4.5.1. Chemicals  
 
Standards of cortisol and cortisone were purchased from Sigma-Aldrich (Dorset, 
UK). Due to the lack of commercially available standards for MT6s, for the 
development of LC-MS/MS method and calibration curve, standards for melatonin 
sulphate from an ELISA kit (IBL International, Germany) were used. Creatinine 
standard was purchased from Acros Organics (Geel, Belgium). 6-α-
methylprednisolone used as internal standard for cortisol and cortisone, indole-3-
acetamide used as IS for MT6s as well as 1-(3-aminopropyl)imidazole used as IS for 
creatinine were also obtained from Sigma-Aldrich (Dorset, UK). Acetonitrile of 
LiChrosolv LCMS-grade was purchased from Merck Millipore (Feltham, UK).  
 
4.5.2. Preparation of stock and standard solutions  
 
Cortisol (1 mg) and cortisone (1 mg) were dissolved in 10 ml of methanol to give 0.1 
mg/ml stock solutions. These solutions were used to prepare standard solutions in 
methanol at concentrations of 2.78, 5.56, 16.67, 50 and 100 ng/ml. Standard 
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solutions from MT6s ELISA kit were used at concentrations of 3.11, 6.22, 18.67, 56 
and 112 ng/ml. Creatinine (5 mg) was dissolved in 5 ml of deionised water to give a 
1 mg/ml stock solution. Standard in the concentration range 0.125-0.75 mg/ml for 
calibration studies were prepared using this stock solution. All the standard solutions 
for the calibration curves were spiked with the internal standards. 
Normal levels of urinary cortisol range between 1.5-37 ng/ml and cortisone between 
2.8-73 ng/ml in 3 to 8 years old children (Mayo Clinic, 
http://www.mayomedicallaboratories.com). Due to the fact that these represents 
mean daily levels of both analytes, morning levels were expected to be closer 
towards higher values. In addition, taking into account the prevalence of anxiety in 
WS, it was expected that WS children may have higher levels of cortisol and 
cortisone. Thus, the standard range for calibration curve was selected in 
concentrations between 2.8 and 100 ng/ml. Subsequently, normal levels of creatinine 
in children range between 0.25 mg/ml to 0.75mg/ml (Vasudevan & Sreekumari, 
2007; MacGregor & Methven, 2011), thus, concentrations chosen for standard curve 
ranged between  0.125-0.75 mg/ml.  
 
4.5.3. Sample preparation 
 
Frozen urine samples were thawed and centrifuged for 5 min at 1500 g, and then 
diluted in water (1:1 v/v). For the analysis of cortisol, cortisone and MT6s, 500 ml of 
diluted samples were spiked with a small volume (2.5 µl) of the internal standards 
working standards (10 µg/ml) and vortexed for 30 s. For the analysis of creatinine, 
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600 ml of diluted samples were spiked with 30 µl of the internal standards working 
standards (10 µg/ml) and vortexed.  
 
4.5.4. LC-MS/MS 
 
A LC-MS/MS system comprising of a Shimadzu UHPLC Nexera system interfaced 
to a triple quadrupole mass spectrometer LCMS-8030 (Shimadzu Corporation, 
Japan) equipped with an ESI source. The chromatographic separations were 
performed using a Kinetex 2.1 x 50 mm, 2.6 µm, C18 (Phenomenex, Maccelsfield, 
UK). The UHPLC system was composed of two LC-30AD pumps, a column oven 
(CTO-20AC) maintained at 40 ºC and a DGU-20A3 solvent degasser. A binary 
gradient elution profile composed of eluent ‘A’ 0.1 % formic acid in water and ‘B’ 
0.1 % formic acid in acetonitrile was used. The eluent was delivered at a flow rate of 
0.4 ml/min. For the separation of cortisol, cortisone, MT6s and their internal 
standards  a linear gradient from 2% to 90% ‘B’ over 4 min followed by a hold at 90 
% ‘B’ for 0.5 min then a drop back to 2% ‘B’ with a final reequilibration at 2 % ‘B’ 
for 1.5 min was used. For the separation of creatinine and its IS a linear gradient 
from 2% to 90% % ‘B’ over 2 min followed by a hold at 90 % ‘B’ for 0.5 min then a 
drop back to 2% ‘B’ with a final reequilibration at 2 % ‘B’ for 1.5 min was used. The 
desolvation line temperature was maintained at 300 °C while the heatblock 
temperature was set at 400 °C. An interface voltage of 4.5 kV was applied to the 
electrospray probe. Nitrogen was used as the nebulising gas at a flow rate of 2.8 
l/min, additionally, the flow rate of drying gas was 16 l/min. Detection and 
quantification of all the compounds apart from MT6s was accomplished using 
multiple reaction monitoring (MRM). MT6s was analysed using the mass 
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spectrometer in the single ion monitoring (SIM) mode. An injection volume of 5 µl 
was used for the main method (analysis of cortisol, cortisone and MT6s) and 0.1 µl 
was injected for the analysis of creatinine. The ESI was operated in a positive ion 
mode using the MRM transitions or m/z values detailed in Table 4.1. includes mass 
ion transitions for the compounds. The raw data were processed using Lab Solution 
Software.  
 
Compound 
Molecular 
ion (m/z) 
Product 
ion (m/z) 
Cortisol 363.25 121.05 
Cortisone 361.05 163.1 
6-sulfatoxymelatonin* 328.8 - 
6-α-methylprednisolone 375.25 161 
Indole-3-acetamide  174.9 130 
Creatinine 113.9 86 
1-(3-aminopropyl-imidazole) 126.1 69.1 
 
Table 4.1. Mass ion transitions for analytes measured in urine. Note 6-
sulfatoxymelatonin was analysed using the m/z for the molecular ion.  
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4.5.5. Method validation 
 
Quality control (QC) samples were a mixture of three control urine samples spiked 
with known amount of all internal standards (see sample preparation Section 4.5.3.). 
These samples were run nine times for analysis of cortisol, cortisone and MT6s, and 
five times for analysis of creatinine.  
The intra-assay precision was determined by analysing 15 replicates of cortisone and 
cortisol at concentrations of 2.78, 5.56, 16.67, 50 and 100 ng/mL, 10 replicates of 
MT6s at concentrations of 3.11, 6.22, 18.67, 56 and 112 ng/mL and 18 repeat 
injections of creatinine at concentrations of 0.125, 0.25, 0.5 and 0.75 mg/mL. The 
results were corrected to peak areas of internal standards prior to calculation of 
repeatability.  
The inter-assay variability was measured by 12 replicate injections of cortisol and 
cortisone at concentrations of 2.78, 5.56, 16.67 and 50 ng/mL, 10 repeat injections 
of, MT6s at concentrations of 3.11, 6.22, 18.67 and 56 ng/mL and 20 replicate 
injections of creatinine at concentrations of 0.125, 0.25, 0.5 and 0.75 mg/mL. These 
samples were analysed over two consecutive days and the HPLC peak areas were 
corrected to peak areas of internal standards.  
 
4.6. Statistical analyses 
 
The statistical analyses for group comparisons were performed according to the 
description in Section 2.5. ANCOVA was used for the analysis of relationship 
between sleep parameters and levels of endocrine markers of sleep and circadian 
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rhythm, namely melatonin, cortisol and their metabolites, as well as to control for the 
effect of health/dietary and sleep habits on sleep in children with WS and TD group.  
 
Summary 
The current chapter included description of sample collection as well as the enzyme 
based immunoassay techniques used for the analysis of salivary melatonin and 
cortisol as well as urinary MT6s. In the last part of this chapter, the novel UHPLC-
MS/MS method for the analysis of 6-sulfatoxymelatonin, cortisol and cortisone in 
urine was described. The salivary analyses of these hormones were carried out to 
observe changes occurring prior to bedtime. In order to determine nocturnal levels of 
melatonin and cortisol and to answer the question whether indeed we can observe 
differences in levels of these hormones between WS and TD children, the novel 
UHPLC-MS/MS method was developed for urine.  
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5. RESULTS- LABORATORY ANALYSES OF BIOMEDICAL 
MARKERS OF CIRCADIAN RHYTHM AND SLEEP 
 
 
The following chapter includes detailed description of the data obtained by analysis 
of melatonin, cortisol and their metabolites in saliva and urine of children with WS 
and TD control group. The comparison of ELISA and UHPLC-MS/MS methods for 
analysis of MT6s is also included. Furthermore, the association between sleep 
parameters and levels of endocrine markers of sleep is described as well. 
 
 
5.1.  Salivary melatonin 
 
Twenty- two children out of 27 in the WS group and all TD children collected at 
least one out of three saliva samples. Of 22 WS children who collected saliva 
samples, 2 were excluded because it was noted that they were taking melatonin as 
medication by the time the assessments were due to be made. Levels of melatonin in 
saliva were determined using ELISA (see Section 4.2.). The standard curve for 
melatonin analyses was in range 0.5 to 50 pg/ml (Figure 5.1.). Each sample was run 
in duplicate and average value was calculated and used for further data analyses. The 
average recovery quoted by the manufacturer of this assay is 96.8%. High individual 
variability in the amount of melatonin secreted was observed between participants in 
both groups. In the WS group melatonin levels ranged from 0.19-17.40 pg/ml in the 
afternoon, 0.06-26.47 pg/ml in the evening and 0.12-14.71 pg/ml in the morning. For 
the TD control group these values were 0.06-9.13 pg/ml, 0.15-26.38 pg/ml and 0.06-
38.10 pg/ml respectively (see Figure 5.2.). 
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Figure 5.1. Standard curve of melatonin, r
2
 = 0.999. The x axis represents concentration 
of the standards and y axis corresponding absorbance value. 
 
 
Figure 5.2. Raw levels of salivary melatonin in the afternoon, bedtime and morning 
samples from children with WS and TD control group. Data are shown as a median and 
quartiles. Circles represents outliers. High individual variability in the amount of melatonin 
secreted was observed between participants in both groups. 
162 
 
In order to compensate for individual variation and to observe the changes of 
melatonin before night time sleep, the morning level of this hormone was set to 
100% and the afternoon and evening levels were normalised as a percentage of the 
morning value (Nowak et al., 1987; Cinaz et al., 2013). 
Mann-Whitney analyses were used for group comparison. There was no significant 
difference in the levels of normalised melatonin in the afternoon and evening 
between WS and TD groups (Table 5.1., Figure 5.3.). 
 
 Groups Median 95% CI p value 
Normalised melatonin 
afternoon (%) 
TD (n=25) 40.37 
-9.43, 55.70 0.13 
WS (n=17) 72.22 
Normalised melatonin  
bedtime (%) 
TD (n=21) 80.48 
-72.7, 35.0 0.78 
WS (n=19) 61.03 
 
Table 5.1. Comparison of normalised levels of melatonin in WS and TD children using 
Mann-Whitney test. Table includes median for afternoon and evening levels of melatonin 
calculated as a percentage of the morning value. 95% confidence interval values (95% CI)  
and p value are also shown for the determination of significance. N value accounts for the 
differences from N = 27, as some children failed to provide all three saliva samples and two 
were excluded because they were taking melatonin as sleep medication. 
 
As described in Section 1.1.5, the evening rise of melatonin secretion facilitates 
sleep. Thus, the increase in level of this hormone between afternoon to evening 
should be observed. In order to investigate changes in level of melatonin before 
bedtime, the ratio between raw, not-normalised levels of melatonin in evening and 
afternoon samples was calculated for each participant. There was a median fold 
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increase of 1.83 in TD control group, whereas there was no such increase observed 
for the WS children (Table 5.2., Figure 5.3.). 
 
Table 5.2. Increase of melatonin levels between afternoon and evening saliva samples 
collected from children with WS and TD controls. Table includes minimum and 
maximum value, as well as median of the ratio of melatonin between afternoon and evening 
samples.  95% confidence interval values (95% CI) and p value are also shown for the 
determination of significance. N value accounts for the differences from N=27, as some 
children failed to provide all three saliva samples and two were excluded because they were 
taking melatonin as sleep medication. 
 
 
Figure 5.3. Normalised levels of salivary melatonin in the afternoon and bedtime in 
children with WS and TD control group. Data are shown as a median and quartiles. There 
was a significant difference in the ratio between afternoon and bedtime levels of salivary 
 Groups Minimum Maximum Median 95% CI p value  
Increase of 
melatonin levels 
from afternoon 
to bedtime 
TD 
(n=20) 
0.36 10.73 1.83 
-1.53, -0.04 0.04 
WS 
(n=17) 
0.19 2.72 0.96 
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melatonin between WS and TD children (p = 0.04) with less pronounced increase in 
melatonin levels in WS prior to bedtime. 
 
 
5.2. Salivary cortisol 
 
Twenty- two children out of 27 in the WS group and all TD children collected at 
least one out of three saliva samples. Cortisol levels rise rapidly during the first 30 
min after awakening (Clow et al., 2010), hence it seemed necessary to collect the 
samples as soon as the child was awake. No difference was observed between both 
groups in the time from waking up to collection of the samples using independent 
samples t-test (t(35) = 0.861, p = 0.40). 
Levels of cortisol were determined using an enzyme immunoassay. The standard 
curve for this assay was in range from 0.012 to 3 µg/dl (Figure 5.4.). Each sample 
was run in duplicates and average value was calculated for further analyses. The 
average recovery quoted by the manufacturer of this assay is 100.82%. The level of 
cortisol was found to be at a maximum in the morning and lowest at bedtime, 
indicating circadian rhythmicity of salivary cortisol levels. Cortisol levels in WS 
group ranged from 0.01 to 0.21 µg/dl in the afternoon, 0.01 to 0.14 µg/dl in the 
evening and 0.04 to 0.75 µg/dl in the morning. For TD control group these values are 
respectively 0.02 to 0.16 µg/dl, 0.01 to 0.12 µg/dl and 0.09 to 0.89 µg/dl (see Figure 
5.5.). As described in the Section 1.1.6. cortisol levels are highest in the morning and 
decline through the day. Obtained values reflect this pattern, the highest levels are 
observed in the morning, lower in the afternoon and finally the lowest at bedtime.  
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Figure 5.4. Standard curve of cortisol, r
2
 = 0.999. The x axis represents concentration of 
standard solutions, while y axis corresponding absorbance value. 
 
 
Figure 5.5. Raw levels of salivary cortisol in the afternoon, bedtime and morning 
samples from children with WS and TD control group. Data are shown as a median and 
quartiles. Circles represents outliers. High individual variability in the amount of melatonin 
secreted was observed between participants in both groups. 
166 
 
In order to compensate for individual variation and to observe the changes of cortisol 
before night time sleep, the morning level of this marker was set to 100% and the 
afternoon and evening levels were normalised as a percentage of the morning value 
(Cinaz et al., 2013). 
For further group comparison Mann-Whitney test was applied. There was no 
significant difference in the levels of normalised cortisol in the afternoon between 
WS and TD groups but a significantly higher value was observed in the evening 
before bedtime in WS participants (Table 5.3., Figure 5.6.).  
Two TD data points and 1 data point from WS group were excluded as outliers 
(scored over 3 values of SD from the mean).  
 
 Groups Median 95% CI p value 
Normalised cortisol 
afternoon (%) 
TD (n=25) 22.22 
-9.02, 14.11 0.69 
WS (n=20) 27.17 
Normalised cortisol 
evening (%) 
TD (n=20) 15.29 
-0.56, 29.99 0.03 
WS (n=20) 33.45 
 
Table 5.3. Comparison of normalised levels of cortisol in WS and TD children using 
Mann-Whitney test. Table includes median for afternoon and evening levels of melatonin 
calculated as a percentage of morning value.  95% confidence interval values (95% CI) and 
p value are shown for the determination of significance. N value accounts for the differences 
from N=27, as some children failed to provide all three saliva samples and two were 
excluded due to taking melatonin as a sleep medication.  
 
A more detailed investigation of the cortisol levels was carried out calculating the 
ratio of raw, not-normalised cortisol levels between afternoon and evening samples. 
There was a median fold decrease of 1.37 in level of cortisol in individuals with WS, 
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whereas for the TD control group a decrease of 2.25 was observed (p < 0.01) (Table 
5.4. and Figure 5.6.).  
 
Table 5.4. Decrease of cortisol levels between afternoon and evening saliva samples 
collected from children with WS and TD controls. Table includes minimum and 
maximum value, as well as median of the ratio of cortisol between afternoon and evening 
samples. 95% confidence interval values (95% CI)  and p value are also shown for 
determination of significance. N value accounts for the differences from N=27, as some 
children failed to provide all three saliva samples and two were excluded due to taking 
melatonin as a sleep medication.  
 
Figure 5.6. Normalised levels of salivary cortisol in the afternoon and bedtime in 
children with WS and TD control group. Data are shown as a median and quartiles. There 
was a significant difference in the ratio between afternoon and bedtime levels of salivary 
cortisol (p < 0.01) between WS and TD children with shallower drop of cortisol levels in 
WS prior to bedtime. Furthermore, children with WS demonstrated significantly higher 
levels of bed-time salivary cortisol (p = 0.03). 
 Groups Minimum Maximum Median CI p value 
Decrease of 
cortisol levels 
from afternoon 
to bedtime 
TD 
(n=22) 
0.21 10.00 2.25 
-2.61, -0.40 <0.01 
WS 
(n=19) 
0.09 3.50 1.37 
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5.3. Analysis of MT6s using ELISA 
 
First void morning urine samples (21 from WS and 24 from TD children) were 
analysed using ELISA. The standard curve for MT6s analyses was in range from 1.7 
to 420 ng/ml (Figure 5.7.). Each sample was run in duplicate and average value was 
calculated and used for further analyses. The average recovery quoted by the 
manufacturer of this assay is 105.8%.  
 
 
 
Figure 5.7. Standard curve of MT6s levels , r
2
 = 0.998. The x axis represents concentration 
of the standard solutions, while y axis represents corresponding absorbance value.  
 
The MT6s levels were corrected to levels of creatinine to account for the dilution of 
urine. MT6s concentration in samples from WS children ranged between 8.91-
398.70 ng/mg creatinine and in TD group ranged from 54.61 to 488.51 ng/mg of 
creatinine. Mann-Whitney test were used for group comparison. As shown in Table 
5.5. children with WS scored significantly lower levels of MT6s compared to healthy 
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controls. One TD sample was removed as an outlier over 3 values of SD from the 
mean. 
 
Table 5.5. Comparison of levels of 6-sulfatoxymelatonin (MT6s) in WS and TD 
children using Mann-Whitney. Table includes median of the compound concentration; 
95% confidence interval values (95% CI)   and p value for determination of significance are 
also shown. N value accounts for the differences from N=27, as some children failed to 
provide urine sample and two were excluded due to taking melatonin as a sleep medication. 
 
ANCOVA tests were used to investigate whether MT6s levels were associated with 
chronological age of groups. No statistical effect of age on MT6s levels measured 
using ELISA was observed in the WS and TD groups (WS: F(1,21) = 0.811, p = 
0.38; TD: F(1,23) = 1.071, p = 0.31).  The effect of bed-wetting on levels of MT6s in 
WS was not significant (F(1,21) = 1.68, p = 0.21). Using independent samples t-test, 
gender difference was analysed in both study groups. It was found that urinary levels 
of MT6s do not differ between boys and girls in WS (t(18) = -0.523, p = 0.61) and 
TD groups (t(21) = -0.976, p = 0.34).  
 
 
 Groups Median 95% CI p value 
MT6s levels in urine 
(ng/mg creatinine) 
TD 
(n=23) 
171.60 
-151.5, -20.4 <0.01 
WS 
(n=21) 
83.40 
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5.4. Effect of chronological age, gender and the time of sample 
collection on levels of salivary melatonin and cortisol 
 
Levels of melatonin and cortisol were analysed using ANCOVA with chronological 
age covariate to control for age effects (Table 5.6.). There was no effect of age on 
the levels of salivary melatonin in samples collected in the afternoon (WS: F(1,17) = 
0.002, p = 0.96; TD: F(1,25) = 0.001, p = 0.98) and bedtime samples (WS: F(1,19) = 
0.006, p = 0.94; TD: F(1,21) = 0.382, p = 0.54). Similarly there was no significant 
effect of age on salivary cortisol in the samples taken in the afternoon (WS: F(1,20) 
= 1.361, p = 0.26; TD: F(1,25) = 0.655, p = 0.43) and bedtime (WS: F(1,21) = 0.034, 
p = 0.855; TD: F(1,22) = 0.713, p = 0.408), for both groups. No gender difference in 
levels of afternoon and bedtime melatonin as well as bedtime cortisol was found in 
either study groups using independent samples t-test (afternoon melatonin: WS: t(15) 
= -0.266, p = 0.79, TD: t(23) = -1.653, p = 0.11; bedtime melatonin: WS: t(17) = 
0.079, p = 0.94, TD: t(19) = -0.933, p = 0.36; bedtime cortisol: WS: t(19) = -1.100, p 
= 0.29, TD: t(20) = -0.013, p = 0.99). For the afternoon cortisol levels it was noted 
that girls have significantly higher levels than boys in WS group (t(18) = -2.414, p = 
0.03). Similar findings were observed for TD control group with marginal 
significance (t(23) = -1.792, p = 0.09). Furthermore, no difference was observed 
between both groups in the time taken to collect saliva samples from the moment the 
child woke up (t(36) = 0.850, p = 0.401), as well as time taken from saliva collection 
to sleep start (t(30) = 0.746, p = 0.461) using independent-samples t test. In addition, 
as the time of collection may influence the results of the current study, raw/non-
normalised levels of melatonin and cortisol were analysed using ANCOVA with 
collection times as covariates (Table 5.6.). No effect of the time taken to collect 
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saliva samples from the moment the child woke up was found on morning melatonin 
levels (WS: F(1,16) = 0.034, p = 0.857; TD: F(1,20) = 0.878, p = 0.361), as well as 
cortisol levels in morning sample (WS: F(1,18) = 0.041, p = 0.842; TD: F(1,20) = 
0.220, p = 0.645). Similarly, no effect of the time taken from saliva collection to 
sleep start was found on evening melatonin levels (WS: F(1,15) = 0.713, p = 0.414; 
TD: F(1,14) = 0.001, p = 0.973), as well as evening cortisol levels (WS: F(1,14) = 
0.613, p = 0.449; TD: F(1,14) = 0.860, p = 0.372). 
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Parameter for which effect 
on levels of melatonin and 
cortisol was analysed 
Time point/hormone Group P value 
Age 
Afternoon melatonin 
TD(25) 0.98 
WS(17) 0.96 
Bedtime melatonin 
TD(21) 0.54 
WS(19) 0.94 
Afternoon cortisol 
TD(25) 0.43 
WS(20) 0.26 
Bedtime cortisol 
TD(22) 0.41 
WS(21) 0.86 
Time taken to collect saliva 
from the moment the child 
woke up 
Morning melatonin 
TD(20) 0.36 
WS(16) 0.86 
Morning cortisol 
TD(20) 0.65 
WS(18) 0.84 
Time taken from bedtime 
saliva collection to sleep 
start 
Bedtime melatonin 
TD(14) 0.97 
WS(15) 0.41 
Bedtime cortisol 
TD(14) 0.37 
WS(14) 0.45 
 
Table 5.6. Effect of chronological age and time of sample collections on levels of 
salivary melatonin and cortisol in children with WS and TD control group using 
analysis of covariance (ANCOVA). Neither of these parameters affected the levels of 
analysed hormones at different time points.  
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5.5. Ultra-high performance liquid chromatography- tandem mass 
spectrometry analyses 
 
5.5.1. UHPLC-MS/MS analysis 
 
In this method, chromatographic separation of the analytes was achieved using a C18 
reverse phase column. The mass spectrometer was operated in a positive ion mode to 
detect the compounds. The total run time for the analyses of cortisol, cortisone and 
MT6s was 6 min including reequilibration, although peaks of interest eluted within 3 
min. For the analysis of creatinine, the total run time was 4 min, however, the peaks 
of interest eluted within 0.5 min. The MRM chromatograms for cortisol, cortisone, 
and the internal standards indole-3-acetamide and 6-α-methylprednisolone together 
with single ion chromatogram of 6-sulphatoxymelatonin are shown in the Figures 
5.8. and 5.9. 
 
Figure 5.8. Multiple reaction monitoring (MRM) chromatograms of indole -3-
acetamide (A), cortisol (B), cortisone (C), 6-α-methylprednisolone (D) and single ion 
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chromatogram of MT6s (E) in urine. Conditions used to obtain these are described in 
Section 4.5.  
 
 
Figure 5.9. Multiple reaction monitoring (MRM) chromatograms of 1-(3-
aminopropyl-imidazole) (A) and creatinine (B) at concentration of 500 ng/ml and 0.25 
mg/ml respectively. 
 
Narrow and symmetrical peaks were obtained. The resolution between compounds 
was calculated to be: between cortisol and cortisone was 0.4; between 6-α-
methylprednisolone and cortisol and as well as cortisone was 2.55 and 2.18 
respectively; between MT6s and its IS was calculated to be 12.62 and between 
creatinine and its IS was 0.83. 
Retention time (RT) for each compound, as well as coefficient of variance (CV%) 
values for internal standards and QC results are presented in the Table 5.7.  
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Compound RT 
CV% for 
RT 
r2 
CV% for IS 
standard 
solutions 
CV% for IS 
samples 
QC CV% 
Cortisol 2.19 0.43 0.999 17.91 12.73 12.42 
Cortisone 2.21 0.18 0.999 17.91 12.73 7.91 
6-Sulfatoxymelatonin 2.51 1.99 0.998 14.83 19.19 11.03 
Creatinine 0.36 1.39 0.999 8.04 16.84 11.85 
6-α-methylprednisolone* 2.33 0.17 
*these three compounds are used as IS thus no values 
for r2, CV% for IS and QC CV% can be given  
Indole-3-acetamide* 1.69 0.39 
1-(3-aminipropyl-imidazole)* 0.31 1.33 
 
Table 5.7. Retention times (RT), r
2
 values and coefficient of variance (CV%) for RT, internal standards (IS) and quality control samples (QC) for cortisol, 
cortisone, 6-sulfatoxymelatonin, creatinine as well as RT and CV% for RT for internal standards. 
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The percentage CVs for retention time for all the analytes ranged between 0.17 to 
1.99%. The intra-assay CVs ranged from 0.02 to 20.83% at concentrations of 2.78-
100 ng/ml for cortisol and cortisone, 3.11-112 ng/ml for MT6s and 0.125-0.75 
mg/ml for creatinine. The higher values of CV were observed for the lowest 
concentrations of analysed compounds. It has been reported that CVs around 20 % 
are acceptable if the concentrations used for CV analysis were at the lower limit of 
quantification or near (Bioanalytical Method Validation, 2001). Inter-assay CVs 
ranged from 0.18 to 22.50% for the glucocorticoids (cortisol and cortisone), MT6s 
and creatinine at concentration ranging from 2.78 to 50 ng/ml, 3.11 to 56 ng/ml and 
0.125 to 0.75 mg/ml respectively. 
Linearity was estimated by dividing the observed value by the expected value for 
each calibration sample. Linear calibrations were obtained for glucocorticoids and 
MT6s in the range of 2.78 to 50 ng/ml and 3.11 to 56 ng/ml respectively. The 
percentages of the expected results for cortisol ranged between 92 % - 105 % for 
cortisone from 92 % to 107 % and for MT6s between 93 % - 120 %. 
 
Calibration curves 
Logarithmic axis scales were chosen in order to avoid compressing small values 
down into bottom of the graph. The R2 values for the curves ranged between 0.998 
and 0.999 (Figures 5.10. to 5.13.).  
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          Figure 5.10. Standard curve of cortisol      Figure 5.11. Standard curve of cortisone 
 
      
         Figure 5.12. Standard curve of MT6s                           Figure 5.13. Standard curve of creatinine 
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5.5.2. Urine samples analysis 
 
Obtained values were multiplied by the dilution factor. Levels of urinary cortisol, 
cortisone and MT6s uncorrected for creatinine in children with WS and TD control 
group are presented in a Table 5.8.  Levels similar to those were reported previously 
(Lin et al., 1997; Mayo Clinic, http://www.mayomedicallaboratories.com).  
 
 
Table 5.8. Levels of urinary cortisol, cortisone and 6-sulfatoxymelatonin (MT6s) 
uncorrected for creatinine in children with WS and TD control group. Table includes 
minimum, maximum and median levels of all the compounds, as well as standard deviation 
(SD). 
 
Levels of cortisol, cortisone and MT6s in urine samples were further corrected with 
respect to level of creatinine prior to statistical analysis. The corrected values 
obtained in this study were: cortisol in WS group 18.84-139.61 ng/mg creatinine 
and in the TD children 14.61-93.52 ng/mg creatinine, levels of cortisone were 
26.50-265.99 ng/mg creatinine and 17.96-110.15 ng/mg creatinine for WS and TD 
Compound (ng/ml) Groups Minimum Maximum Median SD 
Cortisol 
TD (n=24) 4.85 32.68 18.08 7.76 
WS (n=22) 7.32 52.46 18.99 11.05 
Cortisone 
TD (n=24) 8.90 49.20 21.60 9.66 
WS (n=22) 11.42 61.81 26.89 12.00 
MT6s 
TD (n=24) 0.36 3.66 1.62 0.98 
WS (n=20) 0.23 2.08 0.86 0.47 
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respectively. High individual variability in the amount of MT6s secreted was also 
observed in both groups. Level of MT6s in urine samples in children with WS 
ranged from 0.60 to 6.96 ng/mg creatinine and in the TD from 1.27 to 13.52 ng/mg 
creatinine.  
Further, Mann-Whitney test for group comparisons was used. Table 5.9. shows that 
level of cortisone is significantly higher in WS children then TD controls. Also, 
levels of MT6s excreted in urine were found to be significantly lower in WS group.  
Creatinine levels were within the normal range (Sugita et al., 1992; Trombetta & 
Foote, 2009) and ranged between 0.10-0.40 mg/ml in WS group and 0.20-0.53 
mg/ml for TD children. No statistically significant difference was observed for 
levels of creatinine between both study groups (U(46) = 246.0, p = 0.69). 
 
Compound 
(ng/mg creatinine) 
Group Median 95% CI p value 
Cortisol  
TD (N=24) 48.13 
-13.52, 18.98 0.90 
WS (N=22) 47.32 
Cortisone  
TD (N=22) 48.82 
-0.47, 39.63 0.05 
WS (N=21) 64.20 
MT6s  
TD (N=24) 4.39 
-3.44, -0.48 <0.01 
WS (N=20) 3.22 
 
Table 5.9. Comparison of urinary levels of cortisol, cortisone and 6-sulfatoxymelatonin 
(MT6s) in WS and TD children using Mann-Whitney test. Table includes median 
concentration of compounds. The 95% confidence interval values (95% CI)  and p value for 
determination of significance are also shown. Significant results are shown in bold.  
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5.5.3. Cortisol/cortisone ratio 
 
Using Pearson’s moment correlations it was found that urinary levels of cortisol 
and cortisone significantly correlate in WS and TD children (WS: r(22) = 0.562, p 
< 0.01; TD: r(24) = 0.638, p = 0.001) (Figure 5.14.). Furthermore, cortisol/cortisone 
ratio was also analysed as an indication of HSD type II activity. The median 
cortisol/cortisone ratio in WS was lower in comparison with TD group (0.59 and 
0.79 for WS and TD groups respectively), however, the level of significance was 
not achieved (U(46) = 184.0, p = 0.08).  
 
 
Figure 5.14. The comparison of levels of cortisol and cortisone measured by UHPLC-
MS/MS method. Using Pearson’s moment correlations it was found that urinary 
levels of cortisol and cortisone significantly correlate in WS and TD children (p < 
0.01). 
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5.5.4. Effect of chronological age, gender, bed-wetting and time of 
samples collection on levels of cortisol, cortisone and MT6s 
 
Levels of urinary cortisol, cortisone and MT6s were compared using ANCOVA with 
age as a covariate to control for the age effects (see Table 5.10). No age effect was 
observed in both study groups for the urinary levels of cortisol (WS: F(1,22) = 0.431, 
p = 0.52; TD: F(1,24) = 0.879, p = 0.36), cortisone (WS: F(1,22) = 0.629, p = 0.44; 
TD: F(1,23) = 1.202, p = 0.29) and MT6s (WS: F(1,20) = 0.487, p = 0.49; TD: 
F(1,24) = 0.340, p = 0.57).  
In addition, in both study groups no gender difference was found in levels of cortisol 
(WS: t(20) = 0.207, p = 0.84; TD: t(22) = -1.641, p = 0.12), cortisone (WS: t(20) = -
1.125, p = 0.27; TD: t(21) = -1.327, p = 0.20) and MT6s (WS: t(18) = -1.346, p = 
0.20; TD: t(22) = -1.063, p = 0.30) using independent samples t-test. 
Four children with WS were reported to wet the bed on the night of sample 
collection (See Table 5.10.). The bed-wetting parameter was used as a covariate to 
assess whether the results were affected. No effect of bed-wetting was observed in 
the data obtained from WS children for urinary analysis of cortisol (F(1,21) = 0.35, p 
= 0.56), cortisone (F(1,21) = 2.10, p = 0.16) and MT6s (F(1,19) = 1.13, p = 0.30). 
Furthermore, the time (min) from get up to sample collection was measured and 
analysed using independent samples t-test. No significance was found for this 
parameter (t(33) = 1.108, p = 0.24). The time from get up to urine collection was 
also used as a covariate in ANCOVA analysis (See Table 5.10.). No significant 
effect of this parameter was found for levels of urinary cortisol (WS: F(1,19) = 
0.971, p = 0.34; TD: F(1,20) = 0.677, p = 0.42), cortisone (WS: F(1,19) = 0.008, p = 
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0.93; TD: F(1,20) = 0.439, p = 0.52) and MT6s (WS: F(1,17) = 0.106, p = 0.75; TD: 
F(1,19) = 0.001, p = 0.98). 
 
Parameter for which effect 
on levels of melatonin and 
cortisol was analysed 
Time point/hormone Group P value 
Age 
Cortisol 
TD(24) 0.36 
WS(22) 0.52 
Cortisone 
TD(23) 0.29 
WS(22) 0.44 
MT6s 
TD(24) 0.57 
WS(20) 0.49 
Bed-wetting 
Cortisol WS(21) 0.56 
Cortisone WS(21) 0.16 
MT6s WS(19) 0.30 
Time from get up to sample 
collection 
Cortisol 
TD(20) 0.42 
WS(19) 0.34 
Cortisone 
TD(20) 0.52 
WS(19) 0.93 
MT6s 
TD(19) 0.98 
 WS(17) 0.75 
 
Table 5.10. Effect of chronological age, bed-wetting and sample collection time on 
urinary levels of cortisol, cortisone and 6-sulfatoxymelatonin (MT6s) in children with 
WS and TD control group using analysis of covariance (ANCOVA). Neither of these 
parameters affected levels of analysed hormones in urine. No effect of bed-wetting in TD 
group is given, as none wet the bed.    
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5.6. Sleep characteristic in children on melatonin as a sleep medication 
 
Two of the WS children were taking melatonin as a medication for their sleep 
problems and were excluded from the main analysis of the results. However, sleep 
parameters and evening levels of melatonin were analysed in these children 
separately from the rest of WS group. Figure 5.15. shows the evening levels of 
melatonin in WS group, TD controls and WS children taking melatonin as a sleep 
medication. The level of melatonin in these two children was over 8 fold higher than 
in WS population without any sleep medicine and over 6 fold higher than TD control 
group.  
 
Figure 5.15. Concentration of salivary melatonin (pg/ml) in WS and TD children 
compared to two WS children taking melatonin as a sleep medicine. The level of 
melatonin in these two children was over 8 fold higher than in WS population 
without any sleep medicine and over 6 fold higher than TD control group.  
 
Such high levels however, did not improve sleep efficiency (67.97 compared to 
79.56 ± 6.90 in WS group and 83.56 ± 4.87 in TD controls), sleep latency (86.67 min 
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compared to 52.83 ± 28.73 in WS and 28.73 ± 18.80 in TD children) or mean 
activity scores during the night measured by actigraphy (58.82 in children on 
melatonin, 17.27 ± 8.22 in WS population, 12.43 ± 4.22 in control group) (Figure 
5.16.). No standard deviation for WS group taking melatonin as sleep medication is 
given, as one of these children failed to keep an actiwatch on, thus the actigraphic 
data was collected for only one child. 
 
 
Figure 5.16. Comparison of mean and standard deviation of sleep efficiency, sleep latency 
(min) and mean activity score measured by actigraphy during three consecutive nights in 
children with WS, TD children and a child taking melatonin as a sleep medication. 
 
The results of urinary MT6s in two children taking melatonin as sleep medication 
were not conclusive. The levels of MT6s using ELISA were found to be 48.79 and 
310.93 ng/mg creatinine, while the mean value for WS group is 119.69 ± 105.41 
ng/mg creatinine. A similar situation is observed for MT6s values obtained by 
UHPLC-MS/MS method. The two children scored 4.17ng/mg creatinine and 
12.17ng/mg creatinine, while the mean and SD for the rest of WS group are 2.99 ± 
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1.43ng/mg creatinine. As there were only two children taking melatonin as a  sleep 
medication, and only one of them kept the actiwatch on over the course of the study, 
these data are not significant, but indicate that effect of melatonin on sleep in 
children with neurodevelopmental disorders should be investigated further.  
 
  
5.7. Comparison of UHPLC-MS/MS and ELISA method for analysis of 
MT6s 
 
As shown in Sections 5.3. and 5.5. significant difference in levels of MT6s in urine 
samples between WS and TD children has been found using both- UHPLC-MS/MS 
and ELISA methods (Figure 5.17.). However, the values obtained using ELISA were 
much higher (69.29 ± 47.57 ng/ml) in comparison with those measured by UHPLC-
MS/MS (1.27 ± 0.87 ng/ml). Pearson’s product moment correlations were used to 
investigate the similarity between MT6s levels analysed using UHPLC-MS/MS and 
ELISA. The significant positive relationship was observed between both methods 
(r(41) = 0.39, p = 0.01) (Figure 5.18.).  
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     * MT6s levels mult iplied by 50 
Figure 5.17. Comparison of 6-sulfatoxymelatonin (MT6s) levels obtained using ultra-high 
performance liquid chromatography- tandem mass spectrometry (UHPLC-MS/MS) and 
enzyme-linked immunosorbent assay (ELISA) in children with WS and TD control group.  
 
 
Figure 5.18. Comparison of 6-sulfatoxymelatonin (MT6s)  levels obtained using enzyme-
linked immunosorbent assay (ELISA)and ultra-high performance liquid chromatography- 
tandem mass spectrometry (UHPLC-MS/MS) methods from all study participants (WS and 
TD children). 
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5.8. Correlation between sleep measures and levels of melatonin and 
cortisol 
 
Pearson’s product moment correlations were used to determine whether the sleep 
problems observed in WS children can be explained by abnormal secretion of 
melatonin and cortisol. The analyses were performed using SPSS for Windows 
Version 19 (SPSS, Inc., Chicago, IL) as well as on the Minitab Version 16 
(Coventry, UK). As the current work focuses on investigation of sleep problems, it is 
particularly interesting to observe changes of hormonal markers of sleep at and prior 
to bedtime. Thus, bedtime samples as well as ratios between afternoon and bedtime 
levels are most relevant to relate with the sleep parameters data. Several significant 
correlations have been, however, found for afternoon levels as well (please see 
sections below).  
 
5.8.1. Correlations between CSHQ data and salivary melatonin and 
cortisol 
 
One of the CSHQ parameters, which scored significantly higher in WS group are 
parasomnias. It was shown that afternoon levels of salivary melatonin significantly 
correlate with parasomnias subscale of CSHQ in WS (r(17) = 0.631, p < 0.01) but 
not TD controls (r(25) = -0.268, p = 0.20) (Table 5.11.). As shown on Figure 5.19., 
the relationship between these parameters follow a different pattern in both groups. 
As the melatonin is a hormone, which facilitates sleep, it is expected that sleep 
disturbances, in this case parasomnias, will decrease with increased concentration of 
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melatonin, and this pattern is observed in the control group. However, in the WS 
group, the relationship between parasomnias and afternoon levels of melatonin is 
directly proportional. Furthermore, using 2 sample t-test of the gradients of the two 
regression fits, it was found that there is a significant difference in relationship 
between salivary melatonin and parasomnias between WS and TD groups (t(31) = 
3.33, p < 0.01).  
 
 
Figure 5.19. The correlation between frequency of parasomnias reported by parents in 
Children’s Sleep Habit Questionnaire (CSHQ) and normalised levels of afternoon 
melatonin (%) in saliva samples collected from WS and TD children. The significant 
positive correlation was observed between afternoon levels of salivary melatonin and 
parasomnias subscale of CSHQ in WS group (r(17) = 0.631, p < 0.01) but not in TD controls 
(r(25) = -0.268, p = 0.20). It can be seen that the relationship between these parameters 
follow a different pattern in both study groups. Parasomnias decrease with increased 
concentration of melatonin in the control group. However, in the WS group, the relationship 
between parasomnias and afternoon levels of melatonin is directly proportional.  Using 2 
sample t-test of the gradients of the two regression fits, significant difference in relationship 
between salivary melatonin and parasomnias was found between WS and TD groups (t(31) = 
3.33, p < 0.01).  
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It was also expected that sleep improves with increasing levels of melatonin. Thus, 
due to the fact that the higher CSHQ score, the greater sleep problems, it is expected 
that the total CSHQ score decreases with the rise of bedtime levels of melatonin. The 
significant negative correlation was observed between bedtime melatonin levels in 
saliva and the total score of CSHQ in TD (r(21) = -0.500, p = 0.02), indicating that 
the higher melatonin concentration, the lower sleep disturbance level in children 
(Figure 5.20.). This relationship was not observed for individuals with WS (r(19) = 
0.079, p = 0.75).  However, using residual diagnostic it was found that the difference 
in relationship between salivary melatonin levels at bedtime and total score of CSHQ 
was not significant between WS and TD groups (t(38) = 0.89, p = 0.38).  
 
 
Figure 5.20. The correlation between Total Children’s Sleep Habit Questionnaire 
(CSHQ) score and bedtime melatonin levels (%) in saliva samples collected from WS 
and TD children. A significant negative correlation was observed between bedtime 
melatonin levels in saliva and the Total score of CSHQ in TD (r(21) = -0.500, p = 
0.02), indicating that the higher melatonin concentration, the lower sleep disturbance 
level. This was not observed in WS (r(19) = 0.079, p = 0.75). Using residual 
diagnostic it was found that the difference in relationship between salivary melatonin 
levels at bedtime and total score of CSHQ was not significant between WS and TD 
groups (t(38) = 0.89, p = 0.38).  
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Also, some evidence of correlation between afternoon levels of cortisol and sleep 
onset delay in WS has been found (r(19) = 0.399, p = 0.09), but this relationship is 
not observed in the TD group (r(25) = -0.045, p = 0.83). Using 2-samples t-test it 
was shown, that there is no significant difference in relationship between afternoon 
cortisol levels in saliva and sleep onset delay score of CSHQ between WS and TD 
groups (t(42) = 1.46, p = 0.15).  
 
Endocrine 
marker of sleep 
Sleep parameter Group r value p value 
Saliva CSHQ  
Afternoon 
melatonin 
Parasomnias 
TD(25) -0.27 0.20 
WS(17) 0.63 <0.01 
Bedtime 
melatonin 
Total CSHQ score 
TD(21) -0.50 0.02 
WS(19) 0.08 0.75 
Afternoon 
cortisol 
Sleep onset delay 
TD(25) -0.05 0.83 
WS(19) 0.40 0.09 
Saliva Actigraphy    
Afternoon 
melatonin 
Sleep latency 
TD(25) -0.54 0.01 
WS(17) 0.25 0.37 
Bedtime 
melatonin 
TD(21) -0.49 0.04 
WS(19) 0.06 0.83 
Afternoon 
cortisol 
 
TD(20) 0.45 0.04 
WS(17) 0.51 0.04 
Afternoon 
cortisol 
Sleep efficiency 
TD(19) -0.58 0.01 
WS(16) -0.09 0.75 
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Wake after sleep onset 
TD(19) 0.44 0.06 
WS(16) 0.24 0.37 
Time spent asleep after 
sleep onset (%) 
TD(19) -0.44 0.06 
WS(17) -0.58 0.01 
Drop of cortisol 
from before 
bedtime 
Number of immobile 
phases 
TD(16) 0.52 0.04 
WS(17) -0.10 0.72 
Urine CSHQ    
Cortisone 
Sleep onset delay 
TD(24) 0.43 0.03 
WS(20) 0.15 0.52 
Cortisol 
TD(24) 0.38 0.07 
WS(20) -0.05 0.84 
 Actigraphy    
Cortisol Total actigraphy score 
TD(19) 0.44 0.06 
WS(19) 0.08 0.75 
Cortisone 
Sleep fragmentation 
TD(16) 0.67 <0.01 
WS(19) 0.09 0.72 
Moving minutes during the 
night 
TD(16) 0.45 0.08 
WS(19) 0.02 0.94 
 
Table 5.11. Pearson’s product moment correlation analysis between endocrine markers 
of sleep (melatonin and cortisol) and parental report (Children’s Sleep Habit 
Questionnaire- CSHQ) as well as actigraphy. Table presents r value and p value. 
Significant correlations are presented in bold.   
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5.8.2. Correlations between actigraphy data and salivary melatonin and 
cortisol 
 
Several correlations were found between levels of melatonin and cortisol and sleep 
latency (Table 5.11.). As expected, TD children that have higher levels of salivary 
melatonin before sleep took shorter time to fall asleep. This was not observed for 
WS group suggesting that melatonin may not function properly as a sleep marker in 
this disorder. From the actigraphic data the sleep latency adversely correlated with 
afternoon (r = -0.540, p = 0.01) and bedtime (r = -0.494, p = 0.04) levels of salivary 
melatonin in TD group, however, no such correlation was observed for the WS 
children (r = 0.249, p = 0.37 and r = 0.058, p = 0.83 for afternoon and bedtime 
samples respectively) (Figure 5.21.). In addition, the difference in relationship 
between afternoon levels of melatonin and sleep latency proved to be significant 
between WS and TD children (t(33) = 2.15, p = 0.04). This was not observed for 
bedtime melatonin levels and sleep latency (t(31) = 1.00, p = 0.33). 
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Figure 5.21. The correlation between sleep latency (min), and normalised levels of 
afternoon melatonin (%) in saliva samples collected from WS and TD children. The 
significant negative correlation was found between afternoon melatonin levels and sleep 
latency in TD children (r(20) = -0.540, p = 0.01), indicating that the higher melatonin levels, 
the shorter time they took to fall asleep. No such correlation was observed for the WS 
children (r(15) = 0.249, p = 0.37). In addition, the difference in relationship between 
afternoon levels of melatonin and sleep latency proved to be significant between WS and TD 
children (t(33) = 2.15, p = 0.04).  
 
The afternoon levels of salivary cortisol correlated positively with sleep latency 
(r(20) = 0.450, p = 0.04) and negatively with sleep efficiency (r(19) = -0.577, p = 
0.01) in TD controls. Thus, the higher the level of cortisol the longer time taken by 
the child to fall asleep and thus, the lower sleep efficiency score. This typical 
relationship was observed in WS individuals for sleep latency (r(17) = 0.514, p = 
0.04), but not for sleep efficiency (r(16) = -0.087, p = 0.75). However, using 2-
sample t-test, no statistically significant difference in relationship between afternoon 
cortisol levels and sleep latency (t(34) = -0.41, p = 0.69) as well as afternoon cortisol 
level and sleep efficiency (t(33) = 1.30, p = 0.20) was observed between both study 
groups.  
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In TD children it was also found that the higher levels of cortisol in the afternoon, 
the longer time spent awake after sleep onset and accordingly, the shorter time spent 
asleep during the night with marginal significance of r(19) = 0.442, p = 0.06 for 
actual wake % and r(19) = -0.436, p = 0.06 for actual sleep %. These typical 
relationship was found in WS children for actual sleep % (r(17) = -0.580, p = 0.01), 
but not actual wake % (r(16) = 0.242, p = 0.37). No statistically significant 
difference in relationship between afternoon levels of cortisol and actual wake % in 
the night (t(33) = -1.31, p = 0.20) as well as actual sleep % (t(34) = 0.88, p = 0.38) 
was found for both study groups.  
The significant correlation was also found between the drop of cort isol levels from 
afternoon to bedtime and the number of immobile phases in TD controls. The higher 
drop of cortisol observed, the more immobile phases recorded by actigraphs in TD 
children (r(16) = 0.519, p = 0.04), but not in WS individuals (r(17) = -0.095, p = 
0.72). However, the difference in this relationship between the two groups was not 
significant (t(31) = -1.13, p = 0.26). 
No significant correlations were found between raw levels of melatonin and cortisol 
in morning, afternoon and bedtime samples and sleep parameters from CSHQ as 
well as actigraphy.  
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5.8.3.  Correlations between CSHQ data and urinary cortisol and 
cortisone 
 
The significant correlation was found between urinary levels of cortisone and sleep 
onset delay in TD children (r(24) = 0.432, p = 0.03), but not in the WS group (r(20) 
= 0.152, p = 0.52). However, the difference in this relationship between both study 
groups did not prove to be significant (t(42) = -0.61, p = 0.55) (Table 5.11.). 
The marginal significance was also observed for urinary cortisol and sleep onset 
delay in TD (r(24) = 0.375, p = 0.07), but again not WS children (r(20) = -0.048, p = 
0.84). However, this time as well, the significant difference in this relationship 
between both groups was not observed (t(42) = -1.34, p = 0.19). 
No correlations between CSHQ data and levels of MT6s were found.  
 
5.8.4. Correlations between actigraphy data and urinary MT6s, cortisol 
and cortisone 
 
The marginal significance was found for the relationship between urinary levels of 
cortisol and total activity score from actigraphic measurements in TD group (r(19) = 
0.436, p = 0.06) indicating that the activity score increased in children with higher 
cortisol levels (Table 5.11.). This relationship was not observed in WS children 
(r(19) = 0.079, p = 0.75) and using 2-sample t-test it was shown that there is no 
significant difference in relationship between urinary cortisol and total activity 
scores between both study groups (t(36) = -0.97, p = 0.34). Furthermore, it was also 
observed that the higher levels of cortisone in first void morning urine, the higher 
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sleep fragmentation scores in TD children (r(16) = 0.673, p < 0.01). Again, this 
typical relationship was not observed in WS group (r(19) = 0.088, p = 0.72). No 
significant difference in relationship between urinary cortisone levels and sleep 
fragmentation index (t(33) = -1.23, p = 0.23) was found between WS and TD 
children.  
A marginal significance was also found in TD group for the Pearson’s product 
moment correlations between urinary cortisone levels in the first void morning urine 
and number of immobile phases (r(17) = 0.448, p = 0.07) as well as moving minutes 
during the night (r(16) = 0.446, p = 0.08). No significant correlations for these 
parameters were observed in WS children (number of immobile phases: r(19) = 
0.081, p = 0.74; moving minutes during the night: (r(19) = 0.017, p = 0.94). 
Marginal significance was found for the difference in relationship between cortisone 
levels and number of immobile phases between both study groups ( t(34) = -1.83, p = 
0.07). The difference in relationship between cortisone levels and moving minutes 
during the night did not prove to be significant between WS and TD children (t(33) = 
-1.27, p = 0.21). No correlations between CSHQ data and levels of MT6s were 
found.  
 
5.9. The effect of health problems and sleep habits on sleep 
parameters and levels of melatonin and cortisol  
 
Several variables from Medical questionnaire (Section 3.5.), including frequent 
colds, thyroid problems, watching TV before sleep and having shared bedroom were 
analysed as covariates using ANCOVA test. It was shown that the frequent colds 
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significantly predicts the occurrence of parasomnias (F(1,48) = 5.445, p = 0.02). 
However, there was still significant difference on the parasomnias score between WS 
and TD children after controlling for the effect of frequent colds (F(1,45) = 9.512, p 
< 0.01). The significant effect of watching TV within 30 min before bedtime on 
bedtime resistance has been found (F(1,50) = 19.706, p < 0.001). Similar findings 
were observed for the effect of having TV/video in bedroom on bedtime resistance 
(F(1,50) = 4.183, p = 0.04). However, after controlling for the effect of these two 
parameters, the significant difference on bedtime resistance between WS and TD 
groups was still observed (watching TV before bedtime: F(1,47) = 11.535, p = 0.001; 
having TV/video in bedroom: F(1,47) = 5.099, p = 0.03). 
No effect of having TV in bedroom, the time spent using computer/watching TV, 
watching TV within 30 min before bedtime, having shared bedroom and bedroom on 
the main road when traffic can be heard at night was found  for sleep efficiency and 
sleep latency. Interestingly, the time spent using a computer have significant effects 
on bed-time melatonin levels (F(1,36) = 8.962, p < 0.01). Furthermore, when 
controlling for the effect of this parameter, the significant difference in levels of bed-
time melatonin were found between WS and TD children (F(1,36) = 3.856, p = 
0.05). Using Pearson’s moment correlations it was noted that the more time spent on 
the computer during the schooldays, the lower levels of melatonin observed in TD 
children (r(20) = -0.518, p = 0.02). The trend towards this relationship was observed 
in WS children, however, it did not prove to be significant (r(19) = -0.385, p = 0.10). 
 No effect of problems with thyroid gland and glucose levels as well as 
extracurricular sport activities on levels of melatonin and cortisol was found.  
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No significant effects were found using raw data, what could be due to the high individual 
variation of both endocrine markers. 
 
Summary 
The effects of sleep problems in WS children are wide-ranging, yet precious little 
research has focused on the causal mechanism of sleep problems in children with 
disorders. The current chapter includes a description of the data obtained from 
laboratory analyses of melatonin, cortisol and their metabolites using enzyme based 
immunoassays and UHPLC-MS/MS method developed for this study. Abnormalities 
in secretion of both, melatonin and cortisol, as well as their metabolites have been 
found in children with WS. These findings may indicate contributing or an 
underlying factor of sleep problems observed among individuals with this disorder. 
Furthermore, different patterns of relationship between sleep parameters and levels 
of endocrine markers of sleep were observed between children with WS and TD 
control group. It was also noted that time spent using a computer can significantly 
affect levels of melatonin at bedtime. Sleep and its consequences is an area that 
requires thorough investigation in children with WS as this group clearly experience 
significant sleep problems. As sleep problems in children with WS may adversely 
affect daytime activity and the quality of life, as well as social, emotional and health 
functioning of the entire family, it is particularly important to assess sleep problems 
in disorder groups in sufficient detail.  
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6. DISCUSSION, CLINICAL IMPLICATIONS AND FUTURE 
WORK 
 
The motivation for this research has its roots in a lack of expertise regarding the 
causality of sleep problems affecting individuals with WS. Since sleep disturbances 
can have a disruptive impact not only on developing brain of a child, but also 
functioning of a family, it is necessary to examine sleep using multi-system analyses. 
Furthermore, it was beneficial for clinical applications to analyse both melatonin and 
cortisol simultaneously in order to assess interrelationships of these substances, such 
as their effect on diurnal rhythm and sleep in both TD and WS children. 
This chapter contains a discussion of the research findings and how they relate to the 
existing research. It covers the limitations and implications of the present study and 
suggestions are made for future research.   
 
6.1. Discussion 
 
The aim of this thesis was to get a deeper understanding of mechanisms contributing 
to sleep problems observed in children with WS. This study is the first to present a 
quantitative approach to sleep problems in WS in relation to parental reports, 
actigraphy and measures of endocrine markers of sleep.  
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6.1.1. CSHQ, actigraphy and pulse oximetry 
Analysis of sleep using CSHQ, actigraphy and pulse oximetry allowed for 
comparisons with previously published studies and provided a platform for further in 
depth examination of sleep in comparison with endocrine markers of circadian 
rhythm. The summary of sleep studies done to date including results of current 
investigation are presented in Table 6.1. The CSHQ data from the current study 
demonstrated that individuals with WS are significantly affected by several types of 
sleep disturbances, such as sleep onset delay, bedtime resistance, sleep anxiety, 
parasomnias and night wakings (see Section 3.4.) These findings are in line with the 
previous studies that have been reported (Bódizs et al., 2009; Goldman et al., 2009; 
Mason et al., 2009; Annaz et al., 2011; Ashworth et al., 2013). Furthermore, in the 
current study, parents of 41% of children with WS reported that their children never 
or rarely fell asleep within 20min and that only 33% have sufficient sleep each night. 
This was comparable to the study of Goldman and colleagues (2009), which has 
shown that over 36% of individuals with WS have trouble sleeping. The CSHQ data 
reported by Annaz and colleagues (2011) are also very similar having shown 
significant bedtime resistance, sleep anxiety and night waking in a WS group 
compared to healthy controls of similar age.   
Actigraphic measurements recorded over three consecutive days and nights provided 
further, more objective evidence of sleep disturbance. Several studies confirmed the 
reliability of actigraphy data obtained over this period of time (Glod et al., 1997; 
Hering et al., 1999; Gertner, 2002). It was found that children with WS had 
significantly increased sleep latency and fragmentation index, which is the indication 
of restlessness (see Section 3.2.). The decrease in sleep efficiency was also observed 
albeit only marginally significant (p = 0.06) requiring larger group samples. In 
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addition, number of wakings and moving time during the night was higher in WS 
population in comparison with TD control group. These findings are similar to those 
previously reported (Gombos et al., 2011; Mason et al., 2011). A recent study by 
Gombos et al. (2011) has shown atypical sleep patterns in children with WS; with 
decreased sleep efficiency and increased wake time after sleep onset. Similar results 
were reported by Mason et al. (2011) demonstrating decreased sleep efficiency with 
higher level of restlessness and arousals from sleep in WS population. Both stud ies 
have been based on PSG analysis. 
Furthermore, investigating similarities between parental reports and actigraphy, it 
was shown that only sleep latency and parentally reported sleep onset delay were 
related in WS group (see Section 3.6.). It has been previously reported that 
actigraphy and parental reports in TD children provide differing, but complimentary 
information about a child's sleep habits (Holley et al., 2010). The positive 
association between actigraphy and parental report of sleep concerns was shown in 
studies of Allik et al. (2006) and Malow et al. (2006) but not in the other studies 
(Hering et al., 1999; Wiggs & Stores, 2004; Wiggs et al., 2005). The inaccuracy of 
parent report underlines the importance of the objective measures for sleep 
assessment especially in children at risk. Furthermore, it is recommended that parent 
reports of sleep characteristics, such as CSHQ should not be used as a subst itute of 
objective measures. However, despite its inaccuracy, parent report may be more 
useful for uncovering specific information regarding sleep, for example parasomnias, 
such as bed-wetting. Another finding from the current investigation was an expected 
general trend in a decrease in sleep time with increasing chronological age, which 
has been demonstrated previously (Ashworth et al., 2013). 
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Actigraphy has some important limitations. The ability to precisely measure sleep 
latency depends on parents accurately reporting bedtime with lights out in the sleep 
diary. Furthermore, although it is assumed that Actiwatch Mini is comparable with 
other validated devices, as far as I am aware of, there are no published va lidation 
studies. Also, the sensitivity and specificity for use with children in clinical groups is 
unknown. It has also been shown that actigraphs can overestimate sleep efficiency 
due to scoring epochs of wakeful inactivity as sleep (Pollak et al., 2001). The study 
of Pollak et al. (2001), however, has not used Actiwatch Mini applied in the current 
work. Despite these limitations, the use of a TD control group allowed for a useful 
comparison and valuable data could be obtained.  Actigraphy is a useful tool for 
monitoring movement and studying sleep-wake cycles. It proved to be particularly 
valuable for the present study as its simplicity made it ideal for use with children 
with intellectual disability. 
It has also been shown that intrinsic sleep disorders, such as sleep apnoea, have the 
potential to disrupt sleep and promote night waking (Gozal, 2008). Thus, 
oxyheamoglobin saturation was also analysed using pulse oximetry monitors, 
(Section 3.3.), which are easy to use in a home environment and provide accurate 
information on oxygen levels (Urschitz, 2003). In line with previous studies (Arens 
et al., 1998; Mason et al., 2009; Gombos et al., 2011), no indication of sleep apnoea 
was found in individuals with WS. However, the use pulse oximetry has its 
limitations. The occurrence of OSAS is likely to be under-diagnosed using this 
method, since hypoxia is not always present. It detects around two thirds of OSAS 
cases (Williams et al., 1991; Golpe et al., 1999; Brouillette et al., 2000; Magalang et  
al., 2003). This method is also sensitive to the effects of body movements and poor 
blood flow, which is another limitation of using pulse oximetry. However, new 
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models are better at correcting for this (Netzer et al., 2001). Furthermore, pulse 
oximetry data could not be obtained for all of the children as over 30% refused to 
wear a sensor or removed it during the night, that is a common occurrence when 
working with children with disabilities (Ashworth, 2013). Also, although parents 
were shown how to use the device correctly, some inadequate recordings might be 
due to incorrect placement of the sensor. Thus, in some cases the data could not be 
used due to insufficient artefact- free recording time. Despite these limitations, pulse 
oximetry provides a non- invasive, straightforward technique that is considerably less 
time-consuming and expensive than PSG. However, as studies examining sleep in 
WS using PSG have not found any indication of sleep apnoea (Arens et al., 1998; 
Mason et al., 2009; Gombos et al., 2011), further analysis using less reliable pulse 
oximetry method might not provide any additional useful data in individuals with 
this disorder. Thus, this technique did not prove to be valuable for analysis of sleep 
in WS.   
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Study 
reference 
Sample size 
Age 
(years) 
Method Parameter measured Findings in WS group 
Current 
study 
n (WS) = 27 
n (TD) = 27 
4 – 11 CSQH 
Actigraphy 
Pulse oximetry 
Immunoassays 
UHPLC-MS/MS 
CSHQ sleep parameters: 
bedtime resistance, sleep onset 
delay, sleep anxiety, night 
waking, parasomnias, sleep 
disordered breathing, daytime 
sleepiness, sleep duration as 
well as total score; Actigraphy 
parameters including: bedtime, 
time in bed, actual sleep time, 
sleep latency, sleep efficiency, 
moving time, fragmentation 
index, night wakings;  
Cortisol, melatonin and their 
metabolites 
CSHQ findings: significantly greater level of 
parasomnias, sleep anxiety, night waking, as well as 
bedtime resistance, sleep duration and sleep onset 
delay; 
Actigraphy findings: increased sleep latency and 
moving time after sleep onset and fragmentation index, 
lower actual sleep time;  
Pulse oximetry findings: no breathing related problems 
that might affect sleep have been found; 
Endocrine markers of sleep: significantly higher levels 
of salivary cortisol prior to bed time, as well as lack of 
increase  of salivary melatonin and decrease of cortisol 
before bed time. Also, significantly higher levels of 
cortisone and lower levels of MT6s in first void 
morning urine 
 
Arens et al., 
1998 
n (WS) = 28 
n (TD) = 10 
1.5 – 10 Telesurvey 
PSG 
Movement arousal sleep 
disorder 
Telesurvey findings: Movement arousal in over 50 % 
of WS individuals 
PSG findings: Significantly higher prevalence of 
periodic limb movement syndrome in comparison to 
control group 
 
Goldman et 
al., 2009 
 
 
 
 
 
 
n (WS) = 23 
 
17 – 35 
 
Sleep habit 
questionnaires: 
Epworth Sleepiness 
Scale, questionnaire 
regarding daytime 
sleepiness in adults 
Actigraphy 
Sleep parameters: sleep 
efficiency, night wakings, 
daytime sleepiness, night 
movement 
Findings from questionnaires: Tiredness during the day 
in 95 % of participants, excessive daytime sleepiness in 
34 %, frequent awakenings during the night . 
Findings from actigraphy: mean sleep efficiency 74.4 
%, mean sleep latency of 37 min and 56 min awaken 
after sleep onset 
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Annaz et al., 
2011 
n (WS) = 64 
n (TD) = 92 
6 – 12 CSHQ Sleep parameters included: 
bedtime resistance, sleep onset 
delay, sleep anxiety, night 
waking, parasomnias, sleep 
disordered breathing, daytime 
sleepiness, sleep duration as 
well as total score 
 
Greater bedtime resistance, sleep anxiety, night waking 
and daytime sleepiness in WS children compared to 
healthy controls 
 
 
Gombos et 
al., 2011 
n (WS) = 9 
n (TD) = 9 
14 – 28 PSG Sleep architecture, leg 
movements, EEG spectra 
Atypical sleep pattern in WS individuals including 
decreased sleep time and sleep efficiency, increased 
wake time after sleep onset, increased percentage of 
NREM sleep and SWS, decreased REM sleep 
percentage, greater number of leg movements 
compared to healthy controls  
 
Mason et al., 
2011 
n (WS) = 35 
n (TD) = 35 
2 – 18 
 
PSG 
Sleep questionnaire 
Sleep architecture, respiratory-
related sleep arousals, limb 
movements, night awakenings 
PSG findings: decreased sleep efficiency, increased 
respiratory-related arousals, increased SWS 
Sleep questionnaire findings: more difficulty falling 
asleep, greater restlessness, more arousals from sleep 
than controls 
 
Bódizs et al., 
2012 
Study 1: 
n (WS) = 9 
n (TD) = 9 
 
Study 2: 
n (WS) = 20 
n (TD) = 20 
 
Study 1: 
14 – 29  
 
 
Study 2: 
6 – 29  
EEG Sleep EEG alternations Alternations in EEG recordings including redistribution 
of NREM sleep EEG power towards higher frequency 
Ashworth et 
al., 2013 
n (WS) = 24 
n (TD) = 52 
6 – 12  CSHQ 
Actigraphy 
CSHQ sleep parameters: 
bedtime resistance, sleep onset 
delay, sleep anxiety, night 
CSHQ findings: problems initiating sleep, bed-wetting, 
body pain, sleep onset delay, night wakings  
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waking, parasomnias, sleep 
disordered breathing, daytime 
sleepiness, sleep duration as 
well as total score 
Actigraphy parameters: 
bedtime, time in bed, actual 
sleep time, sleep latency, sleep 
efficiency, moving time, 
fragmentation index, night 
wakings 
Actigraphy findings: greater sleep latency, reduced 
sleep efficiency, increased percentage of moving time 
after sleep onset 
 
 
Table 6.1. Summary of studies on sleep in WS reported to date and the summary of the current work. Table presents study cohort, age range of 
participants, methods used and parameter measured as well as findings of sleep studies in WS. Underlined author’s names represents studies reported prior to 
start of current Ph. D. Abbreviations: CSHQ – Children’s Sleep Habit Questionnaire, EEG- electroencephalography, MT6s- 6-sulfatoxymelatonin, NREM- 
non-rapid eye movement, PSG- polysomnography, REM- rapid eye movement, SWS- slow wave sleep, UHPLC-MS/MS- ultra-high performance liquid 
chromatography-tandem mass spectrometry.  
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6.1.2. Endocrine markers of circadian rhythm 
 
The data collected through CSHQ and actigraphy indicated that children with WS 
indeed suffer from sleep problems, thus, levels of endocrine markers of circadian 
rhythm, namely melatonin, cortisol and their metabolites were investigated. Both of 
these markers are known to affect and regulate sleep/wake patterns.  
 
6.1.2.1. Salivary melatonin  
 
To date, very few studies have been carried out to analyse endocrine sleep markers 
in children with developmental disorders and none of them included individuals with 
WS (Potocki et al., 2000; Tordjman et al., 2005; Corbett et al., 2006). Alterations in 
secretion of both endocrine markers (melatonin and cortisol) in WS have been found  
in the current work. As shown in the Section 5.1. high individual variability in the 
amount of melatonin secreted was observed in children in WS and TD groups. High 
variation of melatonin levels has been reported previously (Wetterberg, 1978; 
Waldhauser & Dietzel, 1985; Burgess & Fogg, 2008; Minami et al., 2009). Burgess 
and Fogg (2008) determined that the peak value of salivary melatonin ranges 
between 2-84 pg/ml, while Minami and colleagues (2009) reported the morning 
levels of MT6s in adult healthy volunteers (n=16) as 26.9 ± 44.0 (representing mean 
and SD respectively). It has been also reported, that the ability to synthesize 
melatonin differs among individuals. There are low and high secretors of this 
hormone (Wetterberg, 1978; Waldhauser & Dietzel, 1985). Bergiannaki et al. (1995) 
suggested that this distinction most likely reflects genetically determined variable 
levels of the noradrenergic secretory drive and/or variable N-
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acetylotransferase/hydroxyindole-O-methyltransferase enzymatic activity during the 
night. In the current study, it was found that the median increase in the level of 
salivary melatonin in TD control group was 1.83 fold between afternoon and 
bedtime samples, whereas for the individuals with WS no such increase was 
observed (median change of 0.96 fold). This finding may possibly explain the 
causality of problems with settling down and falling asleep affecting children with 
this syndrome, as the nocturnal secretion of melatonin is known to facilitate sleep 
(Arendt, 2005). Similarly the study reported by Potocki et al. (2000) has shown 
abnormalities in the circadian rhythm of melatonin in patients with Smith-Magenis 
syndrome (n = 19). Tordjman and colleagues (2005) also reported significantly 
reduced nocturnal production of MT6s in children and adolescents with autism 
spectrum disorder (n = 49). 
 
6.1.2.2. Children taking melatonin as a sleep medication 
 
Melatonin is taken on average by 14% of children with WS (Annaz et al., 2011) and 
more surprising most toddlers with WS are taking melatonin (personal 
communication with the Williams Syndrome Foundation UK). However, there is no 
published evidence of any clinical efficacy for such hormonal sleep therapy in this 
disorder. Upon analysis it was noted that two children were taking melatonin as sleep 
medication and had to be excluded from analysis post study. It was shown that very 
high levels of salivary melatonin (8 fold higher than in the rest of WS group) 
observed in these children did not improve sleep quality (see Section 5.6.), 
suggesting that this hormone may not be effective for treating sleep problems in WS. 
However, as this was observed for only one child (the second child failed to keep an 
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actiwatch on), so this indication should be investigated further. Furthermore, results 
of urinary MT6s analysed by both, ELISA and UHPLC-MS/MS in these two 
children were not conclusive. One child had approximately 3-6 fold higher levels of 
MT6s than the other. This situation may be explained by the short biological half- life 
of melatonin, which according to different sources ranges between 30 min (Brown et  
al., 1997) and 1 h (Claustrat et al., 1986; Mallo et al., 1990). Melatonin 
supplementation is usually taken at least an hour prior to habitual sleep time. Thus, 
when the child passed urine in the time between taking melatonin and going to bed, 
the higher levels of this hormone may not be observed in the first void morning 
urine. Nocturnal excretion of urine has not been measured in the current study and 
there are no studies reporting urine excretion in WS. Gringras et al. (2012) reported 
significant decrease in sleep onset latency in children with various 
neurodevelopmental disorders (n = 146) while given oral melatonin. However, there 
are also studies showing no evidence that melatonin is effective in treating sleep 
problems, such as secondary sleep disorders (n = 97) (Buscemi et al., 2006). 
Furthermore, despite limited evidence of the effectiveness of exogenous melatonin 
and some concerns regarding safety, melatonin is being prescribed as a medication 
for sleep disorders to children with neurodevelopmental delay by an increasing 
number of physicians (Czeisler, 1997; Stone et al., 2000; Owens et al., 2003), and 
there is no standardisation as a wide variations of dose are being used (Phillips & 
Appleton, 2004; Waldron, et al., 2005). This indicates a major question as to any 
clinical benefit from melatonin administration and whether these children should be 
given melatonin to help with their sleeping problems.  The results of a current pilot 
study suggest that more research is needed in order to establish standard dosage and 
investigate efficacy of melatonin treatment in children with WS and possibly other 
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neurodevelopmental disorders. Furthermore, prior to introducing melatonin 
treatment, levels of this hormone should be examined at the individual level.    
 
6.1.2.3. Salivary cortisol 
 
Unlike melatonin, cortisol has not been studied as a sleep marker in children with 
developmental disabilities caused by various genetic disorders, such as WS or DS. 
Physiological levels of cortisol are highest in the morning and decline through the 
day (McVicar et al., 2007, Clow et al., 2010). Values obtained in the current study 
reflect this pattern (Section 5.2.). The highest level was observed in the morning and 
the lowest at bedtime in both TD and WS study groups. It was also found that there 
was a lack of decrease of salivary cortisol levels from afternoon to bedtime in many 
of the WS children (median fold decrease of cortisol levels in WS was 1.37 as 
opposed to 2.25 in TD group). In addition, significantly higher bedtime levels of this 
hormone in children with WS were observed in comparison to TD control group. 
Since cortisol is often described as a stress hormone and its actions include 
increasing blood pressure, heart rate and releasing glucose into the circulation 
(Seaward, 2006), high levels of cortisol before bedtime could potentially 
cause/contribute to sleep problems such as difficulty with relaxing and falling asleep 
(Talbott, 2007). Thus, findings of the current study may be another explanation of 
sleep problems such as delayed sleep onset affecting children with WS.  
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6.1.2.3.1. Cortisol and anxiety 
WS individuals display tendency towards anxiety as well as specific phobias and 
worrying (Dykens, 2003; Morris, 2006; Leyfer et al., 2009), that could result in 
higher levels of cortisol or vice versa and as a result may experience disordered 
sleep. Furthermore, as a prevalence of sleep problems is high in WS, it could be 
hypothesised that the bedtime struggles may also affect cortisol levels and /or cause 
sleep anxiety. However, no correlation was found between sleep anxiety parameter 
of CSHQ and cortisol levels in saliva and urine. Similar to the current study, Lense 
et al. (2013) analysed diurnal cortisol profile in adults with WS. However, the 
objective of that study was to examine cortisol as a biomarker of stress in both, novel 
(during a residential summer camp) and familiar settings (at home), so any 
association with sleep disturbance was not explored. Nevertheless, participants with 
WS demonstrated elevated cortisol levels late in the day in the novel setting when 
social demands were higher. The current study used natural home environment, what 
was the familiar setting for children, as opposed to sleep laboratory or hospital 
settings, in order to minimise effect of study procedure on participating children, 
such as stress effect on levels of cortisol. In addition, parents were trained how to 
collect samples, thus, children did not have to deal with an unfamiliar person. 
However, if collection procedure would still cause additional stress in children with 
WS and result in the rise of levels of cortisol, significantly greater concentration of 
this hormone would be observed between WS and TD children in all three saliva 
samples (morning, afternoon and bedtime). This difference was found only for the 
bedtime sample suggesting that the increase of anxiety and cortisol levels in WS 
children are unlikely to be caused by the sample collection procedure.  
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It is proposed that deletion of GTF2IRD1 contributes to increased anxiety and in turn 
higher cortisol levels in individuals with WS (Schneider et al., 2012). Schneider et 
al. (2012) and Howard et al., (2012) have shown elevated ACTH release in Gtf2ird1 
homozygous mice, what could be due to altered regulation of stress in the 
hypothalamus. As described in Section 1.1.6, ACTH acts on the adrenal cortex 
causing the synthesis of cortisol, thus, increased levels of ACTH cause elevated 
cortisol secretion. In addition, expression studies have shown that GTF2IRD1 is 
densely expressed in the hypothalamus and pituitary throughout murine embryonic 
development and this expression continuous to be high in the pituitary through 
adulthood (Palmer et al., 2007). This indicate the importance of the GTF2IRD1 in 
regulating anxiety response in adulthood and could be possible explanation of 
anxiety affecting not only children, but also adults with WS. Furthermore, the 
elevated endocrinological response to stress as well as decreased circadian activity 
was previously reported in Gtf2ird1 knock-out mice (Schneider et al., 2012). 
Thus, taking into account the abnormalities in secretion of endocrine markers of 
sleep found in the current work and the previously reported genotype/phenotype 
correlations of the genes deleted in WSCR, the model linking genetics with 
neurophysiological and biochemical parameters of sleep in WS was created (Figure 
6.1.). To date, there is no published model representing these interactions in WS.  
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Figure 6.1. The model of interaction between genetics and biochemical as well as 
neurophysiological sleep parameters in WS. It has been reported that GT2IRD1 knock-out 
mice demonstrate elevated adrenocorticotropic hormone (ACTH) release as well as elevated 
endocrinological response to stress (Howard et al., 2012; Schneider et al., 2012). It is 
proposed that deletion of GTF2IRD1 contributes to increased anxiety and in turn higher 
cortisol levels in individuals with WS (Schneider et al., 2012). Higher levels of cortisol may 
consequently cause/contribute to sleep problems observed in WS, such as sleep onset delay 
and sleep anxiety. 
 
Corbett and colleagues (2006) also analysed salivary cortisol in children with autism 
spectrum disorder (n=12) compared to healthy controls (n=10). The expected 
circadian variation of this hormone was seen in all study groups, but the objective 
was to evaluate the response to environmental stressors. The authors reported that 
children with autism demonstrated significant elevations of cortisol levels following 
exposure to novel, non-social stimulus, however, no significant difference in 
circadian variation (morning/afternoon/evening samples) as well as in baseline levels 
of cortisol was found between both study groups. The tendency towards cortisol 
hypersecretion in this disorder was also reported by Richdale and Prior (1992). The 
elevation of cortisol levels was observed during school integration in those children 
who were integrated into the normal school system. The authors suggested that this 
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tendency might indicate environmental stress response in children with ASD. 
Furthermore, Kiess et al. (1995) reported that analysis of cortisol levels in saliva 
provides a reliable tool for the determination of physiology of cortisol and 
characteristics of its metabolism. 
Analyses of salivary cortisol and melatonin from this study have indicated possible 
contributing/underlying factors for sleep problems in WS. However, it did not 
provide the data regarding the nocturnal levels of sleep hormones. There is a 
possibility that melatonin levels increase later in the night in children with WS than 
in TD control group. Thus, analysing nocturnal levels of this hormone would answer 
whether melatonin levels are/are not similar to those observed in healthy control 
group. Furthermore, although saliva is a diagnostic medium that can be easily 
collected at repeated intervals, the collection from children has its disadvantages. 
Children with WS often experience dryness of mouth, which I have observed during 
the course of my work. Thus, in some cases it was difficult to wet the swab 
thoroughly as it is recommended (Salimetrics, 2013) and collect enough saliva for 
immunoassay analysis. These difficulties would not be experienced while collecting 
urine. In addition, it has been shown that the concentration of melatonin and cortisol 
in the first void urine samples reflect their nocturnal levels (Smith & French, 1997; 
Benloucif et al., 2008). 
The current study used natural home environment as opposed sleep laboratory or 
hospital settings. This is an important factor when examining children with 
developmental disorders or young typically developing children, in order to 
eliminate the possibility that response differences are due to WS sensitivity to novel, 
non-social stimuli as demonstrated in those with autism (Richdale & Prior, 1992; 
Corbett et al., 2006) as well as adults with WS (Lense et al., 2013). In addition, 
215 
 
although the bedtime varies among children, melatonin and cortisol patterns are 
dependent on individual routine, melatonin levels rises approximately 2 h before 
habitual night-time sleep (Wulff, 2012), thus, different timing should not cause 
inconsistency, and in turn alter the results. Also, cortisol levels rise rapidly during 
the first 30 min after awakening (Wilhelm et al., 2007; Clow et al., 2010), hence it 
seemed necessary to collect the samples as soon as the child was awake. In this study 
no effect of collection times on levels of melatonin and cortisol was found.  
 
6.1.2.4. Novel analysis of simultaneous analysis of cortisol, cortisone 
and MT6s 
The new method is presented that enables simultaneous determination of most robust 
circadian markers, namely cortisol, cortisone and MT6s in urine. The structure of 
internal standards was similar to the structure of analysed compounds. Both, 6-α-
methylprednisolone and indole-3-acetamide were previously used as internal 
standards for analysis of cortisol (Turpeinen et al., 1997) and MT6s (Minami et al., 
2009). As shown in Section 5.5., the short run time with all peaks of interest eluting 
within 3 min was obtained. This demonstrates the feasibility of the method to carry 
out large multi-scale studies when the determination of the circadian rhythm of 
melatonin and cortisol require rapid sample processing. Another advantage of this 
method is direct sample injection, that eliminates the necessity for lengthy 
preparative steps, resulting in considerable saving of both time and chemicals. 
Simultaneous analysis of melatonin and cortisol, as well as testosterone was already 
reported (Jensen et al., 2011), however, the medium used were saliva samples 
collected from four healthy volunteers. In field studies it is often a problem to collect 
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sufficient amounts of  saliva for analysis (Hansen et al., 2008). The amount of saliva 
samples necessary for the analysis of melatonin and cortisol using LC-MS based 
methods in the previously reported studies range between 0.1 ml to 1 ml (Eriksson et  
al., 2003; Motoyama et al., 2004; Turpeinen et al., 2009). In the current work the 
injection volume of diluted urine samples was 5 µl for analysis of cortisol, cortisone 
and MT6s. In contrast, the 0.5 ml of urine was necessary for analyses of cortisol in 
previously reported LC-MS/MS methods (Nassar et al., 2001; Taylor & Singh, 2002; 
Kushnir et al., 2003). In addition, Jensen et al. (2011) in their method for 
simultaneous analysis of melatonin, cortisol and testosterone used liquid- liquid 
extraction prior to injection to the LC-MS/MS system. Following liquid- liquid 
extraction samples were evaporated to dryness and redissolved in over 5- fold lower 
volume of solution (methanol), which allowed for increase in concentration of 
hormones. Thus, their method obtained very good sensitivity with the limits of 
detection of approximately 1 pg/ml for melatonin and 10 pg/ml for cortisol with the 
run time of 6.5 min, while the lowest values detected by the UHPLC-MS/MS 
method involving direct sample injection, developed in the current study are         
106 pg/ml for MT6s, 2.23 ng/ml for cortisol and 2.78 ng/ml for cortisone. However, 
analysis of samples from WS and TD children showed that the method is sensitive 
enough to provide clinical data that will allow diagnosis of endocrine-related sleep 
problems. It has been reported that the advantages of analysis of cortisol and 
cortisone using LC-MS/MS methods include higher sensitivity and specificity as 
well as elimination of drug interference and a high throughput and short 
chromatographic run time (Taylor et al., 2002). The UHPLC-MS/MS method 
developed in this study could enable easier diagnosis of different types of sleep 
disorders, where there are abnormalities in the secretion of melatonin and/or cortisol.  
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One of the limitations of the current study was inability to obtain a good standard of 
MT6s due to two factors, namely, it is commercially unavailable and the synthesis 
was not possible in the current laboratory. In order to overcome this problem it was 
decided to use the MT6s standard from an ELISA kit for MT6s. As these standards 
were prepared in a buffer for ELISA analysis (containing sodium ions) (Melatonin 
sulfate ELISA instruction of use, http://www.ibl- international.com), ion suppression 
or enhancement could be observed during UHPLC-MS/MS measurements of MT6s. 
Ion suppression/enhancement results from the presence of less volatile compounds 
that can change the efficiency of droplet formation or droplet evaporation, that can 
consequently affect the amount of charged ion in the gas phase that ultimately 
reaches the detector. Compounds often causing ion suppression includes salts, ion-
pairing agents, metabolites, drugs or proteins (Annesley, 2003).  Sodium can either 
form a salt or act as an ion-pairing agent. This may possibly explain why MT6s 
levels obtained with UHPLC-MS/MS were much lower (approximately 55 fold) than 
those measured by ELISA (Sections 5.3. and 5.5.). Regardless this difference, the 
significant positive correlation was found between MT6s levels analysed by these 
two methods.  
 
6.1.2.5. Urinary levels of melatonin and cortisol 
 
In line with previous findings regarding analyses of salivary melatonin and cortisol,  
children with WS demonstrated significantly lower levels of MT6s in the first void 
morning urine (p = 0.03) in comparison with healthy controls (see Section 5.5.). 
Thus, it can be concluded that apart from the lack of increase of melatonin levels 
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before bedtime, overall nocturnal levels of this hormone are decreased in individuals 
with WS as well. This may explain the problems with maintaining good quality sleep 
at night observed in this disorder. In addition, it was shown, that children with WS 
demonstrate significantly higher levels of cortisone in first void morning urine in 
comparison with healthy controls, this may be another explanation of sleep problems 
affecting individuals with this disorder and confirmed the results obtained for 
salivary bedtime cortisol levels. The summary including data obtained for cortisol, 
melatonin and their metabolite using immunoassays and UHPLC-MS/MS is shown 
in Table 6.2. WS individuals also display tendency towards anxiety (Morris, 2006), 
that could result in higher levels of cortisol or vice versa and as a result may 
experience disordered sleep. Moreover, although four children with WS were 
reported to wet bed during the night prior sample collection, no effect of bed-wetting 
was observed in WS children for urinary analysis of cortisol, cortisone and MT6s 
using ANCOVA (all p > 0.05).  
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Method Matrix Compound Time point Median P value 
Im
m
u
n
o
a
ss
a
y
s Saliva  
% of the 
morning 
value 
Melatonin 
Afternoon 
TD = 40.37 
WS = 72.22 
0.13 
Bedtime 
TD = 80.48 
WS = 61.03 
0.78 
Ratio between 
bedtime/afternoon 
level (increase of 
melatonin level) 
TD = 1.83 
WS = 0.96 
0.04 
Cortisol 
Afternoon 
TD = 22.22 
WS = 27.17 
0.69 
Bedtime 
TD = 15.29 
WS = 33.45 
0.03 
Ratio between 
afternoon/bedtime 
level (decrease of 
cortisol level) 
TD = 2.25 
WS = 1.37 
<0.01 
Urine 
ng/ mg 
creatinine 
MT6s 
Morning, first 
void 
TD = 171.60 
WS = 83.40 
<0.01 
U
H
P
L
C
-M
S
/M
S
 
Urine 
ng/ mg 
creatinine 
MT6s 
Morning, first 
void 
TD = 4.39 
WS = 3.22 
<0.01 
Cortisol 
TD = 48.13 
WS = 47.32 
0.90 
Cortisone 
TD = 48.82 
WS = 64.20 
0.05 
 
Table 6.2. Summary table presenting median levels of normalised melatonin and 
cortisol in saliva as well as 6-sulfatoxymelatonin (MT6s), cortisol and cortisone in first 
void morning urine analysed in samples collected from children with WS and TD age - 
and gender-matched control group using immunoassays and ultra-high performance 
liquid chromatography- tandem mass spectrometry (UHPLC-MS/MS). It can be seen 
that urinary analyses reflect data obtained for the saliva indicating: increased salivary 
cortisol at bedtime and greater urinary cortisone in the first void morning urine in WS group; 
lack of increase of melatonin prior bedtime and lower MT6s levels in morning urine 
indicating decreased nocturnal secretion in children with WS. Significant results obtained at 
95 %  confidence interval are presented in bold.  
 
Since melatonin and cortisol secretion is affected by the environment, as many 
environmental variables as possible should be controlled and regulated. In order to 
completely manage environmental factors, it would be necessary to conduct the 
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study at a sleep laboratory, however, this could cause stress to children and result in 
the rise of cortisol levels.  
 
6.1.2.6.  Comparison of immunoassay based method and UHPLC-
MS/MS for analysis of endocrine markers of sleep 
 
Both, salivary melatonin and cortisol were analysed using standard enzyme 
immunoassays. General clinical analysis of both melatonin and cortisol are mostly 
based on the use of immunoassay based methods, mainly because of the convenience 
and limited number of clinical laboratories with liquid chromatography tandem mass 
spectrometry (LC-MS/MS) equipment (Inder et al., 2012). The novel UHPLC-
MS/MS method developed in this study could significantly contribute to the clinical 
laboratory field. There is no regular clinical method used for analysis of melatonin 
and cortisol as well as their metabolites, with some laboratories using immunoassay 
based methods, mainly RIA (ARUP Laboratories, http://ltd.aruplab.com; Cambridge 
Specialist Laboratory Services Information Manual, 2011), while other LC-MS/MS 
methods (Cardiff and Vale University Heath Board, 2013/2014; NMS Labs, 
http://www.nmslabs.com). Using immunoassay based techniques, hand pipetting 
necessary for these methods can create errors. On the other hand, these errors would 
be avoided while using automated HPLC system. Furthermore, using immunoassay 
based methods only one analyte and limited number of samples can be measured at 
one time. These assays require several hours to complete. For instance, 6-
sulfatoxymelatonin ELISA requires 2.5 hrs incubation time, thus, running whole 
assay takes several hours and only 40 samples can be analysed in duplicate. The 
UHPLC-MS/MS method developed in the current work allow for analysis of over 
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one hundred samples during the course of the day and multiple compounds are 
analysed at the same time. Another disadvantage of using immunoassays is cross-
reactivity with structurally similar compounds. As an example, ELISA kit for 
analysis of cortisol in urine reported over 30 % cross-reactivity with other analytes 
(cortisone, 11-α-deoxycortisol and corticosterone) (IBL International Cortisol (urine) 
ELISA instruction of use http://www.affinitydiagnostics.ca/; DiaMetra Urinary 
“free” cortisol ELISA instruction of use http://www.alpco.com/). LC-MS/MS 
methods could overcome these limitations and minimise the variability. In addition, 
no evidence was found for simultaneous analysis of melatonin and cortisol in clinical 
laboratories, while there is an increasing evidence suggesting that simultaneous 
measurements of more than one biomarker in the same sample provides greater 
confidence to the acceptance or rejection of specific diagnoses (Lin et al., 1997; 
Taylor et al., 2002; Remer & Maser-Gluth, 2007). Thus, in light of these problems, 
the specific UHPLC-MS/MS method for simultaneous analysis of MT6s, cortisol 
and cortisone was developed and could enable easier diagnosis of different types of 
sleep disorders, where there are abnormalities in the secretion of melatonin and/or 
cortisol. The LC-MS based methods have however some disadvantages. They require 
elaborate and expensive instrumentation. Nevertheless, in these laboratories that 
already work on these machines, measurements of endocrine markers of sleep using 
method developed in the current work is very cost effective. The cost of all 
chemicals and standards to run couple of hundred samples is up to £300 for cortisol, 
cortisone and MT6s to be analysed simultaneously. Whereas, cost of one plate for 
analysis of MT6s in only 40 samples is over £500. In addition, there is no standard 
immunoassay kit for analysis of cortisone. In summary, once the instrumentation is 
in place, the use of UHPLC-MS/MS method for analysis of cortisol, cortisone and 
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MT6s is cost effective, no cross-reactivity with similar compounds is observed, the 
method enables simultaneous analysis of many compounds at the same time and has 
a much shorter run time in comparison to enzyme immunoassays. All these factors 
demonstrate the feasibility of utilising the method for large multi-scale studies, 
where high throughput is required for studying the circadian rhythm of melatonin 
and cortisol secretion. 
 
6.1.3. Correlations between sleep parameters and endocrine markers of 
sleep 
When analysing associations between levels of endocrine markers of sleep with 
sleep parameters, several typical correlations were observed for the TD control 
group, but not WS children (Section 5.8.). As expected, it was noted that the higher 
levels of salivary melatonin at bedtime, the lower sleep disturbance score (Total 
score of CSHQ) and the shorter time taken to fall asleep by TD children. These 
typical relationships were not observed for WS group. In addition, it was found that 
TD children having higher bedtime and afternoon levels of salivary cortisol, as well 
as higher levels of cortisol and cortisone in the first void morning urine experienced 
greater accounts of sleep problems including increased sleep latency and activity 
scores during the night, reduced sleep efficiency as well as longer time spent awake 
after sleep onset. The increased afternoon levels of salivary cortisol in WS also 
affected time taken to fall asleep in children with this disorder. In addition, no gender 
difference as well as no effect of age or sample collection times (time between the 
collection of evening saliva sample and child’s bedtime as well as time taken to 
223 
 
collect saliva samples from the moment the child woke up) was observed on levels 
of melatonin, cortisol and their metabolites.  
Reviewing sections 3.6. and 5.8. regarding correlations between parental reports and 
actigraphy, as well as correlation between sleep measures and levels of melatonin 
and cortisol, it could be observed that only sleep latency from actigraphy was 
correlated to both, endocrine markers of sleep and parental reports. As seen in 
Section 3.6. sleep latency and parentally reported sleep onset delay were related in 
WS group. Furthermore, it was also observed that the higher levels of afternoon 
cortisol in saliva in WS, the longer time these children took to fall asleep. Some 
additional possible effects could be seen if the sample size was larger. However, due 
to the rarity of WS, most studies have small sample sizes. The studies of Bodizs et  
al. (2009), as well as Gombos et al. (2011) investigating sleep in WS using PSG 
included 9 participants with this disorder. The largest WS group in sleep research 
study included 64 children, however, it was based on parent-report questionnaire 
rather than empirical research (Annaz et al., 2011). Although, the sample size in this 
thesis accounts for ~30% of school-age children with WS (from Williams Syndrome 
Foundation database), the greatest number of participants could add power to 
analyses where significant effects were expected but not found. Due to time 
constraints as well as the unavailability of participants and equipment, this was not 
possible.  
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6.2. Clinical implications 
 
Managing sleep in developmental disorders is paramount not only for the health of a 
child but also for cognitive functioning and family life as whole. It has been reported 
that sleep deprivation negatively affects cognition (Killgore, 2010), while 
abnormally high secretion of cortisol during sleep is associated with poorer 
performance of declarative memory and executive function (Li et al., 2006; Scher et 
al., 2010; Evans et al., 2011). This study indicates that sleep problems should be 
treated at individual levels. A number of studies showed that levels of both 
melatonin and cortisol could be managed through behavioural management or 
pharmacologically. For instance, cortisol levels could be reduced with a specific diet 
containing low-glycemic- index foods and foods rich in vitamin C as well as omega 3 
fats (e.g. salmon, walnuts, almonds) (Moss, 2009). In addition, opiates as well as 
some benzodiazepines (alprazolam, temazepam) can decrease levels of cortisol 
(Carlson, 2011). Melatonin is also widely used medication for sleep problems 
(Owens et al., 2003). Furthermore, the new method for simultaneous analysis of 
MT6s, cortisol and cortisone in urine could be used clinically for measuring 
circadian disruption. 
Results from the current work regarding each child as well as summarised data were 
presented to the parents of a particular child, either personally or in a form of a letter. 
According to the research ethic’s committee, it is not permitted to give clinical 
advice based on research study.  
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6.3. Future work 
 
Both cortisol and melatonin play significant role in circadian rhythm and sleep/wake 
cycle, therefore it is necessary to look closely at these endocrine markers in 
individuals suffering from sleep disorders/problems. Although secretion of 
melatonin and cortisol proved to be stable across days and weeks amongst a wide 
range of individuals, and typical bedtime routine was ensured for the children, it 
would be beneficial to conduct a detailed study with sampling on more than one day. 
Also, obtaining repeated saliva samples would be useful in order to assess dim light  
melatonin onset as well as cortisol awakening response.  
Future work should also be focused on extending age groups, since sleep problems 
are shown in toddlers with WS (Axelsson et al., in press), and also on extending 
developmental trajectory to adolescence as well as cross-syndrome approach to 
examine if these findings are specific to WS or syndrome general (Annaz & 
Ashworth, 2011). Clinical studies are necessary to examine the modulation of 
melatonin and cortisol in individuals suffering from abnormalities in the levels of 
these hormones. It would be valuable to extend analysis of melatonin and cortisol on 
other neurodevelopmental disorders and individual suffering from sleep problems. In 
addition, despite very high levels of melatonin, sleep quality was shown to be poor 
in a child taking melatonin as a sleep medication. Thus, the efficacy of such 
treatment should be further investigated in children with WS and possibly other 
neurodevelopmental disorders.  
Future work could also include analysis of clock genes. Clock genes are components 
of the circadian clock critical to the generation of circadian rhythm (Dunlap, 1999; 
Albrecht & Ripperger, 2009). It would be beneficial to ascertain whether sleep as 
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well as melatonin and cortisol production anomalies observed in individuals with 
WS are due to an alternation of the molecular mechanisms of the circadian clock. 
Several studies suggest that human clock gene variants contribute to phenotypic 
differences observed in various behavioural and physiological processes and can 
have an impact on circadian rhythm (Albrecht, 2002; Viola et al., 2007; Lee et al., 
2010; Franken, 2013; Zhang et al., 2013). Furthermore, it has been shown that in the 
Per2/Cry1 mutant mouse, the HPA axis regulating cortisol secretion is defective 
(Oster et al., 2006), which may be another rationale for analysis of clock genes in 
individuals demonstrating abnormalities in levels of endocrine markers of circadian 
rhythm. In contrast, it has also been reported that expression of clock genes (such as 
Per1, Cry1, Npas4) can be influenced by secretion of both, melatonin and cortisol 
(Yamamoto et al., 2005; Imbesi et al., 2009; Mavroudis et al., 2012; Zeman & 
Herichová, 2013).  
It would also be beneficial to investigate the expression of melatonin receptors. It has 
been shown that the genetic inactivation of melatonin receptors MT1 and MT2 result 
in increased wakefulness and decreased NREM sleep time (Ochoa-Sanchez et al., 
2011; Comai et al., 2013). Studies by Imbesi et al. (2009) indicated also that 
melatonin receptor 1 is involved in the regulatory action of melatonin on neuronal 
clock gene expression. Thus, melatonin receptor MT1 may control clock gene 
expression and in turn generation of circadian rhythm.  
As described in the Sections 1.1.7. and 1.3.2. as well as in the current section, mouse 
models have been widely used to determine the function of clock genes, melatonin 
receptors as well as the genes from the WSCR (Yamamoto et al., 2005; Oster et al., 
2006; Li et al., 2009; Schneider et al., 2012; Comai et al., 2013). The mouse models 
of various genetic disorders, including WS, play an important role in defining 
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genotype/phenotype correlations. Moreover, mice are ideal candidates to model 
human genetic disorder, due to the fact that 99 % of a mouse genome sequence has 
direct counterparts in humans, thus, genomic alternations should affect the same 
biological pathways throughout development and result in similar phenotypes 
(Gunter & Dhand, 2002). There are several other studies using mouse models for the 
analysis of various sleep disorders, such as narcolepsy and sleep-disordered 
breathing (Tagaito et al., 2001; Zhang et al., 2007; Scammell et al., 2009). Thus, it 
would be beneficial to analyse sleep disturbances in mouse model of WS. Future 
work should also include the examination of correlations between genes deleted in 
the WSCR and levels of endocrine markers of sleep. This association would be 
particularly interesting between cortisol levels and the GT2IRD1 gene, as decreased 
circadian activity and elevated endocrinological response to stress, was previously 
reported in GT2IRD1 knock-out mice (Schneider et al., 2012). In addition, Schneider 
et al. (2012) and Howard et al., (2012) have shown elevated ACTH release in 
GTF2IRD1 homozygous mice, what is another rationale why the effect of GT2IRD1 
deletion on cortisol secretion should be investigated further.  
 
In light of the findings of the current thesis, and accounting for its limitations,  it is 
clear that sleep problems should be treated at individual levels. Increased bedtime 
cortisol and less pronounced rise in melatonin levels before sleep may play a role in 
the occurrence of sleep disturbances, such as delayed sleep onset, observed in 
children with WS. Since, both markers play a significant role in our circadian rhythm 
and sleep/wake cycle it is necessary to look closely at these endocrine markers in 
individuals suffering from sleep disorders. Sleep problems in children with WS may 
adversely affect daytime activity and the quality of life, as well as social, emotional, 
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health and economic functioning of the entire family. Hence, finding their cause is of 
great importance for affected children and their families. 
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APPENDIX 1  
INFORMATION SHEET FOR PARENTS  
Sleep patterns and hormonal markers of sleep, such as 
melatonin and cortisol levels in children with Williams 
syndrome 
We would like to invite you and your child to participate in this research 
project. You and your child should only participate if you want to; choosing 
not to take part will not disadvantage you or your child in any way. Before 
you decide whether you want to take part, it is important for you and your 
child to understand why the research is being done and what your 
participation will involve. Please take time to read the following information 
carefully and discuss it with others if you wish. Ask us if there is anything that 
is not clear or if you would like more information.  
What is the study about? 
The study is to investigate the secretion of salivary melatonin and cortisol as 
well as urinary metabolites such as metabolite of melatonin and cortisol, with 
the heart rate and respiratory rate variability and its contribution to the 
sleeping pattern in the children with Williams Syndrome.    
Why is the study being done? 
Melatonin and cortisol play an important role in sleep. Sleep disturbances 
have been shown to have an adversely effect on daytime activities of 
children and of the entire family. The aim of this study is to investigate 
causes of sleep problems in children with Williams syndrome.   
What are the benefits of taking part? 
Your family participation in this project will increase our understanding of 
sleep problems in developmental disorders such as Williams syndrome. 
What does taking part mean? 
You will be asked to fill in the questionnaires and to take saliva and urine 
samples 3 times in one day of your child. All collection devices will be 
provided. We will also measure pulse rate and respiratory rate of your child 
over the three nights using sensor attached to your child’s finger or toe. Your 
child’s activity and sleep/wake cycle will be also monitored with actiwatch. It 
is priority for us not to cause any inconvenience to your child. All participants 
will be asked to take part voluntarily and can withdraw at any stage of the 
project. 
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Who will have access to the research records? 
Only the researchers will have access to the data collected during this study. 
Your child’s identity will be confidential (a code will be used for all documents 
and data collected, not your child’s name) and is safeguarded by the Data 
Protection Act 1998 (DPA). The DPA places an obligation on those who 
record or use personal information, but also gives the rights to people whom 
information is held. This project is conducted in a manner that is consistent 
with the World Medical Association Declaration of Helsinki: Ethical Principles 
for Medical Research Involving Human Subjects. Middlesex University has 
Licenses for the storage of the tissue for research issued by The Human 
Tissue Authority Human Tissue Act 2004).  
Do I have to take part in the study? 
If you or your child decides, now or at a later stage, that you wish not to 
participate in this research project that is entirely your right and will not in any 
way prejudice your involvement in future studies. You or your child does not 
have to give a reason for withdrawal. 
Will I get notified of the outcome of the study? 
We are more than happy to provide you with information of our findings. We 
will send this to you as soon as the project is completed. 
What will happen to the results of the study? 
Results will be published as a part of doctoral dissertation as well as 
scientific publications and Williams Syndrome Foundation newsletter. The 
copy of publication may be obtained from researcher. Participants will not be 
identified in any report or publication. 
Who has reviewed the study? 
Study was reviewed by the Middlesex University, School of Health & Social 
Sciences, Natural Sciences Ethics sub-Committee.  
Whom do I speak to if I have a question?  
If you have any questions or comments discuss them with Dr. Dagmara 
Annaz via email: d.annaz@mdx.ac.uk or call on 020 8411 4695 or Anna 
Sniecinska, MSc, email: a.sniecinska@mdx.ac.uk, 020 8411 6223, 077 9533 
8880 
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APPENDIX 3 
MEDICAL HISTORY QUESTIONNAIRE 
 
1. Your name: …………………………………………………………................................... 
2. Your child’s full name: …………………………………………..................... ...Gender:   M        F 
3. Your child’s date of birth: ………………………………………………………. 
4. Child’s ethnicity......................................................................... 
5. What’s the parents’ occupation? 
Mother        
High managerial, administrative or professional (director/chairman/general manager) 
Intermediate managerial, administrative or professional  (public service managers/HE/FE 
teachers /headmasters) 
Supervisory, clerical and junior managerial, administrative or professional  (nurses /junior 
doctors/primary/secondary teachers/secretarial) 
Skilled manual workers (emergency services/electrician/carpenter etc) 
Semi and unskilled manual workers (retail /shop assistants etc) 
Housewife/ househusband 
Other.................................................................................................................. ...... 
 
Father 
High managerial, administrative or professional (director/chairman/general manager) 
Intermediate managerial, administrative or professional  (public service managers/ Education       
(HE / FE teachers / Headmasters) 
Supervisory, clerical and junior managerial, administrative or professional (nurses /junior 
doctors/primary/secondary teachers/secretarial) 
Skilled manual workers (emergency services/electrician etc) 
Semi and unskilled manual workers (retail / shop assistants etc) 
Housewife/ househusband 
Other........................................................................................................................ 
 
 
6. Where there any problems with this pregnancy or delivery (prematurity, high blood 
pressure, etc.)? 
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.....................................................................................................................................................
.......................................................................................................................... ........................... 
  
7. What was the birth weight? ......................................... 
 
8. What is your child’s weight and height? Weight.........................../height......................... 
 
9. Has your child had a genetic blood (FISH) test?   Yes           No 
If yes, what’s the result:  positive   negative 
 
10. Is your child:  right handed              left handed            don’t know  
 
11. Does your child wear glasses or contact lenses?   Yes             No 
 
12. Has your child been officially diagnosed with a developmental disorder such as ADHD/ 
ADD/Autism/ Asperger’s/ other? Yes       No 
If yes, please specify: ................................................................................................................ 
 
13. Is your child in any pain due to chronic medical conditions?  Yes          No 
If yes, please 
describe:.................................................................................................................... ..................
..................................................................................................................................................... 
 
14. Has your child ever had any operations (other than tonsils/adenoids removal)? 
            Yes          No 
If yes, type of operation? ..................................................................... Age .............................. 
     ..................................................................... Age .............................. 
     ..................................................................... Age .............................. 
 
 
15. Have your child’s tonsils or adenoids been removed?  
a. Tonsils:   Yes  At what age? ..................... 
For what reason: ................................................................ .................................................. 
b. Adenoids:   Yes       At what age?......................  
For what reason: ............................................................................................................ ...... 
c. Describe briefly any changes you noticed in your child’s sleep or waking behaviour after 
removal of tonsils or adenoids: ............................................................................................ 
............................................................................................................................................... 
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16. If NO, do you think the tonsils or adenoids are a problem?  Yes           No           Don’t know 
 
17. Has your child ever broken his/her nose or other facial bones?  Yes      No  
 
18. Does your child have difficulty breathing through his/her nose?  Yes      No 
 
19. In the past year, has your child had strep throats/tonsillitis?        Yes        No 
Frequent colds/ respiratory infections?                  Yes        No 
Frequent sinus infections?                   Yes        No 
 
20. Does your child have allergies?   Yes       No           Possibly  
If yes, to what? ............................................................................................................................ 
 
21. Does your child have asthma?   Yes           No                 
If yes, how many asthma attacks has your child had in the last year?................ None  
 
22. Does your child frequently complain of heartburn?   Yes  No      Don’t know  
Has he/she ever been diagnosed with gastroesophageal (stomach) reflux? 
Yes      No       Only when younger  
 
23.  Has your child ever been tested for glucose level in blood?   Yes          No           Don’t know 
If yes, is your child’s glucose level in blood abnormal/over the range?  Yes  No 
 
24. Does your child suffer from hypercalcaemia?   Yes             No             Don’t know  
 
 
25. Has your child ever been tested for level of thyroid hormones (THS, T3, T4)? 
Yes             No              Don’t know 
        If yes, which hormone and what was the result? ...................................................................... 
 ............................................................................................................................. ........................ 
 
26. Has your child had any injuries requiring medical evaluation and/or treatment or loss of 
consciousness? If yes, please describe: ...................................................................................... 
............................................................................................................................. ........................ 
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27. List any prescription or over- the counter medications your child has taken in the last month: 
Type:...................................................Reason for medication................................................ ..... 
Type:...................................................Reason for medication..................................................... 
Type:...................................................Reason for medication................................................ ..... 
 
28. Does your child take part in any extracurricular sport activities?  Yes              No 
If yes, how many hours a week and what kind of sport? 
Type: ...................................................................................Hours/week................................... 
Type: ...................................................................................Hours/week................................... 
Type: ...................................................................................Hours/week................. .................. 
 
29. Do you have any additional comments about your child’s medical history?  
............................................................................................................................. ........................
........................................................................................................................................... ..........
......................................................................................................................... ............................ 
 
HEALTH HABITS 
 
30. How much television and/or videos does your child watch on school days? 
none 
up to 2 hours 
2-4 hours per day 
4-6 hours per day 
More than 6 hours per day  
Don’t know
 
31. How much time does your child spend on the computer on school days? 
none 
up to 2 hours 
2-4 hours per day 
4-6 hours per day 
More than 6 hours per day  
Don’t know
 
32. How much television and/or videos does your child watch on weekend days? 
none 
up to 2 hours 
2-4 hours per day 
4-6 hours per day 
More than 6 hours per day  
Don’t know
 
33. How much time does your child spend on the computer on weekend days? 
none 
up to 2 hours 
2-4 hours per day 
4-6 hours per day 
More than 6 hours per day  
Don’t know
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34. Does your child watch TV and/or videos in the 30 minutes before falling asleep?  
Every night 
5-6 nights per week 
3-4 nights per week 
1-2 nights per week 
                Not at all 
 
35. Does your child have a television set in his/her bedroom?   Yes               No 
 
36. Does your child have a computer or game console (including handheld such as Nintendo DS) 
in his/her bedroom?   Yes               No 
 
37. Does your child share a bedroom?  Yes               No  
 
38. Is child’s bedroom on a main road where traffic can be heard at night?   Yes               No 
 
39. Please list any other factors that you think may affect your child’s sleep. 
 
.......................................................................................................................................... ...........
.....................................................................................................................................................
............................................................................................................................. ........................
.............................................................................. ....................................................................... 
 
DIET 
40. Is your child vegetarian?   Yes                   No  
41. How much caffeinated drinks does your child drink? 
More than 3 glasses per day 
Between 1 and 3 glasses per day 
Less than one glass per day 
None 
Don’t know 
42. How many main meals does your child eat per day? 
Less than 3   
3 
4 
5 or more 
Not eating regularly 
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43.  How many snacks does your child eat per day? 
None 
1 or 2 
3 
4 or more 
 
43. Does your child have gluten-free diet?  Yes                      No 
 
44. Do you have any additional comments about your child’s diet?  
......................................................................................................................................
............................................................................................................................. .........
......................................................................................................................................
............................................. 
 
Many thanks for filling out this questionnaire. Your answers will be treated in the 
strictest confidence and will be used only for this research project. 
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APPENDIX 4 
Child’s name........................................... 
 D.O.B.................................... 
Please fill in the table below as accurately as possible for each night that your child is 
wearing the Actiwatch. 
Date 
 
Getting up time Bedtime (in bed 
with light out) 
Time and 
duration of any 
daytime naps 
Time and 
duration of any 
night time 
awakenings 
 
 
 
 
 
    
 
 
 
 
 
    
 
 
 
 
 
    
 
 
 
 
 
    
 
 
 
 
 
    
 
 
 
 
 
    
 
 
 
 
 
    
Any Comments: 
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APPENDIX 5     
Tanner Stage of Puberty 
Please circle the right stage for your child 
Boys: 
 
Stage 1: Prepubertal 
 
Stage 2: Enlargement of scrotum and testes; scrotum skin reddens and changes in 
texture 
 
Sparse growth of long, slightly pigmented hair, straight or curled, at base of 
penis 
 
Stage 3: Enlargement of penis (length at first); further growth of testes 
 
Darker, coarser and more curled hair 
 
Stage 4: Increased size of penis with growth in breadth and development of glans; 
testes and scrotum larger, scrotum skin darker 
 
Hair adult in type, but covering smaller area than in adult; no spread to 
medial surface of thighs 
 
Stage 5: Adult genitalia 
 
Girls: 
Stage 1: Prepubertal 
Stage 2: Breast bud stage with elevation of breast; enlargement of areola 
 Sparse growth of long, slightly pigmented hair, straight or curled along the 
labia 
  
Stage 3: Further enlargement of breast and areola; no separation of their contour 
 
Darker, coarser and more curled hair 
 
Stage 4: Nipple form a secondary mound above level of breast 
 
Hair adult in type, but covering smaller area than in adult; no spread to 
medial surface of thighs 
 
Stage 5: Mature stage, adult genitalia 
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APPENDIX 6 
Collection mode        
The room should be dimly lit (table lamp) 
1.15 minutes before each saliva sample, rinse child’s mouth thoroughly with water  
2. Put on the gloves and remove the swab from the tube 
 
 
 
 
 
 
 
 
 
 
 
 
 
6. Put the swab back into the tube and put the lid on securely.  
7. Record time on the tube 
8. Put the tube/s in the fridge as soon as saliva is collected.  
 
3. Wearing gloves put 
the swab into the child’s 
mouth between the teeth 
and cheek  
4. Ask your child keep it 
for 3-5 minutes, until the 
swab is thoroughly 
soaked with saliva.  
 
5. If this doesn’t work, 
ask your child to spit into 
the big tube provided in 
the pack. 
 
5. If this doesn’t work, 
ask your child to spit into 
the big tube provided in 
the pack. 
 
5. If this doesn’t work, 
ask your child to spit into 
the big tube provided in 
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APPENDIX 7 
SAMPLE COLLECTION REMINDER: 
Drinking: Drinks containing artificial colorants, caffeine (coffee, black or green tea, 
iced tea, cola) are not allowed on the evening of collection  
 
Eating: Nothing should be eaten during the collection time. The last meal must be 
taken at least 15 minutes before starting the collection.  Bananas and chocolate 
should not be eaten during entire day before the collection.  
 
Teeth should not be washed at least 30 minutes prior to saliva collection 
 
Please collect saliva and urine samples at following times: first one in the afternoon 
(4-6pm), next one in the evening before going to bed, and the last one in the 
morning, just after awaking. Please note the time of collection on the tubes and 
pots.  
 
Please collect saliva samples under the muted light: light from reading lamp or from 
the television is preferable 
 
If by mistake, you forget to collect the first urine sample in the morning, please do 
this next day instead. It is extremely important that we get the very first urine 
sample 
 
Keep all saliva urine samples in fridge 
 
Give actiwatch to your child 
 
Please note down the time when your child go to bed and get up in the morning  
 
Please set up the masimo pulsoximetry for three nights  
 
Please fill in the questionnaires 
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